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Summary……         
   
The organisation of the actin cytoskeleton is regulated by abundant actin-binding proteins. 
Functional alteration of these proteins contributes to pathologies such as cancer where 
structural and functional modifications of the actin cytoskeleton are linked to uncontrolled cell 
motility and signalling. The actin-bundling protein L-plastin has initially been detected in 
haematopoietic cells where it plays a role in the immune response. L-plastin is also 
ectopically expressed in several solid tumours and is often considered as a metastatic 
marker. L-plastin is known to be phosphorylated in vitro and in vivo with residue serine 5 
(Ser5) being the major phosphorylation site. Ser5 phosphorylation increases the F-actin-
binding and -bundling activity of L-plastin and regulates actin turn-over. Recent findings 
demonstrate that L-plastin Ser5 phosphorylation is crucial for invasion and metastasis 
formation. This research work has unravelled the signalling pathways leading to L-plastin 
Ser5 phosphorylation in breast cancer cells. 
 
Previously, protein kinase A, protein kinase C and phosphoinositide-3-kinase have been 
reported to play a role in L-plastin Ser5 phosphorylation depending on the cell type and 
environment. This work however reveals that RSK kinases are the predominant kinases 
responsible for L-plastin Ser5 phosphorylation in breast cancer cells. In vitro kinase assays 
revealed that RSK1 and RSK2 are able to directly phosphorylate L-plastin on Ser5 and a 
whole genome microarray analysis pointed to an involvement of the ERK/MAPK pathway in 
this event. The involvement of this pathway was consolidated by activation and inhibition 
studies as well as by siRNA-mediated knockdowns. To our knowledge, this is the first 
evidence that L-plastin Ser5 phosphorylation occurs via the downstream ERK/MAPK 
pathway kinases, RSK1 and RSK2.  
 
Moreover, a computational modelling approach enabled us to show that RSK is the most 
important activator of L-plastin in breast cancer cell lines compared to other previously 
identified kinases. 
 
We performed migration and invasion assays which showed that RSK knockdown, besides 
reducing L-plastin Ser5 phosphorylation, also impaired breast cancer cell migration and 
invasion. The identification of a novel substrate of RSK kinases whose phosphorylation is 
important for cancer cell invasion underlines the importance of RSK in cancer progression 
and highlights RSK as a promising drug target in certain invasive carcinomas. 
Introduction   
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Chapter 1 Introduction  
 
1.1 The actin cytoskeleton 
 
1.1.1 Generalities 
The 42 kDa actin monomer, which is the cornerstone of the actin cytoskeleton, has been 
discovered in muscle cells in the 1940’s (Straub, 1942) and is found as the most abundant 
protein in almost all eukaryotic cells. Its sequence and structure are strongly conserved 
among species. Vandekerckhove and Weber revealed that six species-independent actin 
isoforms exist (Vandekerckhove and Weber, 1978): 2 smooth muscle actin isoforms 
(α-smooth and γ-smooth muscle), two striated muscle isoforms (α-skeletal and α-cardiac) 
and two cytoplasmic isoforms (β-cytoplasmic and γ-cytoplasmic). The α-actins are primarily 
expressed in muscle cells, β-actin is primarily expressed in non-muscle cells and γ-actins are 
expressed in both cell types.  
Actin is a globular protein with overall dimensions of 67x40x37 Å. It consists of a single 
polypeptide chain of 375 residues comprising a small domain further divided into subdomains 
I and II and a large domain further divided into subdomains III and IV (Figure 1.1.1.1). The 
crystal structure of free globular actin (G-actin) was solved by (Otterbein et al., 2001).  
 
 
Figure 1.1.1.1 Atomic structure of free actin as revealed by (Otterbein et al., 2001). 
Subdomains are labelled I, II, III, IV. Adapted from (dos Remedios and Chhabra, 2008).  
 
In animals, actin filaments complement with two other cytoskeletal polymers, microtubules 
and intermediate filaments (Figure 1.1.1.2). All three are involved in the maintenance of cell 
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shape. Microtubules are long, hollow cylinders made up of polymerised α- and β-tubulin 
dimers and involved in organelle transport, cell motility by flagella or cilia, membrane 
trafficking, and the formation of the mitotic spindle during cell division. Intermediate filaments 
are composed of fibrous proteins supercoiled into thicker cables that are localised 
underneath the cell cortex. Besides maintaining cell shape, they organise the internal 
tridimensional structure of the cell by anchoring the nucleus and other intracellular 
organelles. Actin filaments are composed of two intertwisted strands of actin. They are 
mainly concentrated just beneath the cell membrane and they are responsible for changes in 
cell shape, muscle contraction, endocytosis, cytokinesis, adhesion, signal transduction, 
intracellular organelle transport and cellular motility.  
 
 
Figure 1.1.1.2 Cytoskeletal polymers. A) Schematic structure and cellular localisation of 
actin filaments, microtubules and intermediate filaments. Adapted from (Lodish et al., 2008). 
B) Electron micrograph of three types of cytoskeletal polymers in a cell permeabilised to 
release soluble components. After rapid freezing, the frozen water was sublimed away and 
cellular components were coated with platinum. Microtubules are highlighted in red. Adapted 
from (Pollard and Cooper, 2009). 
 
1.1.2 Actin polymerisation 
The assembly of globular actin monomers to form long, stable filaments (F-actin) with a 
helical arrangement of subunits (Figure 1.1.3) is essential in allowing the actin cytoskeleton 
to carry out its various functions. ATP-G-actin can polymerise into ATP-F-actin and occurs 
spontaneously under physiological conditions. Polymerisation starts slowly as small 
oligomers are unstable, but once filaments have been created, actin polymerises rapidly. The 
net rate of filament elongation is slightly less than 200 monomers/second (dos Remedios et 
al., 2003). Filaments are polar since all subunits point in the same direction. One end of the 
filament, the barbed end (also called + end) grows much faster than the other pointed end 
(also called – end) (Pollard et al., 2000; Wegner and Isenberg, 1983). Polymerisation can be 
divided into activation, nucleation, elongation and annealing (Gaszner et al., 1999). During 
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activation, actin-ATP binds an Mg2+ ion through its cation binding site which induces a 
conformational change that reduces the negative charge of the actin monomers, thus 
favouring an interaction between two monomers (Gaszner et al., 1999). Nucleation consists 
of the formation of a trimer of actin monomers. This is an energetically unfavourable process, 
the dimer intermediate being highly unstable (Wegner and Engel, 1975). Elongation refers to 
the association of actin monomers at both ends of the actin filament and annealing occurs 
when short actin filaments rapidly bind end-to-end to form longer filaments. All these steps 
are reversible and thus account for a highly dynamic actin turnover. As the actin filament is 
polar and as one end of the filament grows rapidly in length while the other end rather tends 
to shrink, this results in a section of filament seemingly moving. This phenomenon is called 
treadmilling (Wegner, 1976) (Figure 1.1.2). 
 
Figure 1.1.2 Illustration of actin treadmilling. Actin treadmilling occurs at the lamellipodium of 
migrating cells and consists of a cycle of actin polymerisation/depolymerisation. Actin 
nucleation occurs at the front of the leading edge and newly nucleated actin filaments are 
attached to the sides of pre-existing filaments. In addition, polymerisation of actin filaments 
occurs in the front and pushes the plasma membrane forward. At the rear end of the leading 
edge however, actin depolymerisation occurs. This polymerisation/depolymerisation cycle 
causes a spatial separation between net filament assembly at the front and net filament 
disassembly at the rear, so that the actin filament network as a whole can move forward, 
even though the individual filaments within it remain stationary with respect to the 
substratum. Adapted from (Alberts B. et al., 2008). 
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1.1.3 Actin-binding proteins (ABPs) 
In the cell, actin polymerisation is controlled by over 100 so-called ABPs. The complex and 
dynamic properties of the actin cytoskeleton are regulated at multiple levels by a variety of 
ABPs that control the turn-over of actin filaments and their organisation into bundles or 
networks, which is required for the assembly of specific cytoskeletal structures (see (dos 
Remedios et al., 2003) for review). ABPs are classified in nine different groups but some 
ABPs can be classified in several groups: 
 
1. monomer binding proteins that prevent actin polymerisation by sequestering G-actin 
(thymosin β4, DNase I),  
2. filament-nucleating proteins that promote the formation of actin trimer nuclei 
(Arp2/3, formin), 
3. filament-depolymerising proteins that induce the conversion of F- to G-actin (CapZ 
and cofilin),  
4. filament end-binding proteins that cap the ends of the actin filament preventing the 
exchange of monomers at pointed (tropomodulin) and barbed (CapZ) ends,  
5. filament severing proteins that shorten filament length by binding to the side of 
F-actin and cutting it into two pieces (gelsolin),  
6. filament branching proteins (Arp2/3, WASP/SCAR/WAVE), 
7. crosslinking proteins that contain at least two binding sites for F-actin, either 
inherent or through dimerisation, thus facilitating the formation of filament bundles 
(α-actinin, fascin, villin, L-plastin) and three-dimensional networks (filamin),  
8. stabilising proteins that bind along the sides of actin filaments to prevent 
depolymerisation and stiffen the actin filament (tropomyosin),  
9. motor proteins that use F-actin as a track upon which to move (myosin family of 
motors). 
 
Crosslinking proteins will be described in more detail under 1.1.4. 
 
1.1.4 Formation of higher order actin structures 
F-actin filaments can be organised in more complex cytoskeletal structures for the 
implementation of diverse cellular functions, such as the maintenance of cell shape or the 
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generation of force for cell motility. Crosslinking proteins can organise the actin cytoskeleton 
to form three-dimensional networks of filaments (e.g. filamin) (Figure 1.1.4), which protect the 
cell from various shear stresses (Kasza et al., 2009). They can also form bundles of parallel 
filaments (e.g. fascin, α-actinin, villin and plastin) (Figure 1.1.4), which shield the cell against 
mechanical deformation and allow force generation. Actin bundles are found in filopodia 
where they exert protrusion forces at the leading edge of a motile cell, in microvilli which are 
passive structural elements that increase the surface area of the cells, in stress fibers which 
are essential for cell adhesion to the substratum and for changes in cell morphology and in 
invadopodia, which are matrix-degrading structures (Alberts B. et al., 2008; Schoumacher et 
al., 2010).  
Crosslinking proteins contain actin-binding domains such as gelsolin domains (e.g. gelsolin, 
villin), spectrin domains (e.g. spectrin, α-actinin) or calponin homology (CH) domains (e.g. 
α-actinin, filamin and plastin). In order to be able to bind two actin filaments, many 
crosslinking proteins form dimers. Plastins are unique as they have tandem actin-binding 
domains consisting of pairs of CH domains (de Arruda et al., 1990). These closely positioned 
actin-binding domains allow plastins to form tight actin bundles. The formation of three-
dimensional networks is mediated by proteins such as filamin containing actin-binding 
domains that are separated by longer, more flexible spacer regions, which allow a more 
perpendicular arrangement of actin filaments (Figure 1.1.4). 
 
 
Figure 1.1.4 Organisation of the actin cytoskeleton by crosslinking proteins. Globular actin 
monomers are assembled to form long actin filaments with a helical arrangement of subunits. 
The equilibrium between G-actin and F-actin is regulated by ABPs. The organisation of actin 
into filaments is essential for the formation of higher-order actin structures such as actin 
networks or bundles governed by actin crosslinking proteins. Actin filaments in networks are 
organised into orthogonal arrays by large flexible proteins such as filamin. Actin bundles of 
parallel actin filaments are formed by actin-bundling proteins such as plastin. 
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1.1.5 Function of higher-order actin structures 
The organisation of actin filaments into higher-order structures is a key step in the 
development of specialised cellular structures, such as filopodia (spike-like protrusions), 
lamellipodia (sheet-like protrusions), stress fibers (elastic contractile bundles), focal 
adhesions (plaques for mechanical linkage to the extracellular matrix), microvilli (finger-like 
surface protrusions) and invadopodia (invasive cell feet). Here we will focus on some 
structures that are required for cell motility. 
Cell motility, important for numerous cellular functions including embryonic morphogenesis, 
wound healing and immune surveillance, is a tightly controlled multistep mechanism 
(reviewed in (Bailly and Condeelis, 2002)). First, the cell responds to an extracellular signal 
by localised actin polymerisation, which results in the rearrangement of the cell surface to 
form specialised cellular structures required for cell motility: filopodia, lamellipodia, 
podosomes or invadopodia. In a next step, these structures make contact with a 
neighbouring cell or with the extracellular matrix (ECM) to form an adhesion site. This 
subsequently generates signals resulting in actomyosin-based contraction, which in turn 
results in the development of tension between the adhesion sites of the cell. The last step 
can vary depending on the action to be completed. For locomotion of the cell, the tension 
developed by the contraction can lead to the detachment of the trailing edge of the cell and 
the pulling of the cell towards the adhesion site in the leading edge of the cell. Alternatively, 
the generated tension can lead to changes in cell shape during embryogenesis or to matrix 
remodelling during wound healing (Bailly and Condeelis, 2002). 
 
 
1.1.5.1 Structures for migration 
For migration on 2D substrates the cell polarises to form a leading edge and a trailing edge. 
The leading edge faces the direction of movement and contains dynamic actin structures 
called lamellipodium and filopodium (Figure 1.1.5.1). Lamellipodia are flat and wide 
membrane protrusions containing a complex bidimensional dendritic network of branched 
actin filaments. Fast elongation of actin filaments predominantly occurs at the barbed ends 
facing the leading edge (Lai et al., 2008; Urban et al., 2010) which allows pushing the 
membrane into the direction of movement. Filopodia are thin, finger-like protrusions that 
extend beyond the leading edge of protruding lamellipodia of migrating cells. They are 
formed by parallel bundles containing 15-20 actin filaments with their barbed ends facing the 
cellular membrane (Lewis and Bridgman, 1992). They sense the environment and determine 
the direction of movement.  
Introduction   
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Figure 1.1.5.1 Organisation of the actin cytoskeleton in a migrating cell. Representation of 
various actin structures involved in cell migration. Adapted from (Parsons et al., 2010). 
 
 
1.1.5.2 Structures for invasion 
Podosomes and invadopodia (Figure 1.1.5.2) can be grouped as invadosomes (Linder et al., 
2011). Podosomes are found in monocytic cells (Linder et al., 1999), dendritic cells (Burns et 
al., 2001), osteoclasts (Destaing et al., 2003), endothelial cells (Moreau et al., 2003) and 
smooth muscle cells (Burgstaller and Gimona, 2004) whereas invadopodia are found in 
invasive tumour cells. The structure of podosomes and invadopodia differs: Podosomes have 
a diameter of around 1 μm, a height of 0.4 μm and are non-protrusive whereas invadopodia 
have a diameter of up to 8 μm, a height of 5 μm and are protrusive (Artym et al., 2011; 
Linder, 2009). Furthermore, in podosomes the actin core is surrounded by a ring structure of 
adhesion proteins, such as vinculin or talin (Linder and Aepfelbacher, 2003), a structure that 
is not found in invadopodia (Gimona et al., 2008). Podosomes contain a branched network of 
actin filaments and possibly also a layer of unbranched radial actin filaments surrounding the 
central core (Linder et al., 2011). Invadopodia however contain parallel actin bundles and a 
meshwork of actin filaments at the base (Schoumacher et al., 2010). Podosomes have been 
shown to be surrounded by G-actin and short actin filaments that may be the source of raw 
material for turnover or podosome growth (Destaing et al., 2003; Hu et al., 2011). On 2D 
surfaces, invadosomes form at the ventral surface, which is in contact with the ECM, and 
they are involved in ECM degradation through the secretion of a variety of proteases, 
especially of the matrix metalloproteinase (MMP) family (reviewed in (Linder, 2007)). 
Podosomes seem to mediate a widespread but superficial matrix degradation whereas 
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invadopodia tend to a more focused and deeper degradation (Linder, 2007). Invadosomes 
are also involved in mechanosensing and it has been shown that matrix stiffness influences 
the spacing and the lifetime of podosomes (Collin et al., 2008; Collin et al., 2006) as well as 
matrix degradation by invadopodia (Parekh et al., 2011). 
Podosomes are involved in adherence to the ECM and are thus enriched in matrix-binding 
proteins and integrins. It has been stated that podosomes may assist directional migration by 
stabilising short-lived cellular protrusions (Dovas et al., 2009). 
Regarding invadopodia, it is not clear whether they adhere to the ECM and reports showing 
recruitment of integrins to invadopodia are rare (reviewed in (Linder et al., 2011)). 
Nevertheless, invadosomes appear to be involved in signal transduction by the fact that they 
contain a multitude of components similar to those in focal adhesions (Block et al., 2008). 
The lifetime of podosomes is 2 to 12 minutes (Linder, 2007) and their actin is turned over 
around three times during their lifetime (Destaing et al., 2003). Invadopodia are more stable 
and can persist up to one hour (Linder, 2007). The lifetime of invadopodia has been shown to 
be dependent on cofilin expression (Yamaguchi et al., 2005a). Invadopodia formation and 
maturation is a dynamic process starting with the formation of a network of actin filaments 
and cortactin which is then followed by the recruitment of the proteinase MT1-MMP with 
subsequent matrix degradation (Artym et al., 2006). In tumour cells, expression of cortactin, 
Tks5, MT1-MMP as well as matrix degradation are unique markers of invadopodia (Bravo-
Cordero et al., 2012). Membrane ruffling and filament-like protrusion from the invadopodia 
occur during maturation (Artym et al., 2011). 
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Figure 1.1.5.2 Invadosomes. The formation of invadosomes is visualised by co-
immunostaining of F-actin (red) and the invadosome-associated protein cortactin (green) (the 
nucleus is shown in blue). Colocalisation of F-actin and cortactin (together indicated by 
yellow) is frequently used, among many markers, to confirm the presence of these structures 
in cells. Cortactin has been removed from the left panels. Podosomes are often found at the 
leading edge of cells. They are shown in macrophages (IC-21 cells; left) and neural crest 
stem cells (JOMA1.3 cells treated with 20 nM PMA to induce podosome formation; right). 
Invadopodia are often found surrounding the nuclei. They are shown in head and neck 
squamous carcinoma cells (SCC61 cells; left) and breast cancer cells (MDA-MB-231 cells; 
right). Arrows indicate individual puncta. Images were taken at ×40 magnification (MDA-
MB-231) and ×60 magnification (JOMA1.3, IC-21 and SCC61) using a fluorescence 
microscope. Adapted from (Murphy and Courtneidge, 2011). 
 
1.1.6 Actin cytoskeleton and cancer 
Cancer figures among the leading causes of morbidity and mortality worldwide, with 
approximately 14 million new cases and 8.2 million cancer-related deaths in 2012 (Stewart 
and Wild, 2014). The word cancer is used for a large group of diseases that can affect any 
part of the body. One defining characteristic of cancer is the multiplication of abnormal cells 
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that grow beyond their usual boundaries, and that can then invade adjoining parts of the 
body and spread to other organs, the latter process being referred to as metastasising.  
The progressive conversion of normal human cells into cancer cells involves genomic 
changes activating oncogenes and inhibiting tumour suppressor genes. Cancer development 
occurs similar to Darwinian evolution in which sequential genetic changes, each conferring 
one or another type of growth advantage, lead to the progressive transformation of normal 
human cells into highly malignant cells (Foulds, 1954; Nowell, 1976).  
In 2000, Hanahan and Weinberg introduced six hallmarks of cancer, namely self-sufficiency 
in growth signals, insensitivity to anti-growth signals, limitless replicative potential, evasion of 
apoptosis, sustained angiogenesis and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). In 2011, they updated their model with the addition of four further cancer 
hallmarks: genome instability and mutation, deregulated cellular energetics, avoidance of 
immune destruction and tumour-promoting inflammation (Hanahan and Weinberg, 2011). 
The metastatic process consists of a series of successive steps. In a first step, tumour cells 
detach from the primary tumour which involves an epithelial to mesenchymal transition 
(EMT) characterised by repression of E-cadherin expression, loss of cell adhesion, and 
increased cell motility. Thereafter the cells invade and migrate through the surrounding tissue 
and eventually enter blood vessels or the lymphatic system by intravasation. Subsequently, 
circulating tumour cells temporarily adhere to endothelial cells and extravasate. At a suitable 
location, the cells undergo mesenchymal to epithelial transition (MET), proliferate and form 
metastases (Engers and Gabbert, 2000; Nicolson, 1988; Orr et al., 2000; Stetler-Stevenson 
et al., 1996). Metastasis accounts for more than 90% of all cancer-related deaths (Siegel et 
al., 2011) and to date no drugs capable of blocking metastasis are available (Bravo-Cordero 
et al., 2012).  
The cytoskeleton is important in normal cell function but it can be subverted in cancer cells 
where it contributes to cell growth, movement and invasiveness. Cell motility plays an 
important role in metastasis as its aberrant regulation drives the progression of cancer 
invasion (Condeelis et al., 2005; Sahai, 2005; Yamaguchi et al., 2005b). The ability of cancer 
cells to form invadopodia is associated with highly invasive and metastatic potentials and 
growing evidence exists that formation of invadopodia is part of the EMT process (Eckert et 
al., 2011; Yilmaz and Christofori, 2009). 
Cell migration and invasion are triggered by a number of chemoattractants, which upon 
binding to surface receptors stimulate intracellular signalling pathways that regulate actin 
cytoskeleton reorganisation. Increased actin polymerisation activity and motility can result 
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from altered signalling pathways in invasive tumour cells (Wang et al., 2004; Wang et al., 
2007b) and many signalling pathways are involved in the regulation of the actin cytoskeleton. 
A critical chemotactic lamellipodia-inducing factor for breast cancer cells for example is 
epidermal growth factor (EGF) and activation of EGF signalling pathways is directly 
correlated with increased invasion, intravasation and metastasis (Xue et al., 2006). 
Downstream of EGF signalling pathways in invasive breast cancer cells, gene expression 
studies revealed an overexpression of components involved in lamellipodia formation such 
as Arp2/3 complex and the LIM-kinase/cofilin pathways (Wang et al., 2004). Arp2/3 complex, 
LIM-kinase/cofilin and cortactin are important proteins that mediate the signalling pathways 
involved in cytoskeleton regulation linked to cell migration and invasion. 
Due to the large number of cellular processes involving the actin cytoskeleton, a fine-tuned 
regulation of the latter is required in order to prevent from disease. 
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1.2 The actin-bundling protein L-plastin 
Three isoforms of plastins have been discovered in mammals: I-plastin, T-plastin and 
L-plastin. The first plastin isoform was discovered in microvilli from chicken intestinal brush 
border (Matsudaira and Burgess, 1979) and it was called fimbrin (from the latin word fimbria, 
meaning “border, fringe”) because it was associated with cell border structures, such as 
membrane ruffles, microvilli, microspikes and focal adhesions. Plastins are conserved and 
expressed in yeast, plant and animal cells. The strong evolutionary conservation of function 
of the plastin gene family can be highlighted by the fact that in yeast with mutations in its 
L-plastin homologue SAC6, human L-plastin and T-plastin can rescue the resulting defects in 
endocytosis (Adams et al., 1995). 
 
Plastin expression is tissue-dependent. I-plastin is specifically expressed in microvilli of the 
small intestine, colon and kidney (Lin et al., 1994) whereas T-plastin is expressed in cells 
derived from solid tissue (Lin et al., 1988). L-plastin expression was first discovered in cells 
of the haematopoietic lineage (Matsushima et al., 1988) and is expressed as one of the most 
abundant proteins in normal, untransformed lymphocytes (Goldstein et al., 1985). Besides, 
L-plastin expression has been found in a great number of cancer cells where it is ectopically 
expressed. A study by Lin and colleagues showed that 68% of epithelial carcinomas and 
53% of non-epithelial mesenchymal tumours express L-plastin (Lin et al., 1993b). 
Furthermore, Park and colleagues discovered that more than 90% of human tumour cell lines 
constitutively express L-plastin at varying degrees (Park et al., 1994). 
 
1.2.1 L-plastin structure 
L-plastin, also called lymphocyte cytosolic protein 1 (LCP1), is a protein with a size of 
approximately 68 kDa as determined by mobility rates in a sodium dodecyl sulfate (SDS)-
polyacrylamide gel (de Arruda et al., 1990; Lin et al., 1988; Lin et al., 1990). The protein 
encompasses 627 amino acids and the description of the complete sequence of L-plastin 
revealed that this protein is organised into headpiece and core domains (de Arruda et al., 
1990). Phosphorylation of L-plastin has been shown to occur specifically within a headpiece 
of 10 kDa (Messier et al., 1993).  
I-, T- and L-plastin genes evolved from a common ancestor as revealed by the analysis of 
the exon-intron junction sequences and share approximately 70% similarity of their amino 
acid sequences (Lin et al., 1993b). Although L-plastin, T-plastin and I-plastin genes have 
evolved from a common ancestral gene, they are now dispersed on chromosome 13 
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(L-plastin), chromosome X (T-plastin) (Lin et al., 1993b) and chromosome 3 (I-plastin) (Lin et 
al., 1994) in human cells. In their N-terminal region the 3 human plastin isoforms contain two 
EF-hands implicated in calcium-binding, followed by 2 tandem actin-binding domains (ABDs), 
each composed of two CH domains (de Arruda et al., 1990) (Figure 1.2.1). An EF hand is a 
helix-turn-helix structural motif that consists of two alpha helices positioned roughly 
perpendicular to one another and linked by a short loop region that often binds calcium ions. 
CH domains are composed of 4 alpha helices of which one is oriented perpendicular to the 
other three which are forming a loose bundle. An isolated CH domain is able to bind to actin, 
but a pair of CH domains is required for a fully functional ABD (Korenbaum and Rivero, 
2002). Plastins fold into a compact, horseshoe-like structure that can simultaneously bind 
two actin filaments and thereby crosslink the filaments into tight bundles (Shinomiya et al., 
2007). For fimbrin of Arabidopsis thaliana it has been shown that the tandem ABDs are 
packed together in an approximately antiparallel arrangement with N- and C-terminal CH 
domains (CH1 and CH4) making direct contact and the same is believed to occur for L-
plastin (Klein et al., 2004; Shinomiya et al., 2007).  
 
 
Figure 1.2.1 L-plastin structure. Human plastins contain two EF-hands implicated in calcium-
binding in their N-terminal region and two tandem actin-binding domains, each composed of 
two calponin homology (CH) domains, in their C-terminal region. Residue serine 5 (Ser5) in 
the N-terminus is an important phosphorylation site involved in L-plastin activation. 
 
L-plastin has been found to undergo co-translational modifications. Methionine removal and 
N-terminal acetylation of the subsequent alanine is reported for L-plastin in the 
UniProtKB/Swiss-Prot database (www.uniprot.org). 
 
1.2.2 L-plastin regulation and function 
As described above, L-plastin belongs to the family of actin crosslinkers and more precisely 
of actin-bundling proteins (Bretscher, 1981; de Arruda et al., 1990). L-plastin has no 
specificity towards different actin isoforms (Lebart et al., 2004). High resolution structural 
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analysis has been used to study the binding of L-plastin to F-actin and to establish a model 
stating that ABD2 of L-plastin initially binds to an actin filament which results in subsequent 
activation of ABD1, which can then bind to a second actin filament resulting in crosslinking of 
two actin filaments into parallel bundles (Galkin et al., 2008). The actin-bundling activity of 
L-plastin is positively regulated by phosphorylation (Janji et al., 2006) and negatively 
regulated by intracellular Ca2+ (Giganti et al., 2005; Namba et al., 1992; Pacaud and 
Derancourt, 1993). Human L-plastin is the only isoform that possesses all the conserved 
amino acids essential for calcium-binding (Delanote et al., 2005b). Significant conformational 
change is induced in the presence of Ca2+ (Shinomiya et al., 2007). As Ser5 is spatially close 
to the EF-hand Ca2+-binding motif of the headpiece domain, it was investigated whether the 
presence of a negatively charged group at amino acid position 5 interfered with the inhibitory 
effect of Ca2+ (Janji et al., 2006). An almost identical decrease in F-actin-bundling was 
observed when non-phosphorylated wild type L-plastin or a Ser5 phosphorylation mimicking 
L-plastin variant were incubated with actin in the presence of increasing concentrations of 
free Ca2+, suggesting that addition of a negative charge in amino acid position 5 does not 
influence Ca2+- dependency of F-actin bundling (Janji et al., 2006). 
Moreover, an interaction of L-plastin with Iba1, a macrophage/microglia-specific protein, was 
shown to increase the actin-bundling activity of L-plastin (Ohsawa et al., 2004). 
Furthermore, the binding of L-plastin to monomeric actin is reduced by increasing amounts of 
phospholipids (Lebart et al., 2004) and recently the binding of L-plastin to actin was shown to 
be reduced following S-glutathionylation of L-plastin in human neutrophils (Dubey et al., 
2015). 
The use of a knockout nanobody in a human prostate cancer cell line suppressed L-plastin 
bundling activity that could not be compensated for by other resident endogenous cross-
linking proteins (Delanote et al., 2010), which highlights an important role for L-plastin in the 
construction and/or rigidity of the cytoskeleton. L-plastin is located in the nucleus and the 
cytoplasm whereas T-plastin localises predominantly to the cytoplasm since it has a more 
conserved nuclear export signal than L-plastin (Delanote et al., 2005a). L-plastin was found 
to localise to actin-rich structures of the cellular cortex, such as focal adhesions, filopodia 
and membrane ruffles which are involved in adhesion, signalling or locomotion (Arpin et al., 
1994; Janji et al., 2006). Besides crosslinking actin filaments, L-plastin also regulates actin 
turnover in vitro and in vivo (Al Tanoury et al., 2010). 
During embryonic mouse development, L-plastin is expressed in the early stages of intestinal 
epithelial cell differentiation and in the visceral endoderm (Chafel et al., 1995). However, 
knockout of L-plastin has no influence on embryonic and neonatal development in 
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L-plastin -/- mice (Chen et al., 2003). In the early stages of intestinal epithelial cell 
differentiation, T- and I-plastin are localised at the apical surface and L-plastin at the basal 
surface which suggests that T- and I-plastin might be involved in the formation and extension 
of microvilli whereas L-plastin appears to play a role in controlling cell adhesion (Delanote et 
al., 2005b). 
Whereas L-plastin expression in tumour cells is ectopic, its expression in leukocytes is 
normal and L-plastin plays a role in the immune response. Wang and colleagues showed 
that L-plastin -/- T cells were defective in proliferation and in T cell receptor-mediated 
cytokine production and demonstrated that L-plastin-dependent actin-bundling facilitates 
formation of lamellipodia and normal immunological synapses and thereby enables T cell 
activation (Wang et al., 2011). Furthermore, it was demonstrated that L-plastin and its 
interaction with the calcium-binding messenger protein calmodulin  are required for the 
maintenance of L-plastin in the immune synapse between T cells and antigen presenting 
cells and for sustained Lymphocyte function-associated antigen 1 (LFA-1) clustering in the 
immunological synapse (Wabnitz et al., 2010). Another study showed an important role for 
L-plastin in the response to chemokines and in T lymphocyte polarity and migration (Freeley 
et al., 2012). Yet another study identified L-plastin as a molecule critical for C-C chemokine 
receptor type 7 (CCR7)-mediated motility in T lymphocytes (Morley et al., 2010). L-plastin 
polarises the chemokine receptor CCR7 and mediates directional migration. Confocal 
imaging showed that upon chemokine stimulation by ligand binding, colocalisation of F-actin 
and CCR7 in the lamellipodium was reduced in L-plastin -/- T cells. Defective migration 
resulted from defective cellular polarisation following CCR7 ligation. This suggests that the 
actin-bundling activity of L-plastin is required for cellular polarisation following CCR7 ligation.  
L-plastin was also shown to be involved in natural killer (NK) cell migration (Serrano-Pertierra 
et al., 2014). 
A certain number of studies point to a role for L-plastin in regulating integrin-mediated 
adhesion in macrophages and polymorphonuclear neutrophils (PMNs) (Correia et al., 1999; 
Jones et al., 1998; Messier et al., 1993; Wang et al., 2001). However, another study reported 
normal adhesion in PMNs isolated from an L-plastin knockout mouse (Chen et al., 2003). 
These cells also showed normal morphology, spreading, migration and phagocytosis but 
they had a defect in generating an adhesion-dependent respiratory burst in response to a 
variety of integrin ligands which was responsible for their inability to kill Staphylococcus 
aureus (Chen et al., 2003). Furthermore, spleen tyrosine kinase (Syk) and paxillin 
phosphorylation were abnormal in L-plastin -/- PMNs (Chen et al., 2003). 
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L-plastin is also involved in alveolar macrophage production which is required for combating 
pneumococcal infections (Deady et al., 2014). 
In osteoclasts L-plastin is an integral component of the actin-core of podosomes (Babb et al., 
1997). Here L-plastin contributes to sealing ring formation and bone resorption by inducing 
the formation of actin aggregates, functioning as a core in the recruitment of signalling 
molecules such as Src kinase, cortactin and integrin αvβ3 (Ma et al., 2010). This suggests 
that L-plastin may act as a scaffolding protein. 
 
1.2.3 L-plastin phosphorylation and protein phosphorylation in general 
Protein phosphorylation is the most widespread type of post-translational modification used 
in signal transduction. It plays a key regulatory role in nearly every aspect of eukaryotic cell 
biology and is a reversible and dynamic process that is mediated by protein kinases and 
phosphatases. These enzymes catalyse the transfer of phosphate between their substrates 
(Figure 1.2.3.1). Protein kinases catalyse the transfer of γ-phosphate from ATP (or GTP) to 
their protein substrates (protein-OH + MgATP- → protein-OPO32- + MgADP + H+) while 
protein phosphatases catalyse the transfer of the phosphate from a phosphoprotein to a 
water molecule (Protein-OPO32- + H2O → protein-OH + HOPO32-). Based upon the nature of 
the phosphorylated –OH group, protein kinases are classified as serine/threonine (Ser/Thr) 
protein kinases or tyrosine (Tyr) protein kinases. Phylogenetic comparisons show that plants 
have relatively few tyrosine kinases and that unicellular organisms completely lack tyrosine 
kinases (Johnson, 2009). In eukaryotes, protein kinase genes constitute about 2% of 
genomes and phosphorylate more than 30% of the cellular proteins (Cohen, 2000; Pinna and 
Ruzzene, 1996). 
Protein phosphorylation provides a control mechanism for various signalling processes and 
regulates protein functions by inducing conformational changes or by disruption and creation 
of protein-protein interaction surfaces (Holt and Corey, 2000; Serber and Ferrell, 2007).  
The first 3D structure of a protein kinase was determined for protein kinase A by X-ray 
crystallography and revealed the basic bilobal scaffold structure that has now been observed 
in all protein kinases as shown below for CDK2 (Figure 1.2.3.2). The catalytic domain of 
protein kinases is about 250 amino acids long and consists of a small N-terminal lobe of 
β-sheets and a larger C-terminal lobe of α-helices (Ubersax and Ferrell, 2007). ATP binds in 
a cleft between the two lobes with the phosphate oriented outwards and the protein substrate 
binds along the cleft. 
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Figure 1.2.3.1 Catalytic cycle for substrate phosphorylation by a kinase. Starting top left: The 
active site of the kinase binds ATP and the substrate. Once bound, the γ-phosphate of ATP 
(red) is transferred to a Ser, Thr or Tyr residue of the substrate. After phosphorylation, the 
substrate and ADP are released from the kinase active site. Different kinases have varying 
orders for the binding or the release of the substrate or ATP/ADP respectively. Adapted from 
(Ubersax and Ferrell, 2007). 
 
 
 
Figure 1.2.3.2 Basic protein fold of the catalytic domain of protein kinases. The protein fold 
of protein kinases comprises two lobes: an N-terminal lobe consisting of mainly β-sheets 
(blue) and a C-terminal lobe consisting of α-helices (green, orange and yellow). This lobe 
structure forms an ATP-binding cleft that constitutes the active site. The crystal structure of 
cyclin-dependent kinase-2 (CDK2) (Protein Data Bank (PDB) ID: 1QMZ) shows this 
representative fold. ATP is modelled bound in the cleft (red). Adapted from (Ubersax and 
Ferrell, 2007). 
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The common catalytic scaffold shared by the eukaryotic protein kinases switches between 
two extreme conformations for the “on” and the “off” states corresponding to high and low 
activity of the protein kinases. The transition from one state to the other can be mediated by 
a variety of strategies in different kinases such as through phosphorylation, interactions of 
additional domains within the protein kinase and/or binding to other regulatory proteins (Huse 
and Kuriyan, 2002). 
A protein kinase must recognise between one and a few hundred phosphorylation sites in a 
background of about 700 000 potentially phosphorylatable residues that they might 
encounter (Ubersax and Ferrell, 2007). Multiple mechanisms exist to confer exquisite 
specificity. The first level of substrate specificity arises from structural characteristics of the 
kinase active site, its depth and charge or hydrophobicity, which will match with 
complementary characteristics of its substrates. Tyrosine kinases for example have a deeper 
catalytic cleft than Ser/Thr kinases (Brown et al., 1999; Hubbard, 1997). However, the 
specificity linked to the cleft depth is not absolute as several Ser/Thr kinases can 
phosphorylate Tyr residues (Zhu et al., 2000). A Tyr kinase that phosphorylates Ser or Thr 
residues appears to be rarer. The next level of substrate specificity is guaranteed by 
consensus sequences: the active site of the kinase usually interacts with four amino acids on 
either side of the phosphorylation site and the nature of these contributes substantially to 
kinase-substrate recognition. A next level includes distal interactions between docking motifs 
on the substrate and interaction domains on the kinases (Biondi and Nebreda, 2003; Holland 
and Cooper, 1999). These binding motifs are usually spatially separated from the kinase 
active site and the substrate phosphorylation site and increase the affinity of kinases for 
specific substrates. Another level of control is the “priming” of substrates which means that 
they have to be phosphorylated on a specific residue before they can become 
phosphorylated on another target residue. Priming makes the phosphorylation dependent on 
the activity of both the priming kinase and the ultimate kinase and it allows for a regulation in 
time. A further level of control is the subcellular localisation of kinases and substrates. 
Another important control of protein phosphorylation is mediated by scaffolds: sometimes the 
interaction between a protein kinase and its substrate occurs through the intermediary of 
adaptors or scaffolds, which act as organising platforms that recruit the kinase and the 
substrate to the same complex (Bhattacharyya et al., 2006; Pawson and Scott, 1997). Yet 
another mechanism for regulating phosphorylation is linked to organism-level. As opposed to 
in vitro where the interaction between a single kinase and a single substrate can be studied, 
in a cell the substrates of kinases are present in a mix of thousands of non-target proteins. A 
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kinase will have more than one substrate in vivo and each substrate can act as a competitive 
inhibitor for other substrates. 
 
Protein kinases have become high-profile targets for drug development. Protein kinase 
inhibitors often target the ATP-binding site on the kinase. They can target active or inactive 
conformations of kinases. As kinases converge to a similar conformation in the active state, 
targeting this state often results in a less specific inhibition. However, targeting the active 
conformation is advantageous when the disease state has arisen from activating mutations 
which inappropriately maintain the protein kinases in an active state (Johnson, 2009). 
 
Our protein of interest, human L-plastin, is the only plastin isoform that has been shown to be 
phosphorylated upon response to diverse stimuli (Henning et al., 1994; Jones and Brown, 
1996; Matsushima et al., 1987; Shibata et al., 1993; Shiroo and Matsushima, 1990). Initially, 
phosphorylation of L-plastin has been shown to occur specifically within a headpiece of 10 
kDa (Messier et al., 1993) and residues serine 5 (Ser5) and serine 7 (Ser7), both amino-
terminally located, were revealed as the phosphorylation sites in haematopoietic cells 
(Shinomiya et al., 1995). A bit later it was shown that the presence of Ser5 is required for 
L-plastin phosphorylation in HeLa cells, but it was not ruled out that Ser7 might also be 
phosphorylated, with a requirement for Ser5 to achieve Ser7 phosphorylation (Jones et al., 
1998).  In non-haematopoietic cells, L-plastin was thought to be only phosphorylated on Ser5 
(Lin et al., 1998; Messier et al., 1993; Shinomiya et al., 1995). More recent studies using 
proteomic discovery-mode MS revealed many more phosphorylation sites. L-plastin has 
been shown to be subject to multiple post-translational modifications as shown by a search 
on the PhosphoSitePlus® website (http://www.phosphosite.org/homeAction.do) (Figure 
1.2.3.3). These include phosphorylations of serine, threonine and tyrosine residues as well 
as other post-translational modifications, such as acetylation or ubiquitination. However, the 
phosphorylation of Ser5 is the only post-translational modification that was found not only by 
proteomic discovery-mode mass spectrometry (MS) but also by site specific methods (such 
as amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies 
and specific MS strategies) (Figure 1.2.3.3). Ser5 is also the only phosphorylation site that 
was described to influence L-plastin activity in many studies (Al Tanoury et al., 2010; Janji et 
al., 2006; Janji et al., 2010; Klemke et al., 2007; Riplinger et al., 2014). 
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Figure 1.2.3.3 Post-translational modification sites of human L-plastin. A) L-plastin post-
translational modification sites have been found in nearly all parts of the protein. B) L-plastin 
post-translational modification sites revealed by site-specific methods including amino acid 
sequencing, site-directed mutagenesis, modification site-specific antibodies and specific MS 
strategies (S.Sp.) or by proteomic discovery-mode mass spectrometry only (M.S.). (p – 
phosphorylation, ac – acetylation, ub – ubiquitination) Results obtained by 
PhosphoSitePlus® (http://www.phosphosite.org/homeAction.do).  
 
L-plastin activity has been shown to be increased following phosphorylation on residue Ser5 
in vitro and in vivo. Notably, the F-actin-binding and –bundling activities of L-plastin are 
increased upon Ser5 phosphorylation and this phosphorylation is required for efficient 
targeting of L-plastin to focal adhesions (Janji et al., 2006). 
In leukocytes where L-plastin is normally expressed, phosphorylation of L-plastin is part of 
the cellular response to inflammation (Jones and Brown, 1996; Matsushima et al., 1987) and 
is involved in the regulation of leukocyte integrin-mediated adhesion (Jones et al., 1998). In 
addition, L-plastin is serine-phosphorylated after stimulation of leukocytes by inflammatory 
cytokines (including IL-8 and TNF), phorbol 12-myristate 13-acetate (PMA), and chemotactic 
peptides, all of which also induce an increase in actin polymerisation (Shibata et al., 1993; 
Shiroo and Matsushima, 1990). Furthermore, Messier and colleagues showed that in 
adherent macrophages stimulated with PMA, the majority of phosphorylated L-plastin 
associates with the cytoskeleton (Messier et al., 1993). Thus, L-plastin serine 
phosphorylation was proposed to be a mechanism to link signal transduction to cytoskeletal 
function. 
Most interestingly, recent findings have demonstrated that L-plastin Ser5 phosphorylation is 
crucial for in vitro invasion and in vivo metastasis formation (Janji et al., 2006; Klemke et al., 
2007; Riplinger et al., 2014). 
So far, only protein kinase A (PKA) has been reported to directly phosphorylate L-plastin in 
vitro (Janji et al., 2006; Wang and Brown, 1999). Other kinases such as protein kinase C 
(PKC) delta, catalytic domain of PKC, casein kinase II, Pak1, protein kinase B, mitogen-
activated protein kinase-activated protein kinase (MAPKAPK) 2, MAPKAPK3 and p38-
regulated/activated protein kinase failed to phosphorylate L-plastin in vitro (Jones et al., 
1998; Wang and Brown, 1999). In cells, distinct protein kinases have been reported to be 
involved in triggering L-plastin phosphorylation depending on the cell type and environment. 
Most frequent are reports of the involvement of PKA (Janji et al., 2006; Matsushima et al., 
1987; Wang and Brown, 1999) and PKC (Al Tanoury et al., 2010; Freeley et al., 2012; Janji 
et al., 2010; Jones et al., 1998; Lin et al., 1998; Paclet et al., 2004; Pazdrak et al., 2011). 
Phosphoinositide-3-kinase (PI3K) has also been reported to play a role in L-plastin 
phosphorylation in human neutrophils (Jones et al., 1998; Paclet et al., 2004), but not in T 
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lymphocytes (Freeley et al., 2012). Nevertheless, the detailed signalling pathway(s) leading 
to L-plastin Ser5 phosphorylation remain(s) to be resolved. 
 
1.2.4 L-plastin interaction partners 
Besides binding to actin, L-plastin also binds a few other proteins. L-plastin has been shown 
to form a complex with cortactin in MCF7 cells (Al Tanoury et al., 2010). Cortactin is a major 
substrate of Src kinase and a regulator of actin dynamics by Rho-GTPases (Lai et al., 2009; 
Wu et al., 1991). It is an actin filament-binding protein that connects signalling pathways to 
cytoskeleton restructuring (Lai et al., 2009). It is found in lamellipodia, invadopodia, 
podosomes and at intercellular contact sites (El Sayegh et al., 2004; Linder and 
Aepfelbacher, 2003). Cortactin’s regulation of cortical actin dynamics depends on its direct 
association with additional actin-associated proteins (reviewed in (Ammer and Weed, 2008)). 
Cortactin is activated by phosphorylation and can then recruit Arp2/3 complex proteins to 
existing actin microfilaments. Cortactin interacts with Arp2/3 and F-actin and stabilises 
nucleation sites both for branching and for formed branches.  
L-plastin has also been shown to interact with grancalcin and this interaction is negatively 
regulated by Ca2+ (Lollike et al., 2001). Grancalcin is a calcium-binding protein that may play 
a role in the adhesion of neutrophils to fibronectin and in the formation of focal adhesions. 
A yeast two-hybrid screen has revealed an interaction of L-plastin with the 
macrophage/microglia-specific calcium-binding and actin-bundling protein Iba1 (Ohsawa et 
al., 2004). Both proteins were shown to colocalise with F-actin in membrane ruffles and 
phagocytic cups in the microglial cell line MG5 (Ohsawa et al., 2004). The interaction is 
independent of Ca2+ and Iba1 was shown to increase the actin-bundling activity of L-plastin 
(Ohsawa et al., 2004). 
L-plastin was also shown to bind Hsp70 in macrophages (Correia et al., 1999) and 
calmodulin in T cells which was required for the maintenance of L-plastin in the immune 
synapse between T cells and antigen presenting cells (Wabnitz et al., 2010). 
In adherent macrophages, L-plastin binds the intermediate filament protein vimentin (Correia 
et al., 1999). Both proteins colocalise in podosomes, filopodia and retraction fibers. Vimentin 
binds L-plastin with its N-terminal domain and the vimentin-binding site localises to the first 
CH domain of L-plastin.  
L-plastin can bind to the cytoplasmic portion of integrin subunits β1 and β2 through its actin-
binding domains and these interactions are inhibited following μ-calpain activity (Le Goff et 
al., 2010). Despite the ability of calpain to cleave both proteins, only the cleavage of β 
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integrin hinders the formation of the L-plastin/integrin complex (Le Goff et al., 2010). Brown 
and colleagues suggest that in PMNs and in K562 lymphoblasts L-plastin peptides activate 
integrin αMβ2 (Jones et al., 1998) and αvβ3 (Wang et al., 2001). 
Additionally, coimmunoprecipitation studies demonstrated a complex formation of 
phosphorylated L-plastin with protein kinase CβII, GM-CSF receptor α-chain, and two actin-
associated proteins, paxillin and cofilin (Pazdrak et al., 2011). 
 
1.2.5 L-plastin and cancer 
The ectopic expression of L-plastin has been observed in various cancer cells (Ang and 
Nice, 2010; Chaijan et al., 2014; Galiegue-Zouitina et al., 1999; Kim et al., 2010; Klemke et 
al., 2007; Lapillonne et al., 2000; Leavitt, 1994; Li and Zhao, 2011; Li et al., 2009; Lin et al., 
1988; Lin et al., 1993a; Lin et al., 2000; Lin et al., 1993b; Otsuka et al., 2001; Park et al., 
1994; Yuan et al., 2010; Zheng et al., 1997). Since L-plastin is normally expressed in 
immune cells required to quickly translocate to sites of infection, the ectopic expression of 
L-plastin in cancer cells may confer these cells with the ability to invade other parts of the 
body during metastasis. In accordance with this, it was shown that in carcinoma cells, similar 
as in haematopoietic cells, L-plastin localises to actin-rich structures of the cellular cortex 
involved in locomotion, adhesion or signalling, including focal adhesions, podosomes, 
filopodia and membrane ruffles (Arpin et al., 1994; De Clercq et al., 2013a; Janji et al., 2006). 
L-plastin has been proposed as a biomarker for several human cancers: colorectal cancer 
(Ang and Nice, 2010), ovarian cancer (Kang et al., 2010), renal cell carcinoma (Kim et al., 
2010), melanoma (Strickler et al., 2014), urinary bladder cancer (Harris et al., 2008) and 
choroid plexus tumours (Hasselblatt et al., 2006).  
Lin and colleagues showed that L-plastin was one of the most abundant polypeptides in the 
majority of tumour cell lines in which its expression was detected (Lin et al., 1993b). 
Moreover, using a microarray chip specific to actin-related genes, our team showed that 
L-plastin is among the most significantly upregulated genes among actin-related genes in the 
invasive breast cancer cell line 1001 as compared to the non-invasive parental MCF-7 cell 
line (Janji et al., 2010). Furthermore, 1001 cells are resistant to TNFα cell death signals 
whereas the parental MCF-7 cells are sensitive to TNFα cytotoxicity (Cai et al., 1997; Janji et 
al., 2010). A former member of our group showed that TNFα resistance of 1001 cells was 
dependent on L-plastin phosphorylation on Ser5 (Janji et al., 2010). 
Moreover, L-plastin is overexpressed in ovarian cancer interface zones corresponding to the 
invasive front between tumours and normal tissues (Kang et al., 2010) and it was shown that 
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L-plastin expression was responsible for increased invasion of the cholangiocarcinoma cell 
line RMCCA1 upon cultivation in matrigel (Chaijan et al., 2014). Furthermore, the expression 
of an L-plastin nanobody which reduced the bundling ability of L-plastin also inhibited 
filopodia formation, motility, and invasion of PC-3 prostate cancer cells (Delanote et al., 
2010). Nanobodies are the smallest functional fragment of a naturally occurring single chain 
antibody which can be used to target a protein domain to inhibit a particular function. 
Interestingly however, L-plastin down-regulation showed no significant effect on filopodia 
extension and a less pronounced effect on motility as compared to nanobody expression 
(Delanote et al., 2010). 
The strong 5,1 kb L-plastin gene promoter contains a classic TATA box and control elements 
which are involved in its suppression in normal non-haematopoietic cells and in its activation 
in human tumour cells (Lin et al., 1993a). The L-plastin promoter harbours hormone receptor-
responsive elements: one estrogen-responsive element and three imperfect androgen-
responsive elements (Lin et al., 1993a; Lin et al., 2000). This might explain why in some 
tumour cells of the steroid-regulated female reproductive tract such as breast, ovary, uterus 
and placenta, the frequency of L-plastin induction seems to be especially high (Lin et al., 
1993b). In addition, a further study demonstrated that L-plastin expression in a prostate 
cancer cell line is up-regulated by both dihydrotestosterone and estradiol (Zheng et al., 
1997). However, another study states that L-plastin expression is hormone-independent 
during malignancy (Leavitt, 1994). 
One study shows that nasopharyngeal tumours with down-regulated L-plastin tend to have a 
more advanced clinical stage and a poorer differentiation than tumours with higher levels of 
L-plastin (Li et al., 2009). However, several other studies rather indicate a positive correlation 
between L-plastin expression and tumour progression (Foran et al., 2006; Harris et al., 2008; 
Kim et al., 2010; Otsuka et al., 2001; Zheng et al., 1999). Notably, for colorectal cancer a 
correlation between L-plastin expression and tumor stages was observed (Otsuka et al., 
2001) and for prostate carcinoma cells it was reported that L-plastin downregulation 
decreased proliferation, migration and invasion rates (Zheng et al., 1999). In the metastatic 
colon cancer cell line SW620 L-plastin is upregulated as compared to its premetastatic 
counterpart SW480 and overexpression of L-plastin in SW480 leads to higher rates in 
proliferation and invasion and to loss of E-cadherin protein expression (Foran et al., 2006). 
E-cadherin is an epithelium-specific tumour suppressor gene whose loss of expression is 
directly associated with increased proliferation and invasion (Behrens et al., 1991). In renal 
cell carcinoma L-plastin was upregulated and proposed as candidate biomarker (Kim et al., 
2010) and for urinary bladder cancer a correlation was described between the expression of 
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L-plastin and clinically important pathologic features such as tumour grade, stage, and 
growth pattern (Harris et al., 2008). 
Surprisingly, no clear correlation between L-plastin expression and tumour stage was found 
in other cancer types (Lapillonne et al., 2000 & Klemke et al., 2007). Lapillonne and 
colleagues detected L-plastin expression in malignant epithelial cells of the mammary gland 
in around 14% of the breast carcinoma tumours analysed whereas no L-plastin expression 
could be detected in untransformed epithelial cells (Lapillonne et al., 2000). However, they 
found that in breast cancer the expression of L-plastin does not relate to tumour size, 
histological grade and lymph node status (Lapillonne et al., 2000). It has to be noted that this 
study by Lapillonne and colleagues (Lapillonne et al., 2000) is based on only 29 breast 
tumour samples. In contrast to Lapillonne’s findings, a study by Schulz and colleagues 
(Schulz et al., 2009) identified L-plastin to be 1.43-fold upregulated in triple-negative (HER2-, 
ER-, PR-) as compared to HER2+, ER-, PR- breast cancers. As in the literature it is so far 
not clear whether L-plastin expression is linked to tumour progression in breast cancer, we 
performed survival curves with the Kaplan Meier plotter tool (www.kmplot.com) (Gyorffy et 
al., 2010). The results indicate that L-plastin expression is not an optimal biomarker for 
breast cancer prognosis as no significant survival differences were obtained for patients with 
high versus low L-plastin expression for overall survival, relapse-free survival and distant 
metastasis-free survival (the survival curves can be found in the appendix). Overall, the level 
of L-plastin expression does thus not seem to be linked to breast cancer stage and outcome. 
Concerning melanoma, Klemke and colleagues (Klemke et al., 2007) found that even though 
knockdown of endogenous L-plastin by siRNA treatment reduced haptotactic migration of the 
melanoma cell line IF6, in melanoma patients, L-plastin expression was not significantly 
higher in tumours with bad prognosis compared to tumours with good prognosis. The fact 
that no correlation existed between L-plastin expression and the penetration depths or 
tumour stages of the malignant melanomas implied that additional factors such as 
phosphorylation of L-plastin may influence its function in tumour cells. Indeed, invasion into 
matrigel was up to three-fold increased for melanoma cells expressing the phosphorylatable 
wild type L-plastin as compared to cells expressing a non-phosphorylatable L-plastin mutant 
or a transfection-control protein (Klemke et al., 2007). In contrast to invasion, haptotactic 
migration of human melanoma cells was similarly enhanced for wild type and non-
phosphorylatable L-plastin-expressing cells compared to transfection-control protein 
expressing cells and migration was thus independent of the L-plastin phosphorylation state 
(Klemke et al., 2007). Klemke and colleagues also analysed the well-established mouse 
melanoma model of two isogenic variants of the mouse melanoma cell line B16 with different 
metastatic capabilities. In line with the invasion-related previous findings, they revealed that 
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the highly metastatic B16F10 cells expressed higher amounts of L-plastin than the low 
metastatic B16F1 cells. Furthermore, only the highly metastatic cells contained substantial 
amounts of phosphorylated L-plastin. Therefore, endogenous expression of phosphorylated 
L-plastin correlates with enhanced in vivo metastasis in the mouse B16F1/B16F10 
melanoma model. Interestingly, these data indicate that an increase in melanoma cell 
invasion and metastasis potential might require not only expression but also phosphorylation 
of L-plastin. 
More recently, the same group also found that knockdown of endogenous L-plastin in human 
prostate carcinoma cells led to reduced tumor cell growth and metastasis and more 
importantly that L-plastin Ser5 phosphorylation was involved in in vivo metastasis formation 
in melanoma (Riplinger et al., 2014). L-plastin wild type was ectopically expressed and 
spontaneously phosphorylated in melanoma MV3 cells which were then intracardially 
injected in mice. This led to an increase in the number of metastases as compared to mice 
that were injected with MV3 cells lacking L-plastin. No increase in the number of metastases 
was observed for mice injected with MV3 cells expressing a non-phosphorylatable L-plastin 
mutant (Riplinger et al., 2014).  
Similarly to what Klemke et al. showed for melanoma cells, it was also found that a decrease 
in L-plastin Ser5 phosphorylation inhibits invasion of HEK293T cells whereas the 
phosphorylation state of L-plastin was not important for migration (Janji et al., 2006). 
Taken together, these findings indicate that L-plastin expression alone might not be sufficient 
but that Ser5 phosphorylation of L-plastin may be additionally required for endowing cancer 
cells with aggressive properties. 
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1.3 Deregulation of signalling pathways in cancer 
The human body consists of a wide variety of cell types that must be able to communicate 
with each other and to respond to their environment in a process called signal transduction. 
The sensing of stimuli such as growth factors, cytokines, hormones, cell-ECM contact and 
cell-to-cell contacts occurs by the corresponding receptors including transmembrane 
receptors such as G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) 
and integrins as well as intracellular receptors such as the nuclear steroid hormone 
receptors. Following ligand binding, these receptors trigger a biochemical chain of events 
inside the cell. The most common route of transducing signals is phosphorylation and 
dephosphorylation of signalling molecules by protein kinases and phosphatases. Common 
signal transduction pathways include the extracellular signal-regulated kinase/mitogen-
activated protein kinase (ERK/MAPK), the PI3K, the phospholipase C gamma/protein kinase 
C (PLCγ/PKC), the cAMP-dependent as well as the Janus kinase and signal transducer and 
activator of transcription (JAK/STAT) pathways. Depending on the cell type, the induced 
response alters the cellular metabolism, shape, gene expression, or ability to divide. Signal 
transduction pathways can thus govern various cellular functions such as proliferation, 
differentiation, growth and division, cell death and cell motility. 
Biochemical signals can be amplified at any step so that one receptor or signalling molecule 
can cause many responses. Moreover, a large number of regulatory mechanisms occur to 
modulate signal transduction processes. These include dephosphorylation by phosphatases, 
proteasomal degradation following ubiquitination and the formation of inactive protein 
complexes. Besides, multiple crosstalk interactions between intracellular signalling pathways 
occur and can fine-tune signals or compensate for disturbed canonical pathways (Mendoza 
et al., 2011). 
Signal transduction pathways are crucial for regulating various biological processes and a 
large number of diseases are attributed to their deregulation. For example, mammalian cells 
require stimulation for cell division and survival and in the absence of such stimuli they 
undergo apoptosis. Thus, requirements for extracellular stimulation are necessary for 
controlling cell behaviour and perturbations in signal transduction due to mutation or 
overexpression of receptors or key signalling molecules can lead to pathological phenotypes 
of the cells. 
Cancer is driven by genetic and epigenetic alterations leading to changes in cell growth and 
division, cell survival, cell fate and cell motility. As all of these events are controlled by 
signalling pathways and the deregulation of signal transduction cascades is an important 
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trigger of many cancers (Sever and Brugge, 2015). An examination of the ERK/MAPK 
pathway illustrates how deregulated signalling can lead to the development of cancer. 
 
1.3.1 ERK/MAPK pathway activation and activity 
The conventional MAPK family consists of four major subfamilies of related proteins, 
ERK1/2, p38 MAPK (α,β,γ,δ), JNK (1,2,3) MAPK, ERK5, that are interconnected by signal 
transduction cascades activated by external stimuli, such as growth factors, stress, cytokines 
and inflammation. Each group of conventional MAPKs is composed of three evolutionarily 
conserved, sequentially acting kinases: a MAPK, a MAPK kinase (MAPKK) and a MAPKK 
kinase (MAPKKK) (Figure 1.3.1). In response to extracellular stimuli, a small GTP-binding 
protein of the Ras/Rho family interacts with and activates a MAPKKK. MAPKKK then leads to 
the phosphorylation of a MAPKK which then phosphorylates a MAPK by dual 
phosphorylation on Threonine and Tyrosine residues in the activation loop. Scaffolding 
proteins can simultaneously bind several components of the MAPK cascade and thereby 
mediate specificity and organise pathways in specific modules. 
A wide range of functions are regulated by the MAPKs through phosphorylation of several 
substrates including members of the MAPK-activated protein kinase (MAPKAPK) family. This 
family is composed of RSKs, MSKs, MNKs, MK2/3 and MK5 (Figure 1.3.1). 
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Figure 1.3.1 MAPK signalling cascade. External stimuli such as mitogens, cytokines and 
cellular stress factors can lead to the activation of diverse MAPKKKs in turn leading to 
activation of diverse MAPKKs and finally to activation of MAPKs. The latter can extend the 
MAPK phosphorylation cascade by phosphorylating MAPKAPKs. Dotted lines indicate 
interactions that need further demonstration. γ and δ isoforms of p38 are in brackets as these 
have not been shown to promote MAPKAPK activation. Adapted from (Cargnello and Roux, 
2011). 
 
This dissertation will focus on the ERK1/2 module. ERK1 was the first mammalian MAPK to 
be cloned and characterised. ERK1 and ERK2 share 83% amino acid identity and are 
expressed ubiquitously. The ERK1/2 module is activated by growth factors (epidermal growth 
factor, platelet-derived growth factor and nerve growth factor), insulin, ligands for GPCRs, 
cytokines, osmotic stress and microtubule disorganisation (Raman et al., 2007). The MAPKs 
ERK1 and ERK2 are activated by the MAPKKs MEK1 and MEK2 which are activated by the 
MAPKKKs A-Raf, B-Raf and Raf-1. ERK1 and ERK2 activations occur following cell surface 
receptor activation upon ligand binding and receptor dimerisation. The phosphorylated 
intracellular domains of the receptor can bind proteins containing Src homology 2 (SH2) or 
phosphotyrosine-binding (PTB) domains such as the adaptor proteins Shc and the growth 
factor receptor-bound protein 2 (Grb2). The guanine nucleotide exchange factor SOS is 
recruited to the plasma membrane by binding Grb2 and it activates Ras which in turn 
sequentially activates the MAPKKKs, the MAPKKs and the MAPKs. In resting cells, ERK1 
and ERK2 are localised in the cytoplasm. Upon activation however, a significant proportion 
accumulates in the nucleus (Chen et al., 1992; Lenormand et al., 1993). ERK1 and ERK2 
phosphorylate numerous substrates (reviewed in (Yoon and Seger, 2006)) located in the 
cytoplasm, the nucleus and at the membranes or the cytoskeleton. 
ERK1 and ERK2 mainly control cell proliferation. Sustained activation of these kinases is 
required for progression from G1 to S phase. ERK1/2 activate the transcription factor Elk-1 
which is involved in expression of immediate early genes such as c-Fos (Gille et al., 1995). 
ERK1/2 extends the MAPK cascade by phosphorylating the MAPKAPKs p90 ribosomal S6 
kinases (RSKs), mitogen- and stress-activated kinases (MSKs) and MAPK-interacting 
kinases (MNKs) (Figure 1.3.1).  
 
Of particular importance for our work were RSK kinases. The human RSK family is a group 
of highly conserved Ser/Thr kinases which contains 4 isoforms, RSKs 1-4, that are 80% 
identical. The RSK family is unique because their isoforms all contain 2 kinase domains: the 
carboxyl-terminal kinase domain (CTKD), which is activated by ERK1/2, subsequently 
activates the amino-terminal kinase domain (NTKD) by autophosphorylation which can then 
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phosphorylate substrates. Only the NTKD has been shown to be involved in substrate 
phosphorylation. The CTKD belongs to the Ca2+/calmodulin-dependent protein kinase 
(CAMK) family and the NTKD belongs to the AGC family of kinases. RSK 1-3 are expressed 
ubiquitously whereas RSK4 has a much lower and more restricted expression. RSK4 is 
found mainly in the cytoplasm and does not translocate to the nucleus upon stimulation 
(Dummler et al., 2005). On the other hand, RSK 1-3 are found in the cytoplasm in resting 
cells and, upon stimulation, a significant proportion translocates to the nucleus (Chen et al., 
1992; Lenormand et al., 1993; Richards et al., 2001; Vaidyanathan and Ramos, 2003; Zhao 
et al., 1995). RSK1 was shown to accumulate at the plasma membrane within minutes upon 
stimulation, where it may receive activating inputs before nuclear translocation (Richards et 
al., 2001).  
Different phosphorylation events are important for the activation of RSK (Figure 1.3.2). Upon 
stimulation, ERK1/2 docks at the C-terminus of RSK and phosphorylates Thr573 in the 
activation loop of the CTKD (Ranganathan et al., 2006; Shaul and Seger, 2006; Smith et al., 
1999) and might also phosphorylate Thr359/Ser363 in the linker region (Dalby et al., 1998). 
The activated CTKD autophosphorylates RSK at Ser380 which allows access of PDK1 to 
RSK (Frodin and Gammeltoft, 1999) which is required for stimulation of RSK 1-3. RSK4 does 
not seem to require PDK1 to be fully active and it is fully phosphorylated and activated in 
unstimulated cells (Dummler et al., 2005). PDK1 phosphorylates Ser221 in the activation 
loop of the NTKD (Richards et al., 1999) leading to the full activation of the protein and 
subsequent substrate phosphorylation (Anjum and Blenis, 2008). The NTKD can then 
phosphorylate Ser749 which in some cases results in dissociation of ERK1/2 from RSK.  
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Figure 1.3.2 Current model of RSK activation. RSK activation relies on several 
phosphorylation events with a final phosphorylation step by PDK1 leading to RSK substrate 
phosphorylation. Adapted from (Anjum and Blenis, 2008). 
 
The RSK1 consensus sequence for substrate phosphorylation is Arg/Lys-X-Arg-X-X-
pSer/Thr or Arg-Arg-X-pSer/Thr (Leighton et al., 1995). RSK1 has a five-fold preference for 
phosphorylating Ser than Thr residues and indeed most of the so far identified RSK 
substrates are phosphorylated on Ser residues. The identification of RSK substrates 
indicates roles for RSK in gene transcription, nuclear signalling, cell cycle progression, cell 
proliferation, cell growth, protein synthesis, cell survival and cell motility. Although most 
studies have not determined isoform specificity, most substrates have been identified for 
RSK2 as compared to the other isoforms. However, many known substrates for RSK2 may 
be shared by different RSK family members. 
 
In physiological conditions, MAPK signalling is activated in a controlled manner in response 
to environmental stimuli and leads to a controlled response. MAPK signalling is involved in 
cell proliferation, differentiation, survival and death. In pathological conditions in contrast, 
deregulation of MAPK signalling can lead to aberrant cellular responses resulting in various 
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diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis 
(ALS) and various types of cancers (Kim and Choi, 2010). 
Various tumours and tumour cell lines display constitutive activation of the MAPK pathway 
and approximately 30% of all human cancers contain a constitutively-activating mutation in 
one of the ras oncogenes (Bos, 1989). K-Ras is frequently mutated in many human cancers 
including lung and colon cancer (Schubbert et al., 2007). Mutations in B-Raf are responsible 
for approximately 66% of melanomas (Halilovic and Solit, 2008). Also ERK1/2 was identified 
as a crucial contributor to the pathogenesis of cancer (Land et al., 1983) and many tumour 
cell lines show high levels of activated ERK1/2 (Hoshino et al., 1999). Moreover, hyperactive 
RSK signalling is found in several human cancers and RSKs are overexpressed in 
approximately 50% of human breast cancer tissues (Smith et al., 2005). However, RSK 
function is dependent on the RSK isoform as well as on the specific type of cancer.  
Since the ERK/MAPK signal transduction cascade is activated upon epidermal growth factor 
receptor (EGFR) stimulation and since the overexpression of RTKs plays a role in cancer 
development and progression, the next section of this dissertation will focus on the EGFR 
family upregulation in cancer. 
 
1.3.2 EGFR signalling in breast cancer 
The EGFR (also called ErbB1 or HER1) belongs to the ErbB receptor family which also 
contains ErbB2 (or HER2 or HER2/neu), ErbB3 (or HER3) and ErbB4 (or HER4). Seven 
ligands are known for the EGFR: EGF, transforming growth factor α (TGF-α), amphiregulin 
(AR), epigen (EGN), epiregulin (EPR), β-cellulin (BC) and heparin-binding EGF-like growth 
factor (HBEGF). ErbB2 has no known ligands, ErbB3 binds neuregulins (NRGs) 1 and 2 and 
ErbB4 binds NRGs 1-4, EPR, BC and HBEGF (Figure 1.3.2). All ligands exist as membrane-
anchored precursors and are released as soluble factors upon cleavage by 
metalloproteases. Ligand binding induces a dramatic conformational change that exposes a 
dimerisation arm which induces the extracellular region of the ErbB receptor to dimerise 
(Burgess et al., 2003). For most RTKs, ligand-mediated receptor dimerisation is thought to 
position the two cytoplasmic tyrosine kinase domains for efficient trans-phosphorylation of 
tyrosine residues in the kinase activation loop. For ErbB family receptor activation however, 
such trans-phosphorylation is not required. Instead, following ligand-mediated dimerisation of 
the ErbB receptors, the two receptor kinase domains form an asymmetric dimer in which one 
kinase activates the other allosterically (Jura et al., 2009; Red Brewer et al., 2009; Zhang et 
al., 2006). The activator kinase interacts with the receiver and induces conformational 
changes leading to the activation of the latter. 
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Figure 1.3.2 ErbB family receptors and their ligands. The ErbB receptor family is composed 
of four different members: 1 – EGFR (also ErbB1 or Her1), 2 – ErbB2 (or Her2), 3 – ErbB3 
(or HER3) and 4 – ErbB4 (or HER4). Diverse ligands can bind to the respective receptors 
and induce receptor homo –or heterodimerisation. ErbB2 has no known ligands but is the 
preferred dimerisation partner of all family members due to an extended interaction loop 
rendering it constitutively available for dimerisation. (AR, amphiregulin; EPG, epigen; EPR, 
epiregulin; BC, β-cellulin; HBEGF, heparin-binding EGF-like growth factor; NRG, neuregulin). 
Adapted from (Hynes and MacDonald, 2009) and (Yarden and Pines, 2012). 
 
Homo- and heterodimerisation of ErbB family receptors enables 10 possible combinations. 
Even though ErbB2 has no known ligands, it is the preferred partner of all family members 
due to an extended interaction loop rendering it constitutively available for dimerisation 
(Figure 1.3.2). ErbB3 is kinase dead and has no ability to phosphorylate other proteins. 
Nevertheless, it can form an active signalling complex with another member of the ErbB 
receptor family, especially ErbB2, where it acts as an allosteric activator (Eccles, 2011). 
 
Upon activation, the EGFR can bind a vast range of direct substrates and/or adaptor proteins 
depending on the mode of activation and the dimerisation partner (Schulze et al., 2005). The 
major signal transduction cascades activated by ErbB receptors are mediated by 
ERK/MAPK, JNK, PLCγ and PI3K pathways. ErbB receptor signalling can result in the 
induction of proliferation, the regulation of adhesion and motility, the avoidance of apoptosis 
and the promotion of invasion and angiogenesis. (Eccles, 2011). In normal mammary gland 
physiology, the ErbB receptors play a key role during puberty, pregnancy and lactation when 
the steroid hormones upregulate the production of many growth factors including those of the 
EGF family (Eccles, 2011). 
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Breast cancer is the most common cancer in women worldwide (Tinoco et al., 2013) and the 
major signalling pathways involved in breast cancer tumour progression and metastasis 
formation are still incompletely understood. Breast cancers are often classified based on the 
presence and absence of three cellular receptors. Hormone receptor positive cancers 
express estrogen and/or progesterone receptors (ER/PR) and represent approximately 60% 
of all breast cancers, the HER2/neu receptor is overexpressed in approximately 20% of all 
breast cancers and approximately 20% of breast cancers are negative for ER, PR and 
HER2/neu and are known as triple-negative breast cancers (TNBCs) (Tinoco et al., 2013). 
Receptor positive breast cancer patients receive treatments targeting the expressed 
receptors whereas patients with the aggressive TNBC do not have these targeted treatment 
options. In this regard it is interesting to note that 50-70% of TNBCs exhibit EGFR 
expression, that TNBCs show a high frequency of EGFR dysregulation and that EGFR status 
negatively correlates with patient survival (Burness et al., 2010; Lehmann and Pietenpol, 
2014). Altogether this has turned focus on the EGFR as a potential clinical target for TNBCs. 
 
The EGFR and its relatives are known as oncogenic drivers in various cancers, including 
lung cancer (Mok, 2011), breast cancer (Arteaga et al., 2012) and glioblastoma (Lee et al., 
2006; Libermann et al., 1985; Vivanco et al., 2012). An overview of the pathological role of 
the EGFR in breast cancer is given in (Foley et al., 2010). Particularly EGFR and ErbB2 are 
mutated to constitutively active forms in a large number of epithelial tumours. ErbB receptors 
become activated by receptor overexpression, ligand-dependent or ligand-independent 
mechanisms. Ligand-independent activity can occur due to forms of the receptor that have a 
deletion of the extracellular domain which results in constitutive receptor activation (Frederick 
et al., 2000). The most common mutation of the EGFR is an in-frame deletion in the tyrosine 
kinase domain which leads to uncontrolled activation of downstream signalling (Paez et al., 
2004). 
 
EGFR signalling is one of the most targeted signalling pathways for the treatment of cancers. 
Two types of drugs against ErbB receptors have shown clinical activity and were approved 
for the treatment of cancer. One type consists of small-molecule tyrosine kinase inhibitors 
(TKIs) competing with ATP for binding to the receptor’s kinase pocket (drug names ending 
with –inib) and the other type consists of humanised monoclonal antibodies targeted against 
the receptor’s ligand-binding extracellular domain (drug names ending with –mab). Seven 
such drugs have so far been approved for cancer treatment by the US Food and Drug 
Administration (FDA), all targeting the EGFR, ErbB2 or both (Table 1.3.2). 
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Table 1.3.2 ErbB inhibitors approved for cancer treatment by the FDA. 
 
 
 
Three ErbB targeting drugs have been approved for breast cancer treatment (Table 1.3.2). 
However, trials using small-molecule TKIs or antibodies only targeting the EGFR have been 
largely disappointing in breast cancer monotherapy (Burness et al., 2010; Foley et al., 2010). 
A possibility to circumvent this problem might be combination therapies of antibodies and 
TKIs which are currently investigated in clinical trials and which already suggest additive or 
even synergistic antitumor activity (Tebbutt et al., 2013).  
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Chapter 2 Aims and outline of the thesis 
 
Several studies highlight aberrant L-plastin expression in diverse cancer types (Ang and 
Nice, 2010; Chaijan et al., 2014; Galiegue-Zouitina et al., 1999; Kim et al., 2010; Klemke et 
al., 2007; Lapillonne et al., 2000; Leavitt, 1994; Li and Zhao, 2011; Li et al., 2009; Lin et al., 
1988; Lin et al., 1993a; Lin et al., 2000; Lin et al., 1993b; Otsuka et al., 2001; Park et al., 
1994; Yuan et al., 2010; Zheng et al., 1997). In some cancers, including breast cancer, there 
is however no correlation between L-plastin expression and cancer progression (Klemke et 
al., 2007; Lapillonne et al., 2000). Findings showing that Ser5 phosphorylation of L-plastin 
increases its F-actin-binding activity and promotes its targeting to sites of actin assembly in 
cells (Janji et al., 2006) and providing evidence that L-plastin Ser5 phosphorylation is 
involved in cell invasion and metastasis formation (Janji et al., 2006; Klemke et al., 2007; 
Riplinger et al., 2014) indicate that it is rather the phosphorylation of L-plastin on Ser5 than 
mere L-plastin expression which plays a role in cancer progression. 
 
Since the signal transduction pathway and the identity of the kinase responsible for L-plastin 
Ser5 phosphorylation are still a matter of debate, the main objective of this study was to 
decipher the signalling pathway(s) upstream of this phosphorylation event and to identify the 
kinase(s) involved in L-plastin Ser5 phosphorylation in breast cancer cells.  
 
As we observed that baseline phosphorylation of L-plastin Ser5 was high in invasive breast 
cancer cell lines and absent or low in non-invasive breast cancer cells, a whole-genome 
microarray analysis approach was applied in order to compare cells with differential L-plastin 
Ser5 phosphorylation focusing on deregulated signalling pathways. In order to narrow down 
the potential candidate kinases for the phosphorylation of L-plastin Ser5, an in vitro kinase 
assay screen was performed in parallel with the company Kinexus. Both experiments pointed 
to an involvement of the ERK/MAPK signalling pathway and of its downstream kinases RSK1 
and RSK2 in Ser5 phosphorylation of L-plastin. We then performed in vitro kinase assays on 
the full-length wild type L-plastin protein as well as activation and inhibition studies to deepen 
the analysis of this pathway. These investigations led to our most significant and novel 
findings that L-plastin Ser5 phosphorylation is mediated by the ERK/MAPK pathway in breast 
cancer cells and that the downstream effector kinases of this pathway RSK1 and RSK2 are 
able to directly phosphorylate L-plastin on residue Ser5. siRNA-mediated knockdown and a 
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systems biology approach using computational modelling also confirmed that RSK is an 
important activator of L-plastin in all studied breast cancer cell lines.  
 
The next part of the work was dedicated to the investigation of a functional outcome of 
L-plastin Ser5 phosphorylation. We performed migration and invasion assays which showed 
that RSK knockdown, besides reducing L-plastin Ser5 phosphorylation, also impaired 
MDA-MB-435S breast cancer cell migration and invasion.  
 
A third aim of the study was to identify L-plastin interaction partners. To this end we 
performed coimmunoprecipitation assays using GFP-Trap and thereby identified the proto-
oncogene tyrosine kinase Src as a binding partner of L-plastin. Moreover we performed high 
performance liquid chromatography mass spectrometry and identified prothymosin α and 
heterogeneous nuclear ribonucleoprotein M as potential L-plastin binding partners. 
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Chapter 3 Materials and methods 
 
3.1 Cell culture 
SK-BR-3 and BT-20 cells were grown in McCoy’s 5A and EMEM (Eagle’s minimal essential 
medium) media respectively and MCF7 and MDA-MB-435S cells were cultured in RPMI 
(Roswell Park Memorial Institute) medium. Human embryonic kidney 293 (HEK) cells were 
grown in DMEM (Dulbecco’s modified Eagle’s) medium. All media were supplemented with 
10% fetal bovine serum, 2 mM of L-glutamine and 100 units/ml of penicillin and streptomycin. 
Cells were grown at 37°C in a humid 5% CO2 atmosphere. All cells were bought from or 
authentified by ATCC (American Type Culture Collection, Manassas, VA, USA). 
 
3.2 Antibodies and reagents 
Mouse monoclonal immunoglobulin (Ig) G1 antibody against L-plastin (LPL4A.1, MA5-11921) 
used for immunoblotting was purchased from Thermo Scientific (Erembodegem, Belgium). 
Rabbit polyclonal IgG antibody against L-plastin used for immunofluorescence was 
characterised in (Lapillonne et al., 2000). Rabbit polyclonal anti-Ser5-P antibody specifically 
recognising L-plastin phosphorylated at Ser5 was raised against a peptide encoding L-plastin 
residues 2-17 in which Ser5 was phosphorylated (ARGS(P)VSDEEMMELREA) 
(characterised in (Janji et al., 2006)). Rabbit polyclonal antibodies against RSK1 (sc-231) or 
RSK2 (#9340) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany) and 
Cell Signaling Technology (Leiden, Netherlands) respectively. Mouse anti-β-actin (A5441), 
mouse anti-α-tubulin (T5168) and mouse anti-GFP (G-6539-1) antibodies were obtained from 
Sigma-Aldrich (Diegem, Belgium). Anti-EGFR (#2232), anti-src (#2109), anti-phosphorylated 
PKA substrates (#9624), anti-PKCδ (#2058) and a P-RSK1/2 antibody specifically 
recognising the phosphorylated forms of RSK1 and RSK2 (Ser221, respectively Ser227) 
(#3556) were from Cell Signaling Technology. Rabbit anti-β-tubulin (sc-9104) antibody was 
from Santa Cruz Biotechnology. Anti-N-cadherin (33-3900) and anti-claudin-3 (341700) were 
from Life Technologies (Carlsbad, CA, USA) and anti-E-cadherin (610182) from BD 
Biosciences (Franklin Lakes, NJ, USA) and anti-vimentin (sc-6260) and anti-cytokeratin-18 
(sc-6259) from Santa Cruz Biotechnology.  
Phorbol 12-myristate 13-acetate (PMA), epidermal growth factor (EGF), 8-Bromo-cAMP 
(8Br-cAMP or 8Br), H89, PP2, endothelin-1, β-estradiol and progesterone were obtained 
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from Sigma, GF109203X (GF), SL0101, BI-D1870 (BID), SU6656 and Src inhibitor I from 
Calbiochem Merck Millipore (Nottingham, UK) and PD98059 (PD) from Cell Signaling 
Technology.  
 
3.3 Treatment of cells with pharmacological agents 
Cells were treated with PMA at a concentration of 0.1 μM for 1 hour (h), with EGF at 1 ng/ml 
for 15 minutes (min), with 8-Bromo-cAMP at 1 mM for 1 h, with endothelin-1 at 100 nM for 5 
to 30 min, with β-estradiol at 10 nM for 1 to 48 h, with progesterone at 100 nM for 1 to 48 h, 
with GF109203X at 1 μM for 3 h, with H89 at 50 μM for 1 h, with PP2 at 10 μM for 1 h, with 
SU6656 at 5 μM or 10 μM for 3 h, with Src inhibitor I at 10 μM for 3 h, with PD98059 at 10 
μM for 1 h, with BI-D1870 at 5 μM for 30 min, or with SL0101 at 80 μM for 4 h. In case of 
combined treatment with activators and inhibitors, the incubation with the inhibitor was 
performed before the incubation with the activator. For serum starvation prior to EGF 
treatment cells were cultured in the absence of serum for 24 h. 
 
3.4 Plasmid constructs 
L-plastinWT, L-plastinS5A (unphosphorylatable) and L-plastinS5E (phosphomimic) 
constructs in pEGFP-N1 and in pDsRed-Monomer-N1 vectors (both from Clontech, Saint-
Germain-en-Laye, France) were available in the lab and generated as described in (Al 
Tanoury et al., 2010). 
GFP-PKCδ was generated by cloning a cDNA corresponding to the full-length PKCδ protein 
into the pEGFP-C3 vector (Clontech) using Xho1-Kpn1 restriction sites. For constitutively 
active PKCδ, a fragment of PKCδ was replaced by a synthesised fragment leading to a point 
mutation of AA144 arginine to alanine and of AA145 arginine to alanine using restriction 
enzymes Sal1-Hind3. For dominant negative PKCδ, a fragment of PKCδ was replaced by a 
synthesised fragment leading to a point mutation of AA278 lysine to arginine using restriction 
enzymes Hind3-Xmn1.  
The v-Src-DsRed vector was a kind gift from Gerhard Müller-Newen (Uniklinik RWTH 
Aachen, Germany). 
All constructs were verified through sequencing by LGC Genomics. 
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3.5 Transfections and siRNA knockdown 
Calcium phosphate transfections were performed on HEK cells prior to GFP-Trap 
immunoprecipitation. A solution of 30-65 μg DNA and 160 μl of 2.5 M CaCl2, completed to 
1300 μl with H2O (for a 145 cm2 dish) was added drop-wise to an equal amount of HEPES-
buffered saline 2x, pH 7.0 (Alfa Aesar, Ward Hill, MA, USA). After 30 min of incubation at 
room temperature (RT) the solution was added to the cells at ≥70% confluence. Cells were 
analysed 24-48 h post transfection. 
Small interfering RNA against RSK-1 (Hs_RPS6KA1_10), RSK-2 (Hs_RPS6KA3_5) and 
PKCδ (Hs_PRKCD11) were purchased from Qiagen GmbH (Venio, Netherlands). 60 nM and 
80 nM of RSK-1 & RSK-2 and PKCδ siRNA respectively were transfected using 
Lipofectamine®2000 (Life Technologies, Gent, Belgium). A solution of 625 μl of OptiMEM 
medium with 25 μl of Lipofectamine®2000 (or 50 μl for the combined addition of two siRNAs) 
was added to a solution of 625 μl of OptiMEM medium with 15 μl of corresponding siRNA. 
The solution was mixed by pipetting and incubated for 10-15 min at RT. 4 ml of RPMI 
medium were added to the mix and 100 μl of this mix were added to each well of a 96-well 
plate. After 4 h of incubation with the transfection solution, the medium was replaced by fresh 
RPMI supplemented with 10% fetal bovine serum, 2 mM of L-glutamine and 100 units/ml of 
penicillin and streptomycin. 
 
3.6 Immunofluorescence 
Epithelial and mesenchymal marker assay 
Cells were washed with phosphate-buffered saline (PBS) supplemented with 0.1 mM MgCl2 
and 0.1 mM CaCl2 (PBS-MgCa), fixed with 3% paraformaldehyde in PBS-MgCa for 20 min at 
RT, saturated with NH4Cl 50 mM in PBS-MgCa for 10 min at RT and permeabilised with 
Triton 0.4% in PBS-MgCa for 5 min at RT. In-between steps the cells were washed with 
PBS-MgCa. Cells were incubated with primary antibodies against N-cadherin, vimentin, 
E-cadherin, cytokeratin-18 and claudin-3 during 1 h at RT, followed by staining with 
secondary antibodies for 30 min at RT. Labelled cells were analysed by a Zeiss laser 
scanning confocal microscope (LSM-510 Meta, Carl Zeiss, Jena, Germany) with a 63x-1.4 oil 
objective. Image acquisition was performed using Zen 2009 software and image analysis 
using ImageJ software. 
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L-plastin and Ser5 phosphorylated L-plastin localisation assay 
Cells were plated on fibronectin-coated (20 μg/ml) glass coverslips 16 h before serum 
starvation which was performed for 24 h. Then the cells were treated with vehicle or EGF 
(100 ng/ml) with or without prior treatment with BI-D1870 (5 μM). 1 h following treatment the 
cells were fixed with 4% paraformaldehyde in PBS with 0.5% Triton X-100 for 10 min, 
permeabilised with 0.5% Triton X-100 in PBS for 5 min and blocked in 2% BSA in PBS-
Tween 0.05% for 10 min. In-between steps, the cells were washed with PBS-Tween. The 
cells were stained with phalloidin and antibodies against L-plastin or Ser5 phosphorylated 
L-plastin. Imaging was performed on an Andor Spinning Disk Revolution system (CSU-W1) 
(Andor Technology, Belfast, United Kingdom) based on a Nikon Ti microscope (Nikon, 
Konan, Minato-ku, Tokyo, Japan) with an Andor iXon Ultra EMCCD camera and a 100x-1.4 
NA oil objective. Image acquisition was performed using Andor iQ3 software and image 
analysis using ImageJ software. 
 
3.7 Microarrays 
RNA extraction was performed using Trizol reagent. RNA quality and concentration were 
evaluated spectroscopically using a NanoDrop2000c instrument (Thermo Scientific). RNA 
integrity was subsequently analysed on an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, CA, USA). Only good quality RNA with integrity numbers > 9 was used. 
Transcriptome profiling assays were performed using the Affymetrix Human GeneChip 1.0 
ST arrays (Affymetrix, Santa Clara, CA, USA). Briefly, 250 ng of total RNA were reverse 
transcribed into cDNA, then transcribed into cRNA and labelled into biotinylated cRNA using 
the GeneChip WT PLUS Reagent kit (Affymetrix) according to the manufacturer’s protocols 
(P/N 4425209 Rev.B 05/2009 and P/N 702808 Rev.6). Labelled cRNA products were 
randomly fragmented and hybridised onto Affymetrix GeneChips. Arrays were washed and 
stained with Affymetrix GeneChip WT Terminal Labelling and Hybridization kit, before being 
scanned using a GeneChip Scanner 3000. Cell intensity files containing hybridization raw 
signal intensities were imported into the Partek GS software (Partek, St. Louis, MO, USA) 
using default options. Resulting expression data (transcript cluster level) were imported into 
R statistical environment for further analysis. Transcript clusters without chromosome 
location were removed. Quality of the data was assessed through boxplot, relative log 
expression and Pearson’s correlation. Linear Model for Microarray Data (LIMMA) was used 
to compare transcript cluster expression between different conditions, according to author’s 
recommendations [LIMMA User’s Guide section 9.5]. Resulting p-values were adjusted for 
false discovery rate (FDR) with Benjamini and Hochberg’s FDR (Benjamini and Hochberg, 
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1995) and transcript clusters with FDR < 0.05 and absolute fold change (FC) ≥ 1.5 were 
considered as significantly differentially expressed and used for further analyses. The 
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA, USA, 
www.ingenuity.com) was used for transcript cluster mapping which led to the identification of 
differentially expressed genes (DEGs) and for data mining, including functional analyses and 
gene network reconstruction. Right-tailed Fisher’s exact test was used to calculate a p-value 
for functional enrichment analysis (threshold: -log(p-value) > 1.301). Microarray expression 
data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under the 
accession number E-MTAB-3487. 
 
3.8 Kinase screening 
The phosphorylation prediction algorithm Kinase substrate predictor version 2.0 (KSPv2) 
from KINEXUS Bioinformatics Corporation (Vancouver, Canada) identified the 50 best 
scored candidate kinases for L-plastin phosphorylation on residue Ser5, out of which 43 were 
subsequently screened by KINEXUS for their ability to phosphorylate L-plastin peptides in in 
vitro kinase assays. The following peptides corresponding to the L-plastin N-terminus and 
comprising residue Ser5 were chosen to be used in the kinase assays: ARGSVSDEERR 
(WT) and ARGSVADEERR (MT), both starting with an N-acetylalanine (taking into account 
co-translational modifications described by the UniProtKB/Swiss-Prot database), as well as 
native MARGSVSDEERR (M-WT) and MARGSVADEERR (M-MT), both still comprising the 
initial methionine residue. Residue Ser7 was substituted by an alanine in order to be able to 
distinguish between Ser5 and Ser7 phosphorylation and to exclude false positives. Two 
arginine residues were added at the C-terminal end of the peptides to ensure adhesion of the 
peptides to the capture phosphocellulose filter paper following the kinase assay, and were 
placed far enough from the Ser5 site so as not to affect the kinase recognition of this site. 
Briefly, L-plastin peptides were mixed with individual protein kinases in the presence of 
[γ-33P] ATP for 20-40 min, depending on the protein kinase tested. The assay was terminated 
by spotting 10 μl of the reaction mixture onto a multiscreen phosphocellulose P81 plate. After 
removing unreacted [γ-33P] ATP from the reaction, radioactivity was quantified in a 
scintillation counter. 
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3.9 In vitro kinase assays of full-length recombinant L-plastin 
10 μg of full-length recombinant L-plastin were incubated with 50 μM of ATP and 100 ng of 
recombinant kinase (RSK1, RSK2, MSK1 or PKCδ) obtained from SignalChem (Richmond, 
British Columbia, Canada) in a reaction volume of 25 μl according to the manufacturer’s 
protocol. For the controls the respective kinase was omitted. Following an incubation of 15 
min at 30°C, Laemmli buffer was added, the samples were boiled at 100°C for 5 min and 
then analysed by immunoblotting. 
 
3.10  In vitro kinase assay of recombinant glutathione S-transferase 
(GST)-tagged L-plastin-deltaABD2 
64 μg of recombinant GST-L-plastin-deltaABD2 were incubated with 100 ng of recombinant 
PKCδ with or without 50 ng recombinant Src and 0.1 mM Na3VO4 and with 50 μM of ATP in a 
reaction volume of 25 μl according to the manufacturer’s protocol. For the negative controls 
PKCδ was omitted. Samples were incubated for 15 min at 30°C. Laemmli buffer was added 
and the samples were boiled at 100°C for 5 min and analysed by immunoblotting. As a 
control for the immunoblotting procedure an MDA-MB-435S cell lysate was included. 
 
3.11 Immunoblotting 
Cells were lysed in situ in ice-cold lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% 
SDS, 5 mM EDTA, 1% Nonidet P-40, 1% Triton X-100, 1% Na-deoxycholate, 1 mM Na3VO4, 
10 mM NaF, 100 μM leupeptin, 100 μM E64D) containing a cocktail of protease inhibitors 
(Roche Diagnostics GmbH, Mannheim, Germany). Lysates were cleared by centrifugation at 
13200 rpm for 15 min at 4°C. The total protein concentration was determined by Bradford 
assay (Bio-Rad, Temse, Belgium). Protein separation was performed by SDS-PAGE gel 
electrophoresis under reducing conditions and proteins were transferred onto nitrocellulose 
membranes by semi-dry transfer. The membranes were saturated with 1% bovine serum 
albumin (BSA) in Tris-buffered saline (TBS) pH 7.4 supplemented with 0.1% Tween for 1 h at 
RT, then incubated with primary antibodies overnight (except for the RSK2 antibody which 
was incubated over 4 nights) at 4°C and with secondary antibodies coupled to a fluorescent 
dye for 1 h at RT. Antibody incubations were followed by membrane washings with TBS 
supplemented with 0.1% Tween. Signal intensities were detected by the Odyssey® infrared 
image system (LI-COR, Westburg, Leusden, Netherlands). For quantification the ratio 
Materials and methods   
49 
 
between the intensities obtained for phosphorylated L-plastin (or phosphorylated PKA 
substrates) versus total L-plastin was determined to make individual samples comparable 
and then normalised to the mean of all the values obtained in one experiment to make blots 
comparable by accounting for technical day-to-day variability. For presentation purposes, 
data were scaled to the highest signal and are represented as means +/- standard deviation 
(SD). Statistical significance was determined by an unpaired T-test with Welch’s correction.  
P < 0.05 was considered significant.  
 
3.12 Two-dimensional (2-D) gel electrophoresis 
BT-20 cells were treated with PMA, EGF or EGF + BI-D1870 and then lysed in a buffer 
containing 7 M urea, 2 M thiourea, 1% CHAPS detergent, 5 mg/ml dithiothreitol, 1 µg/ml 
pepstatin A, 1 mM Na3VO4, 10 mM NaF and protease inhibitor cocktail. Lysates were kept on 
ice for 30 min, sonicated and then centrifuged at 13000 rpm for 10 min at 4°C. Supernatants 
were collected and total protein concentrations were determined by Bradford assay (Bio-
Rad). Lysates were prepared to contain 80 μg in 200 μl and 2 μl (1%) IPG buffer pH 4-7 (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK) was added right before starting the first 
dimension. For isoelectric focusing, each sample was then loaded in a strip holder of a 
Multiphore electrophoresis system (GE Healthcare) and an 11 cm Immobiline DryStrip with a 
pH range from 4 to 7 (GE Healthcare) was placed on top of the sample with the gelside 
facing down. To prevent evaporation, a mineral oil solution (Immobiline DryStrip Cover Fluid, 
GE Healthcare) and a lid were added on top of the strip. The following programme was 
applied: 11 h of rehydration at 50 μA/strip, 1 h at 300 V, 3 h with a gradient from 300 to 6000 
V, 9 h at 6000 V, 1 h at 8000 V. Following isoelectric focusing, the gelstrips were equilibrated 
for 15 min at RT in 10 ml of a solution containing 50 mM Tris-HCl pH 6.8, 6 M urea, 30% 
glycerol, 1% SDS, 10 mg/ml dithiothreitol, followed by another 15 min equilibration step at RT 
in a 10 ml solution containing 50 mM Tris-HCl pH 6.8, 6 M urea, 30% glycerol, 1% SDS and 
0.45 g iodoacetamide. For the second dimension, protein separation according to the 
molecular weight was performed by SDS-PAGE placing the gelstrips on top of a stacking gel 
with the high pH side (negatively charged side) next to the molecular weight marker. Proteins 
were then transferred onto nitrocellulose membranes by wet transfer. The membranes were 
saturated with a 1:1 solution of PBS 1x and Odyssey® Blocking Buffer (LI-COR) for 1 h at 
RT, then incubated with an anti-L-plastin antibody overnight at 4°C and with a secondary 
antibody coupled to a fluorescent dye for 1 h at RT. Antibody incubations were followed by 
membrane washings with TBS supplemented with 0.1% Tween. Signal intensities were 
detected by the Odyssey® infrared image system (LI-COR). Subsequently the same 
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procedure was repeated on the same membranes with an anti Ser5-phosphorylated L-plastin 
antibody and a secondary antibody coupled to a different fluorescent dye. 
 
3.13 Invasion and migration assays 
Cancer cell lines were seeded in collagen I-coated (200 μg/ml) 96-well plates (Essen 
Imagelock, Essen Bioscience, Hertfordshire, UK). At appoximately 90% confluence, a wound 
was scratched across each well with the CellplayerTM 96-well woundmaker (Essen 
Bioscience). (For siRNA knockdown, cells were transfected with siRNA 24 h before wound 
scratching.) To study invasion, cells were covered with collagen I (1.5 mg/ml) diluted in cell 
culture medium. To study migration, only cell culture medium was added to the cells. Wound 
confluence was monitored with the IncuCyte LiveCell Imaging System (Essen Bioscience) by 
measuring cell confluence every 3 h for a total of 72 h. The IncuCyte software calculates a 
relative wound density for every time point, measuring the spatial cell density in the wound 
area relative to the spatial cell density outside of the wound area. It is designed to be 0 at t=0 
and 100% when the cell density inside the wound is the same as the cell density outside the 
initial wound. The graphs depict means +/- standard error of the mean (SEM) from all 
technical replicates obtained from three independent experiments, each including at least 
five technical replicates. 
 
3.14 Modelling 
The literature-derived model topology of L-plastin signalling including the interactions 
between Src, PKC, PKA and the ERK/MAPK pathway were described as Boolean rules with 
corresponding selection probabilities in the probabilistic Boolean network (PBN) framework 
(see review in (Trairatphisan et al., 2013)). The experimental data obtained from immunoblot 
analysis of activation/inhibition studies for ratios of phosphorylated L-plastin versus total 
L-plastin (P-LPL/LPL) and phosphorylated PKA substrates versus total L-plastin 
(P-PKAsubstrates/LPL) from the four cell lines were used for model contextualisation. 
Normalisation of immunoblot data was performed as described above in the immunoblotting 
paragraph. Data generated from different experimental sets were normalised to the calibrator 
PMA, subsequently pooled and scaled to the maximal value. We applied an improved 
version of the optPBN toolbox (Trairatphisan et al., 2014) to optimise the selection 
probabilities of the L-plastin signalling model in PBN format. Optimisation was performed on 
a stand-alone machine (Intel CPU Xeon @3.50GHz, 16GB Ram) for the different model 
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variants based on random initial conditions. Bootstrapping was performed by randomly 
sampling 100 artificial datasets based on means and SD as acquired from our experimental 
datasets. Optimisation was subsequently performed 100 times to identify the distribution of 
the identified selection probabilities. 
3.15 GFP-Trap 
GFP-Trap is an immunoprecipitation technique based on monovalent Lama antibodies 
directed against GFP (Rothbauer et al., 2008). The antibody is fixed to beads allowing the 
purification of GFP fusion proteins and their interacting partner proteins. 24 h post-
transfection for immunoblot analysis and 48 h post-transfection for mass spectrometry 
analysis, transfected cells were harvested on ice with a lysis buffer containing 10 mM Tris-
HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 0.5% Nonidet P-40, 1 mM PMSF, complemented 
with protease inhibitor cocktail 7X (Roche Diagnostics GmbH). The cells were then incubated 
in the lysis buffer for 30 min on ice. After centrifugation at 20000 g at 4°C for 10 min, the 
supernatant was recovered and the protein concentration was determined by Bradford 
assay. 50 μl of the supernatant were diluted in 50 μl of Laemmli buffer and used as input. For 
every condition 30 µl of GFP-Trap beads (ChromoTek GmbH, Planegg-Martinsried, 
Germany) were used. In a first step, the beads were washed 3 times in 500 μl dilution buffer 
(10 mM Tris-HCL pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 1 mM PMSF, complemented with 
protease inhibitor cocktail 7X), followed by a centrifugation at 2700 g at 4°C for 5 min. The 
cell extracts were incubated with the beads for 2 h, followed by a centrifugation at 2700 g at 
4°C for 5 min. 50 μl of the supernatant were diluted in 50 μl of Laemmli buffer and were used 
as non-bound samples. The beads were washed 2 times with 500 μl dilution buffer followed 
by a centrifugation at 2700 g and 4°C for 5 min. For immunoblot analysis, the beads were 
then resuspended in 100 μl Laemmli buffer and boiled at 100°C for 10 min for elution, 
followed by a centrifugation at 2700 g for 5 min. The supernatant was recovered and 
considered as bound fraction. For mass spectrometry, the samples were loaded to an affinity 
column and eluted with 4% formic acid. 
 
3.16 Mass spectrometry 
Sample preparation 
Stable isotope labelling by amino acids in cell culture (SILAC) of HEK cells was performed in 
SILAC DMEM medium supplemented with 10% dialysed fetal bovine serum, 2 mM of 
L-glutamine, 50 units/ml of penicillin and streptomycin, 146 mg/l lysine (C12 or C13) and 16.8 
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mg/l arginine (C12 or C13). Cultured cells were transfected with constructs of interest, lysed 
and subjected to GFP-Trap. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 
Following GFP-Trap, protein complexes were eluted from the affinity column using 4% formic 
acid. These protein samples were vacuum-dried and re-dissolved in 100 µl 50 mM 
triethylammonium bicarbonate pH 8.0. Digestion occurred overnight at 37°C using 
sequencing-grade porcine trypsin (Promega, Leiden, Netherlands). The resulting peptide 
mixtures were acidified with 10% trifluoroacetic acid for subsequent LC-MS/MS analysis. Of 
each sample, 2.5 µl were first analysed on the LTQ-Orbitrap Velos (Thermo Scientific) in 
LC-MS/MS mode (operated as described in (De Antonellis et al., 2014)) to determine the 
quantity of the material present in the sample. For final analysis, 5 µl of each sample were 
subjected to LC-MS/MS analysis using a Q Exactive mass spectrometer (Thermo Scientific) 
that was operated as previously described (Stes et al., 2014). Data were converted to 
Mascot generic format files using Mascot Distiller (Matrix Science, London, United Kingdom) 
and, using the Mascot database search engine (Matrix Science), these were presented to the 
Swiss-Prot database restricted to human proteins. Peptide-to-spectrum matches were 
allowed with confidence settings of 99% and were withheld only if ranked first and if scores 
were above the corresponding threshold.  
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Chapter 4 Results 
 
Parts of the discussion section are taken from a manuscript which can be found in the 
appendix and which was recently published in The FASEB Journal: L-plastin Ser5 
phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the 
ERK/MAPK pathway (Lommel et al., 2015). 
 
4.1 Characterisation of four breast cancer cell lines 
The four breast cancer cell lines MCF7, SK-BR-3, BT-20 and MDA-MB-435S chosen as a 
working model for this study were carefully selected in order to cover different molecular 
profiles (Kao et al., 2009; Kenny et al., 2007; Subik et al., 2010) with the main prerequisite 
being the expression of our protein of interest L-plastin. Figure 4.1 shows that L-plastin is 
present in all four cell lines at different expression levels. 
 
Figure 4.1 Protein level of L-plastin in four breast cancer cell lines. Cell extracts were 
subjected to immunoblot analysis using antibodies specific for L-plastin and β-tubulin as a 
loading control. 
 
4.1.1 Epithelial and mesenchymal signature 
For the characterisation of our cell lines, we investigated the morphology as well as typical 
epithelial and mesenchymal markers. Invasive cell lines usually have a more mesenchymal 
phenotype whereas non-invasive cell lines are more epithelial. Figure 4.1.1.1 shows phase 
contrast images of breast cancer cells and indicates an epithelial phenotype for MCF7 and 
SK-BR-3 for which cells adhere to each other and do not show an elongated, fibroblast-like 
phenotype whereas for MDA-MB-435S cells a clear mesenchymal phenotype with a 
fibroblast-like morphology is observed. BT-20 cells display an intermediate phenotype.  
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Figure 4.1.1.1 Epithelial and mesenchymal phenotypes of breast cancer cell lines. Phase 
contrast images were taken with a Leica phase contrast microscope with a 10x objective. 
 
 
The expression of epithelial and mesenchymal markers in the four cell lines was assessed by 
immunoblot analysis (Figure 4.1.1.2) as well as by immunofluorescent staining (Figures 
4.1.1.3-7) and the results are summarised in Table 4.1.1. Notably we analysed the 
expression of two mesenchymal markers, N-cadherin, a transmembrane protein that is found 
in adherens junctions, and vimentin, a type III intermediate filament protein, and of three 
epithelial markers, E-cadherin, a transmembrane protein found in adherens junctions, 
cytokeratin-18, an intermediate filament protein and claudin-3, a tight junction protein. 
Immunoblot as well as immunofluorescence assays show that both mesenchymal markers 
are present in the most invasive cell line MDA-MB-435S. Immunoblot analysis shows that the 
epithelial marker E-cadherin is expressed in MCF7 and BT-20 and immunofluorescent 
staining shows its localisation in cell membranes as expected. Staining for E-cadherin is also 
weakly observed in dot-like structures for some SK-BR-3 cells and extremely rarely in MDA-
MB-435S cells. However the dot-like staining in these cells does not correspond to the 
expected localisation of this transmembrane protein. Both analyses also reveal that the 
epithelial marker cytokeratin-18 is expressed in MCF7, SK-BR-3 and BT-20 and not in MDA-
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MB-435S cells. Immunoblot analysis shows similar levels of cytokeratin-18 for the three cell 
lines whereas immunofluorescence shows a strong staining in MCF7 and BT-20 and a 
weaker staining in SK-BR-3. Both analyses show strong expression of the epithelial marker 
claudin-3 in MCF7. 
Overall the expression of epithelial markers roughly corresponds to the invasive capacity of 
the cells. According to the expression of epithelial and mesenchymal markers, 
MDA-MB-435S is the most mesenchymal of the four cell lines as it is positive for all tested 
mesenchymal markers and negative for all epithelial markers. MCF7 presents the most 
pronounced epithelial phenotype as it is positive for all tested epithelial markers and negative 
for all mesenchymal markers. SK-BR-3 and BT-20 do not express mesenchymal markers but 
they are also not positive for all epithelial markers and they thus have an intermediate 
phenotype. 
 
 
Figure 4.1.1.2 Protein level of epithelial and mesenchymal markers of breast cancer cell 
lines. Cell extracts were subjected to immunoblot analysis using antibodies specific for 
N-cadherin, vimentin, E-cadherin, cytokeratin-18 and claudin-3. Loading controls were used 
for all membranes to confirm loading of equal protein amounts. (MDA refers to MDA-MB-
435S). 
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Figure 4.1.1.3 N-cadherin expression and localisation in breast cancer cell lines. Breast 
cancer cells were fixed and processed for immunofluorescence. Cells were stained using 
DAPI (in blue) and an antibody against N-cadherin (in green) and analysed with a laser 
scanning confocal microscope. 
 
 
Figure 4.1.1.4 Vimentin expression and localisation in breast cancer cell lines. Breast cancer 
cells were fixed and processed for immunofluorescence. Cells were stained using DAPI (in 
blue) and an antibody against vimentin (in green) and analysed with a laser scanning 
confocal microscope. 
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Figure 4.1.1.5 E-cadherin expression and localisation in breast cancer cell lines. Breast 
cancer cells were fixed and processed for immunofluorescence. Cells were stained using 
DAPI (in blue) and an antibody against E-cadherin (in green) and analysed with a laser 
scanning confocal microscope. 
 
Figure 4.1.1.6 Cytokeratin-18 expression and localisation in breast cancer cell lines. Breast 
cancer cells were fixed and processed for immunofluorescence. Cells were stained using 
DAPI (in blue) and an antibody against cytokeratin-18 (in green) and analysed with a laser 
scanning confocal microscope. 
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Figure 4.1.1.7 Claudin-3 expression and localisation in breast cancer cell lines. Breast 
cancer cells were fixed and processed for immunofluorescence. Cells were stained using 
DAPI (in blue) and an antibody against claudin-3 (in green) and analysed with a laser 
scanning confocal microscope. 
 
 
 
Table 4.1.1 Combined western blotting and immunofluorescence results on the presence of 
epithelial and mesenchymal markers in the four breast cancer cell lines. 
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4.1.2 Epidermal growth factor receptor (EGFR) 
As the EGFR plays key roles in normal mammary gland physiology as well as in breast 
cancer (Eccles, 2011), we tested the presence of the EGFR in the four breast cancer cell 
lines by immunoblot analysis. As previously decribed by others (Subik et al., 2010), both 
SK-BR-3 and BT-20 cells expressed high levels of EGFR, whereas in MCF7 and 
MDA-MB-435S cells the expression was very low or absent (Figure 4.1.2). 
 
 
Figure 4.1.2. EGFR is expressed in SK-BR-3 and BT-20 breast cancer cells. Cell extracts 
were analysed by immunoblotting using antibodies specific for the EGFR and β-actin as a 
loading control. Adapted from (Lommel et al., 2015). 
 
4.1.3 Migration and invasion capacities 
The migration and invasion capacities of our four breast cancer cell lines were assessed by 
performing in vitro scratch wound assays. MDA-MB-435S had the highest migration capacity, 
relatively tightly followed by MCF7 and BT-20 whereas SK-BR-3 had a remarkably lower 
migration capacity (Figure 4.1.3.1). 
MCF7 and SK-BR-3 cells are only weakly invasive whereas invasiveness was considerably 
more important in BT-20 and most prominent in MDA-MB-435S cells (Figure 4.1.3.2). These 
results are in line with the literature, MCF7 and SK-BR-3 being considered as non- or merely 
weakly invasive cell lines in contrast to BT-20 and MDA-MB-435S which have been 
described as invasive cell lines (Lacroix and Leclercq, 2004; Zajchowski et al., 2001). 
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Figure 4.1.3.1 Migration assays for the four model breast cancer cell lines. Cells were 
seeded in collagen I-coated (200 µg/ml) 96-well plates. At appoximately 90% confluence, a 
wound was scratched across each well with the Cellplayer 96-well woundmaker. Cells were 
covered with cell culture medium and wound confluence was monitored with the IncuCyte 
LiveCell Imaging System by measuring cell confluence every 3 h over a total period of 72 h. 
The graph depicts means +/- SEM from all technical replicates obtained from three 
independent experiments. 
 
 
Figure 4.1.3.2 Invasion assays for the four model breast cancer cell lines. Cells were seeded 
in collagen I-coated (200 µg/ml) 96-well plates. At appoximately 90% confluence, a wound 
was scratched across each well with the Cellplayer 96-well woundmaker. Cells were covered 
with collagen I (1.5 mg/ml) diluted in cell culture medium. Wound confluence was monitored 
with the IncuCyte LiveCell Imaging System by measuring cell confluence every 3 h over a 
total period of 72 h. The graph depicts means +/- SEM from all technical replicates obtained 
from three independent experiments. Adapted from (Lommel et al., 2015). 
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4.1.4 L-plastin Ser5 phosphorylation levels 
Since a correlation between the invasive capacity of cells and the phosphorylation state of 
L-plastin on Ser5 has been suggested before (Janji et al., 2006; Klemke et al., 2007; 
Riplinger et al., 2014), we continued by investigating baseline L-plastin Ser5 phosphorylation 
in the four breast cancer cell lines. To this end, we used an antibody specifically recognising 
Ser5-phosphorylated L-plastin (anti-Ser5-P antibody) raised and characterised by our group 
(Al Tanoury et al., 2010; Janji et al., 2006; Janji et al., 2010). Although the L-plastin 
expression level is higher in the invasive as compared to the non-invasive cell lines, our 
results clearly show high baseline L-plastin Ser5 phosphorylation in the invasive cell lines 
BT-20 and MDA-MB-435S as compared to absent or extremely weak phosphorylation in the 
non-invasive cell lines MCF7 and SK-BR-3 (Figure 4.1.4).  
 
 
Figure 4.1.4 High baseline L-plastin Ser5 phosphorylation in highly invasive versus low 
baseline L-plastin Ser5 phosphorylation in non- or weakly invasive breast cancer cell lines. 
Cell extracts were analysed by immunoblotting using antibodies specific for Ser5 
phosphorylated L-plastin (anti-Ser5-P antibody, P-LPL) and total L-plastin (LPL). Adapted 
from (Lommel et al., 2015). 
 
4.1.5 Arguments in favour of a breast cancer origin of MDA-MB-435S 
It is noteworthy that considerable doubt had been raised about the origin of the cell clone 
MDA-MB-435S (Ross et al., 2000). Concerning the issue of the identity of MDA-MB-435S, 
the scientific community appears to agree that MDA-MB-435S and the M14 melanoma cell 
line are essentially identical with respect to cytogenetic characteristics and gene expression 
as confirmed by microsatellite analyses (Hollestelle et al., 2010; Rae et al., 2007). 
Nevertheless there is no agreement whether both cell lines should be classified as breast 
(Chambers, 2009; Hollestelle and Schutte, 2009; Sellappan et al., 2004) or melanoma 
(Ellison et al., 2002; Rae et al., 2007) cancer cell lines. Cell Lines Service GmbH sells 
MDA-MB-435S as breast cancer cell line (http://www.clsgmbh.de/p513_MDA-MB-435S.html) 
whereas American Type Culture Collection (ATCC) sells it as melanoma cell line 
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(http://www.lgcstandards-atcc.org/Products/All/HTB-129.aspx#characteristics) refering to 
publications from 2000 to 2007. They thus ignored the more recent publication from 
Chambers (Chambers, 2009) pointing to the fact that MDA-MB-435S and M14 cells currently 
in circulation have female karyotypes whereas M14 was originally derived from a male 
patient which implies that current cultures of both cell lines are more likely to be derived from 
MDA-MB-435S. 
 
Another important publication favoring the breast origin of MDA-MB-435S shows that these 
cells express breast and epithelial-specific markers and that these cells can be induced to 
express breast differentiation-specific proteins and secrete milk lipids, as observed in other 
well-established breast cancer cell lines (Sellappan et al., 2004). They also detected some 
melanocyte-specific proteins in MDA-MB-435S but these were also expressed at lower levels 
in BT-474, another breast cancer cell line. Overall they concluded that MDA-MB-435S is 
most likely a breast epithelial cell line which has undergone lineage infidelity. 
 
Be that as it may, the experiments performed in this study were conducted in four cancer cell 
lines including MDA-MB-435S and three other cell lines being undoubtedly of breast origin.  
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4.2 Signal transduction cascade leading to L-plastin Ser5 
phosphorylation 
As the detailed signalling cascade leading to L-plastin Ser5 phosphorylation remains elusive, 
we decided to investigate the pathways upstream of L-plastin Ser5 phosphorylation. 
 
4.2.1 Analysis of protein kinases previously described to play a role in 
L-plastin Ser5 phosphorylation 
As stated in the introduction (under 1.2.3 L-plastin phosphorylation), mainly PKC and PKA 
have been described to play a role in L-plastin Ser5 phosphorylation. Most of these studies 
have been performed in cells of the immune system where L-plastin is typically expressed. 
Only two studies investigated L-plastin phosphorylation in cancer cells and showed that 
siRNA-mediated knockdown of PKCδ reduced L-plastin Ser5 phosphorylation in MCF7 cells 
(Al Tanoury et al., 2010) and in the MCF7-derived invasive 1001 cells (Janji et al., 2010).  
We thus started by investigating the involvement of PKC in L-plastin Ser5 phosphorylation in 
all our model breast cancer cell lines. Indeed the activation of PKC by PMA led to a 
significant increase in L-plastin Ser5 phosphorylation in all tested cell lines regardless of their 
baseline phosphorylation level (Figure 4.2.1.1).  
 
 
Figure 4.2.1.1 PKC activation increases L-plastin Ser5 phosphorylation in the four breast 
cancer cell lines. Cells were treated with PMA 0.1 μM for 1 h and cell extracts were analysed 
by immunoblotting using antibodies specific for Ser5 phosphorylated L-plastin (anti-Ser5-P 
antibody, P-LPL) and total L-plastin (LPL). 
 
As it was suggested that it is the PKCδ isoform that is responsible for L-plastin Ser5 
phosphorylation in MCF7 and 1001 cells, we investigated whether this isoform was also 
involved in L-plastin Ser5 phosphorylation in SK-BR-3, BT-20 and MDA-MB-435S cells. To 
this end we proceeded to PKCδ knockdown which resulted in efficiently decreased levels for 
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all cell lines. We observed a significant decrease in L-plastin Ser5 phosphorylation in 
MDA-MB-435S cells, a small decrease in BT20 and no decrease in SK-BR-3 cells (Figure 
4.2.1.2). The involvement of PKCδ in L-plastin Ser5 phosphorylation appeared thus to be cell 
type-dependent. 
 
Figure 4.2.1.2 Effect of PKCδ knockdown on L-plastin Ser5 phosphorylation in breast cancer 
cells. siRNA against PKCδ was transfected in SK-BR-3, BT-20 and MDA-MB-345S cells and 
L-plastin Ser5 phosphorylation and PKCδ levels were assessed by immunoblot analysis 48 h 
post transfection. SK-BR-3 cells were treated with PMA 1 h before cell lysis. For 
quantification the ratio between the intensities obtained for phosphorylated L-plastin (P-LPL) 
versus total L-plastin (LPL) and for PKCδ versus β-actin respectively were determined to 
make individual samples comparable and then normalised to the mean of all the values 
obtained in one experiment to make blots comparable by accounting for technical day-to-day 
variability. For presentation purposes, data were scaled to the highest signal and are 
represented as means +/- standard deviations (SD). For experiments with at least 3 
replicates, statistical significance was determined by an unpaired T-test with Welch’s 
correction. *P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant. (Scr refers to 
scrambled) 
 
In parallel to the PKCδ knockdown experiments, we cloned a wild type construct of PKCδ as 
well as dominant negative and constitutively active PKCδ into a pEGFP-C3 vector. Dominant 
negative PKCδ contains a lysine to arginine mutation at amino acid position 378 in the 
C-terminal ATP binding site which impairs ATP binding (Soh et al., 1999). Constitutively 
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active PKCδ contains two arginine to alanine mutations at amino acid positions 144 and 145 
in the pseudosubstrate domain of the regulatory domain of PKCδ (Ueda et al., 1996). The 
three constructs were transfected into MCF7 and MDA-MB-435S cells using lipofectamine 
transfection. None of these transfections had an effect on L-plastin Ser5 phosphorylation 
(data not shown). As the transfection efficiency in these cells was low, the same experiment 
was performed in human embryonic kidney 293 (HEK) cells where a transfection efficiency of 
about 95% was reached using calcium-phosphate transfection. We observed that 
constitutively active PKCδ increases L-plastin Ser5 phosphorylation (Figure 4.2.1.3). This 
confirms previously obtained data showing a role for PKCδ in the signalling pathway leading 
to L-plastin Ser5 phosphorylation (Al Tanoury et al., 2010; Freeley et al., 2012; Janji et al., 
2010; Jones et al., 1998; Lin et al., 1998; Paclet et al., 2004; Pazdrak et al., 2011). 
 
 
Figure 4.2.1.3 Constitutively active PKCδ increases L-plastin Ser5 phosphorylation in HEK 
cells. HEK cells were transfected with L-plastinWT-DsRed and with a pEGFP-C3 vector 
containing the indicated PKCδ variant. Cell lysates were analysed by immunoblotting using 
antibodies specific for Ser5 phosphorylated L-plastin and L-plastin. 
 
In cells, PKC can be activated in response to physiological stimuli inducing inositol 
phospholipid hydrolysis such as endothelin-1 (Griendling et al., 1989). Endothelin-1, a 
peptide derived from endothelial cells, is a constrictor of vascular smooth muscle. We tested 
whether this PKC activator had an effect on L-plastin Ser5 phosphorylation in our four breast 
cancer cell lines and in HEK cells. No effect was observed in the four breast cancer cell lines 
whereas in HEK cells endothelin-1 led to a significant increase in L-plastin Ser5 
phosphorylation (Figure 4.2.1.4). 
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Figure 4.2.1.4. Endothelin-1 increases L-plastin Ser5 phosphorylation in HEK cells. HEK 
cells were treated with 100 nM of endothelin-1 for 5 or 15 min. Quantification was performed 
as described in Figure 4.2.1.2. Data are represented as means +/- SD. Statistical 
significance was determined by an unpaired T-test with Welch’s correction. *P<0.05, 
**P<0.01 and ***P<0.001. 
 
In order to get a more complete overview of L-plastin Ser5 phosphorylation by PKC and 
PKA, we treated our four model breast cancer cell lines with PKC and PKA activators and 
inhibitors as well as with combinations of activators and inhibitors. PMA was used for PKC 
activation, GF109203X (GF) for PKC inhibition, 8-Bromo-cAMP (8Br) for PKA activation and 
H89 for PKA inhibition. After treatment, the cells were lysed and the samples were loaded on 
SDS-PAGE and blotted against phosphorylated L-plastin (P-LPL) and L-plastin (LPL) or 
phosphorylated PKA substrates (P-PKAsubstrates) and L-plastin respectively (Figures 
4.2.1.5-8). 
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Figure 4.2.1.5. Effect of PKC or PKA activation with or without prior inhibition on L-plastin 
Ser5 phosphorylation in non-invasive cell lines. Cells were treated with the indicated 
inhibitors and/or activators before being lysed and analysed by immunoblotting. 
Quantification was performed as described in Figure 4.2.1.2. Data are represented as means 
+/- SD. Statistical significance was determined by an unpaired T-test with Welch’s correction. 
*P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant with comparisons to PMA in red 
and to 8Br-cAMP in green. 
 
 
Figure 4.2.1.6 Effect of PKC or PKA activation with or without prior inhibition on L-plastin 
Ser5 phosphorylation in invasive cell lines. Cells were treated with the indicated inhibitors 
and/or activators before being lysed and analysed by immunoblotting. Quantification was 
performed as described in Figure 4.2.1.2. Data are represented as means +/- SD. Statistical 
significance was determined by an unpaired T-test with Welch’s correction. *P<0.05, 
**P<0.01, ***P<0.001 and n.s. – non-significant with comparisons to PMA in red, to 
8Br-cAMP in green and to minus in black. 
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Figure 4.2.1.7 Effect of PKC or PKA activation with or without prior inhibition on PKA 
substrate phosphorylation in non-invasive cell lines. Cells were treated with the indicated 
inhibitors and/or activators before being lysed and analysed by immunoblotting. 
Quantification was performed as described in Figure 4.2.1.2. Data are represented as means 
+/- SD. Statistical significance was determined by an unpaired T-test with Welch’s correction. 
*P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant with comparisons to PMA in red 
and to 8Br-cAMP in green. 
 
Figure 4.2.1.8 Effect of PKC or PKA activation with or without prior inhibition on PKA 
substrate phosphorylation in invasive cell lines. Cells were treated with the indicated 
inhibitors and/or activators before being lysed and analysed by immunoblotting. 
Quantification was performed as described in Figure 4.2.1.2. Data are represented as means 
+/- SD. Statistical significance was determined by an unpaired T-test with Welch’s correction. 
*P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant with comparisons to PMA in red, to 
8Br-cAMP in green and to minus in black. 
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In contrast to PKC activation, PKA activation with 8-Bromo-cAMP had no significant effect on 
L-plastin Ser5 phosphorylation in MCF7, SK-BR-3, BT-20 and MDA-MB-435S cells (Figures 
4.2.1.5 and 4.2.1.6). Looking at the phosphorylation of PKA substrates, an increase is 
observed as expected in all cell lines for treatment with the PKA activator 8-Bromo-cAMP 
(Figures 4.2.1.7 and 4.2.1.8). Strikingly, the phosphorylation of PKA substrates was also 
increased with the treatment of the PKC activator PMA (Figures 4.2.1.7 and 4.2.1.8). This 
could be an indication that PKC is an upstream activator of PKA.  
 
In order to be able to draw more conclusions from this relatively large dataset, the data 
represented in figures 4.2.1.5-8 were analysed (together with data from the following 
sections) by a systems biology approach using computational modelling detailed under 4.2.5. 
 
Preliminary experiments performed by the former group member Ziad Al Tanoury (Al 
Tanoury, 2009) and by myself suggest that L-plastin interacts with the proto-oncogene 
tyrosine-protein kinase Src (see under 4.4.1). In this regard we investigated whether Src 
might be indirectly involved in L-plastin Ser5 phosphorylation. Indeed the inhibition of Src by 
three different inhibitors led to a considerable decrease in L-plastin Ser5 phosphorylation in 
all cell lines except MCF7 (Figures 4.2.1.9 and 4.2.1.10).  
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Figure 4.2.1.9 The Src inhibitor PP2 decreases L-plastin Ser5 phosphorylation in SK-BR-3, 
BT-20 and MDA-MB-435S cells. Cells were treated with the Src inhibitor PP2 with or without 
subsequent PMA stimulation. L-plastin Ser5 phosphorylation was determined by immunoblot 
analysis. Quantification was performed as described in Figure 4.2.1.2. Data are represented 
as means +/- SD. Statistical significance was determined by an unpaired T-test with Welch’s 
correction. P<0.05 was considered significant. *P<0.05, **P<0.01, ***P<0.001 and n.s. – non-
significant. For each immunoblot shown, samples were run on the same gel, but for the 
MCF7 blot bands were cut and put in another order for presentation purposes. 
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Figure 4.2.1.10. The Src inhibitors SU6656 (SU) and Src inhibitor I (Src i I) decrease 
L-plastin Ser5 phosphorylation in invasive breast cancer cells. Cells were treated with Src 
inhibitors and L-plastin Ser5 phosphorylation was determined by immunoblot analysis. 
Quantification was performed as described in Figure 4.2.1.2. Data are represented as means 
+/- SD. Statistical significance was determined by an unpaired T-test with Welch’s correction. 
P<0.05 was considered significant. *P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant. 
For each immunoblot shown, samples were run on the same gel, but bands were cut and put 
in another order for presentation purposes. 
 
Moreover, we transfected cells with viral Src (v-Src) which has a constitutively active tyrosine 
kinase activity. Compared to human Src, v-Src is truncated in the C-terminal region and thus 
is devoid of residue Tyr530, the phosphorylation of which inactivates human Src. 
Transfection of v-Src-DsRed into all four cell lines led to a considerable increase in L-plastin 
Ser5 phosphorylation compared to cells transfected with DsRed alone (Figure 4.2.1.11). 
When cells were treated with the PKC inhibitor GF109203X following transfection, a 
decrease in L-plastin Ser5 phosphorylation was observed compared to the non-treated 
transfected cells (Figure 4.2.1.11). This is an indication that PKC might act downstream of 
Src in mediating L-plastin Ser5 phosphorylation. Interestingly, only the PKCδ isoform can be 
tyrosine phosphorylated and activated by Src (Li et al., 1994; Steinberg, 2004) and this is the 
isoform that was suggested to be involved in L-plastin phosphorylation in breast cancer cells 
(Al Tanoury et al., 2010; Janji et al., 2010). Tyrosine phosphorylation is specifically implicated 
in the regulation of only the PKCδ isoform as, in contrast to serine/threonine residues, 
tyrosine phosphorylation residues are not conserved across PKC family members 
(Steinberg, 2004). Tyrosine phosphorylation of PKCδ has been shown to involve Src kinase 
(Li et al., 1994; Sumandea et al., 2008). However, studies on the effects of Src-mediated 
tyrosine phosphorylation of PKCδ exhibit some discrepancy as tyrosine phosphorylation has 
been described to activate PKCδ (Gschwendt et al., 1994; Li et al., 1994), to modifiy PKCδ 
substrate specificity (Haleem-Smith et al., 1995), or to decrease PKCδ activity (Denning et 
al., 1993; Zang et al., 1997). These studies differ in several aspects such as cell type, nature 
of stimulus and whether PKCδ was tyrosine phosphorylated in vitro after purification or 
extracted from stimulated cells. Overall, tyrosine phosphorylation by Src seems to have two 
main effects: It increases the specific activity of PKCδ and it causes the protein to become 
unstable and prone to degradation (Blake et al., 1999). Moreover, alongside the studies 
showing that Src activation influences PKC activity (Gschwendt et al., 1994; Zang et al., 
1995), it has also been shown that PKC can lead to Src activation (Brandt et al., 2002; 
Brandt et al., 2003; Levi et al., 1998). Some studies indicated that PKC directly activates Src 
by phosphorylation of Ser12 and Ser48 (Gould et al., 1985; Moyers et al., 1993) and some 
report that other proteins such as PTPα and AFAP-110 play a role by relaying signals from 
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PKC to Src kinase (Brandt et al., 2003; Gatesman et al., 2004). In any case, our results 
suggest that Src acts upstream of PKC in the phosphorylation of L-plastin. 
 
 
Figure 4.2.1.11 Viral Src (v-Src) increases L-plastin Ser5 phosphorylation in breast cancer 
cells and this effect is abolished with PKC inhibition. Cells were transfected with v-Src-DsRed 
or DsRed alone. PKC inhibition with GF was performed before lysis as indicated. L-plastin 
Ser5 phosphorylation was determined by immunoblot analysis. Quantification was performed 
as described in Figure 4.2.1.2. Data are represented as means +/- SD. Statistical 
significance was determined by an unpaired T-test with Welch’s correction. P<0.05 was 
considered significant. *P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant.  
 
Overall, the above mentioned results show an involvement of Src and PKC and to a lesser 
extent PKA in L-plastin Ser5 phosphorylation. In vitro kinase assays already showed that 
PKA can directly phosphorylate L-plastin (Janji et al., 2006; Wang and Brown, 1999). In vitro 
L-plastin Ser5 phosphorylation by any isoform of PKC could not be shown (Jones et al., 
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1998). Accordingly, we performed an in vitro kinase assay to investigate whether PKCδ was 
able to directly phosphorylate L-plastin Ser5 with or without activation of PKCδ by Src and 
tyrosine phosphatase inhibition with Na3VO4. The addition of Src was performed on the basis 
of our finding that Src might act upstream of PKC in L-plastin Ser5 phosphorylation and of 
studies that provided evidence that Y311 phosphorylation of PKCδ was required to “fine 
tune” the PKCδ substrate specificity and was a prerequisite for the phosphorylation of 
cardiac troponin at T144 by PKCδ (Steinberg, 2012). However, in none of the tested 
conditions PKCδ was able to directly phosphorylate L-plastin Ser5 (Figure 4.2.1.12). 
Regrettably, we have to admit that we were lacking a known PKCδ substrate to be used as a 
proper positive control for this experiment. 
 
Figure 4.2.1.12 PKCδ cannot directly phosphorylate L-plastin Ser5 in vitro. 64 μg of 
recombinant GST-L-plastin-deltaABD2 were incubated with 100 ng of recombinant PKCδ 
with or without 50 ng recombinant Src and 0.1 mM Na3VO4 and with 50 μM of ATP in a 
reaction volume of 25 μl according to the manufacturer’s protocol. For the negative controls 
PKCδ was omitted. The “positive control” is an MDA-MB-435S cell lysate and is a control for 
the correct functioning of the immunoblotting procedure. Samples were incubated for 15 min 
at 30°C. Following incubation, Laemmli buffer was added, the samples were boiled at 100°C 
for 5 min and analysed by immunoblotting, visualising Ser5 phosphorylated L-plastin (P-LPL) 
and total L-plastin (LPL). 
 
As L-plastin Ser5 matches the consensus phosphorylation sequence for the Ser/Thr casein 
kinase II (CKII) (along with PKC and PKA), we also investigated whether this kinase is 
involved in L-plastin Ser5 phosphorylation by using the CKII-specific inhibitors tetra-bromo-
benzo-triazole (TBB) and tetra-bromo-cinnamic acid (TBCA). Moreover, as 
phosphatidylinositol 3-kinase (PI3K) was described to play a role in L-plastin phosphorylation 
in human neutrophils (Jones et al., 1998; Paclet et al., 2004), we investigated its effect in 
breast cancer cells by using the inhibitor wortmannin. None of these three inhibitors showed 
consistent effects on L-plastin Ser5 phosphorylation in the four breast cancer cell lines. 
 
Results   
74 
 
Since the hormones estrogen and progesterone play important roles in the regulation of 
normal mammary gland biology as well as in breast cancer, we investigated their effect on 
the estrogen and progesterone receptor-positive MCF7 cells (SK-BR-3, BT-20 and 
MDA-MB-435S being negative for both receptors). β-estradiol was used at 10 nM for 
incubation times between 1 h and 48 h and progesterone was used at 100 nM for 1 h to 48 h. 
However, we could not observe an increase of L-plastin Ser5 phosphorylation upon 
treatment with these hormones. 
 
Altogether, so far we can state that in our breast cancer cell lines PKC appears to be more 
important than PKA for mediating L-plastin Ser5 phosphorylation and that the tyrosine kinase 
Src appears to be an important contributor acting upstream of L-plastin Ser5 
phosphorylation. Nevertheless, since knockdown of PKCδ by siRNA was not equally efficient 
for reducing L-plastin Ser5 phosphorylation in all breast cancer cell lines and since no 
evidence for direct L-plastin phosphorylation by PKC could be provided, other yet to be 
identified kinases are likely to be involved in this process.  
 
4.2.2 Whole genome microarrays reveal enrichment of the ERK/MAPK 
pathway in breast cancer cells with high L-plastin Ser5 
phosphorylation 
This part was accomplished in collaboration with Dr. Laurent Vallar, Arnaud Muller and Tony 
Kaoma from the Genomics Research Unit of the Luxembourg Institute of Health. 
 
In parallel to the analysis of the potential involvement of various kinases in L-plastin Ser5 
phosphorylation, a whole genome microarray study was set up in order to compare non-
invasive breast cancer cell lines with low baseline Ser5 phosphorylation (MCF7 and 
SK-BR-3) versus invasive breast cancer cell lines with high baseline Ser5 phosphorylation 
(BT-20 and MDA-MB-435S) in order to detect differences in signal transduction pathways.  In 
addition, we treated the two non-invasive cell lines with PMA to obtain a strong L-plastin Ser5 
phosphorylation and compared the PMA-treated to untreated cells (Fig. 4.2.2 left). In order to 
perform microarray analysis total RNA was isolated from triplicate cell cultures and 
microarray data were obtained using Affymetrix technologies. Lists of differentially expressed 
transcript clusters were established as described in the Materials and Methods section and 
transcript cluster mapping and analysis was performed using Ingenuity Pathway Analysis® 
(IPA). For the comparison of PMA-treated cells versus untreated controls, we thus obtained a 
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first list of DEGs for MCF7 and a second for SK-BR-3 cells. For the comparison of our two 
invasive and two non-invasive cancer cell lines, we obtained another four lists of differentially 
expressed transcript clusters (Fig. 4.2.2 right), the intersection of which was mapped by IPA 
to obtain a third list of DEGs. Taking the intersection of the four lists enabled us to focus on 
the genes that are differentially expressed between all comparisons of invasive versus non-
invasive cells, thus setting a stringent filter. The three lists can be found in the appendix. 
In order to assess a difference in signalling pathways between the compared conditions, we 
focused on canonical signalling pathways in IPA. For each of the three comparisons of 
interest, IPA revealed a list of canonical signalling pathways (see appendix) from which we 
selected those that were significant (-log(p-value)>1.301) and thus enriched by genes that 
are significantly differentially expressed. Interestingly, we identified three canonical signalling 
pathways that were common to the three lists: ERK/MAPK Signalling, UVA-Induced MAPK 
Signalling and Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
(Fig. 4.2.2 bottom). These results suggest an involvement of one or more of these pathways 
in L-plastin Ser5 phosphorylation. 
 
 
Figure 4.2.2 Enrichment of the ERK/MAPK pathway in breast cancer cells with high L-plastin 
Ser5 phosphorylation. Non-invasive cell lines were treated with PMA and resulting L-plastin 
Ser5 phosphorylation was determined by immunoblot analysis. Whole genome microarray 
analysis was then used to compare breast cancer cells with differential L-plastin Ser5 
phosphorylation levels and invasive capacities. Three comparisons were analysed: 1. PMA-
treated versus untreated MCF7 cells; 2. PMA-treated versus untreated SK-BR-3 cells; 3. 
intersection between comparisons of invasive versus non-invasive cells (BT-20 vs. MCF7, 
MDA-MB-435S vs. MCF7, BT-20 vs. SK-BR-3 and MDA-MB-435S vs. SK-BR-3). 
Differentially expressed transcript clusters (DE transcr. cl.) were identified for the three 
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comparisons and were mapped and analysed by IPA. For each of the three comparisons of 
interest, IPA revealed a list of canonical signalling pathways (see Supplemental microarray 
data in the appendix) from which we selected those that were significant (-log(p-value) > 
1.301) and thus enriched by genes that are differentially expressed. Three canonical 
signalling pathways were common to the three lists: ERK/MAPK Signalling, UVA-Induced 
MAPK Signalling and Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid 
Arthritis. Adapted from (Lommel et al., 2015). 
 
4.2.3 RSK1 as well as RSK2 specifically phosphorylate residue Ser5 of 
L-plastin in vitro 
L-plastin peptides were synthesised and screened for Ser5 phosphorylation by 43 candidate 
kinases identified using the phosphorylation prediction algorithm KSPv2 from KINEXUS. In 
addition to PKA, which was previously shown to be able to phosphorylate L-plastin Ser5 in 
vitro (Janji et al., 2006; Wang and Brown, 1999), our screening identified RSKs as well as 
MSK1 as top candidate kinases for phosphorylating this residue. As shown in Table 4.2.3, 
these kinases led to high radioactivity counts for the wild type L-plastin peptide (WT) as well 
as for the Ser7-to-alanine mutated peptide (MT), both peptides being devoid of the initiator 
methionine and acetylated on the N-terminal alanine. The WT peptide displayed higher 
counts for the named kinases than the MT peptide indicating that phosphorylation occurs not 
only at residue Ser5, but also at Ser7. It is however noteworthy that Ser7 phosphorylation is 
not required for Ser5 phosphorylation by the investigated kinases, as significant Ser5 
phosphorylation was always also observed in the absence of the Ser7 residue. This is in line 
with the finding of Jones and colleagues, showing that Ser5 is necessary for L-plastin 
phosphorylation and that Ser7 might also be phosphorylated but with a requirement for Ser5 
phosphorylation to achieve Ser7 phosphorylation (Jones et al., 1998). Importantly, the same 
kinases appear in the top positions for both WT and MT peptides. Validation experiments as 
well as experiments with the WT and MT peptides still containing the initiator methionine 
were performed and showed higher radioactivity counts for methionine containing peptides 
but always similar rankings (in appendix). 
 
 
 
Table 4.2.3 For in vitro kinase assays on L-plastin peptides, the peptides were mixed with 
individual protein kinases in the presence of [γ-33P] ATP for 20-40 min, depending on the 
protein kinase tested. The assay was terminated by spotting 10 μl of the reaction mixture 
onto a multiscreen phosphocellulose P81 plate. After removing unreacted [γ-33P] ATP from 
the reaction, radioactivity was quantified in counts per minute (cpm) in a scintillation counter. 
Adapted from (Lommel et al., 2015). 
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Ranking Kinases Counts (cpm) Kinases Counts (cpm) 
  *ARGSVSDEERR 
(WT) 
 *ARGSVADEERR 
(MT) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
RSK2 
PKAca 
RSK1 
MSK1 
RSK3 
PKAcb 
RSK4 
PKAcg 
SGK3 
SGK2 
PRKG2 
PKCh 
p70S6Kb 
AURORA B 
STK33 
PKCq 
VRK1 
PRKX 
PRKG1 
CAMK1b 
VRK2 
CAMK4 
PKCe 
DCAMKL2 
MNK1 
DCAMKL1 
NDR 
PKCd 
PIM2 
SGK1 
116698 
109766 
101952 
86947 
71917 
54673 
45174 
40167 
32646 
32129 
29921 
29273 
19894 
12688 
9990 
9671 
9054 
8310 
8189 
8126 
7876 
6955 
6779 
5726 
5718 
5437 
5072 
4597 
4405 
4243 
RSK1 
PKAca 
MSK1 
RSK2 
PKAcb 
PKAcg 
RSK3 
PRKG2 
RSK4 
SGK2 
SGK3 
STK33 
PKCh 
AURORA B 
PRKG1 
PRKX 
DCAMKL1 
VRK1 
VRK2 
MNK1 
PKCe 
CAMK4 
DCAMKL2 
p70S6Kb 
CAMK1b 
NDR 
PKCq 
IKKe 
NDR2 
ASK1 
55774 
53986 
53254 
48800 
34148 
33572 
32917 
26041 
22477 
22249 
20290 
10761 
10007 
9696 
9110 
8113 
5899 
5745 
5470 
5430 
5053 
4668 
4447 
4242 
3996 
3797 
3589 
3422 
3284 
2771 
Results   
78 
 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
NDR2 
MSK2 
IKKe 
AKT1 
ASK1 
PIM3 
p70S6K 
AKT3 
AKT2 
PIM1 
CK2a2 
AURORA C 
CHK1 
3821 
3741 
3437 
3257 
3241 
2732 
2454 
2196 
2142 
892 
892 
588 
176 
SGK1 
PKCd 
AKT1 
p70S6K 
PIM2 
PIM3 
AKT3 
AKT2 
MSK2 
PIM1 
AURORA C 
CHK1 
CK2a2 
2540 
2329 
1920 
1911 
1813 
1537 
1460 
1242 
1005 
922 
663 
256 
44 
*N-terminal alanine is acetylated 
 
As the in vitro kinase assays performed on L-plastin peptides identified RSK1, RSK2 and 
MSK1 as candidate kinases (Table 4.2.3), we also tested these kinases for their ability to 
phosphorylate recombinant full-length L-plastin on residue Ser5 in vitro. As shown in Figure 
4.2.3, both RSK1 and RSK2 were able to strongly phosphorylate L-plastin on residue Ser5 
while MSK1 was merely able to induce a weak L-plastin Ser5 phosphorylation. In parallel, 
PKCδ was again tested here on the full-length recombinant L-plastin and did again not show 
any phosphorylation activity towards L-plastin Ser5. 
 
 
Figure 4.2.3 RSK1 and RSK2 are able to directly phosphorylate L-plastin Ser5 in vitro. 10 μg 
of recombinant full-length L-plastin were incubated with 100 ng of recombinant kinase and 
with 50 μM of ATP in a reaction volume of 25 μl according to the manufacturer’s protocol. For 
each kinase assay a control was performed by omitting the respective kinase. Samples were 
incubated for 15 min at 30°C. Following incubation, Laemmli buffer was added, the samples 
were boiled at 100°C for 5 min and analysed by immunoblot visualising Ser5 phosphorylated 
L-plastin (P-LPL) and total L-plastin (LPL). Adapted from (Lommel et al., 2015). 
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4.2.4 RSK1/2 protein expression levels largely correlate with the 
invasive status of breast cancer cell lines whereas RSK protein 
activity levels do not 
Following our findings that RSK1 and RSK2 mediate in vitro L-plastin Ser5 phosphorylation 
and because in invasive breast cancer cell lines we have higher L-plastin Ser5 
phosphorylation than in non-invasive cell lines, we analysed whether there is a correlation 
between RSK1/2 expression and/or activity level and the invasive status of breast cancer cell 
lines. 
 
We started by performing IPA upstream analysis to investigate whether RSK1/2 proteins are 
differentially activated in invasive compared to non-invasive cell lines, making use of our 4 
lists (corresponding to invasive versus non-invasive) and applying the parameters false 
discovery rate FDR<0.01 and absolute fold change FC>4. As a result, we could not infer in 
silico significant enrichment of RSK1/2 activity in any of the 4 lists. Thus, no upregulation of 
RSK1 or RSK2 activity upstream of transcriptional regulation could be detected in any of the 
four invasive versus non-invasive comparisons.  
 
Since RSK activity is not limited to transcriptional regulation, we proceeded by directly 
comparing RSK1/2 protein levels as well as the levels of the phosphorylated, active form of 
RSK1/2 between the different investigated cell lines. RSK1 protein levels were found to be 
higher in the two invasive cell lines BT-20 and MDA-MB-435S compared to the two non-
invasive cell lines MCF7 and SK-BR-3 (Figure 4.2.4.1). RSK2 was highly expressed in the 
invasive cell lines BT-20, MDA-MB-435S as well as in MCF7 cells and at a lower level in 
SK-BR-3 cells (Figure 4.2.4.1).  
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Figure 4.2.4.1 Protein levels of RSK1 and RSK2 in four breast cancer cell lines. Cell extracts 
were subjected to immunoblot analysis using antibodies specific for RSK1, RSK2 and β-actin 
as a loading control. 
 
Using an antibody specifically recognising the phosphorylated forms of RSK1 and RSK2, we 
investigated the phosphorylation levels in our four cell lines (Figure 4.2.4.2). Our results 
indicate that SK-BR-3 and MDA-MB-435S have higher RSK1/2 phosphorylation levels than 
MCF7 and BT-20. In addition, phosphorylation of RSK1/2 was increased upon EGF or PMA 
stimulation in the four cell lines. 
So far, higher RSK1 and RSK2 protein levels in invasive versus non-invasive cells seem to 
largely correlate with higher baseline L-plastin Ser5 phosphorylation in invasive versus non-
invasive cells. However, the levels of the phosphorylated RSK1/2 forms do not correlate with 
the invasiveness of the respective cell lines. 
 
 
Figure 4.2.4.2 Levels of phosphorylated RSK1/2 in four breast cancer cell lines with or 
without EGF or PMA stimulation. Cell extracts were subjected to immunoblot analysis using 
antibodies specific for P-RSK1/2 and tubulin as a loading control. (Note: MDA refers to 
MDA-MB-435S.) 
 
 
4.2.5 The ERK/MAPK pathway and its downstream RSK kinases are 
involved in L-plastin Ser5 phosphorylation in breast cancer cells 
The two newly identified prime candidate kinases capable of phosphorylating L-plastin on 
Ser5 in vitro, RSK1 and RSK2, are downstream effectors of the ERK/MAPK pathway (Anjum 
and Blenis, 2008). In addition, the results of our microarray experiments have also suggested 
an involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation. Altogether 
these findings prompted us to further investigate the role of the ERK/MAPK pathway in 
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L-plastin Ser5 phosphorylation. In a first step, we inhibited selected signalling molecules of 
this pathway and we showed that PKC inhibition with the widely-used pan-PKC inhibitor 
GF109203X, MEK1/2 inhibition with PD98059 as well as RSK inhibition with BI-D1870 
decreased baseline L-plastin Ser5 phosphorylation in invasive cells (Fig. 4.2.5.1).  
 
Figure 4.2.5.1 Inhibitors of molecules of the ERK/MAPK pathway reduce L-plastin 
Ser5 phosphorylation in invasive breast cancer cells. Invasive cell lines exhibiting high 
baseline L-plastin Ser5 phosphorylation were treated with inhibitors of selected signalling 
molecules of the ERK/MAPK pathway GF109203X (GF), PD98059 (PD) and BI-D1870 (BID). 
Subsequent to inhibitor treatment, residual L-plastin Ser5 phosphorylation was determined 
by immunoblot analysis. Quantification was performed as described in Figure 4.2.1.2. Data 
are represented as means +/- SD. Statistical significance was determined by an unpaired 
T-test with Welch’s correction. P<0.05 was considered significant. *P<0.05, **P<0.01, 
***P<0.001 and n.s. – non-significant. Samples were run on the same gel, but for BT-20 
bands were cut and put in another order for presentation purposes. Adapted from (Lommel et 
al., 2015). 
 
In a second step, we took advantage of the fact that the ERK/MAPK pathway is one of the 
major signalling pathways activated upon binding of various growth factors to the 
corresponding receptor tyrosine kinases. Knowing that the EGFR family plays a key role in 
normal breast development and in breast cancer (Eccles, 2011), and as the EGFR is capable 
to trigger cell migration through ERK/MAPK pathway signalling (Tarcic et al., 2012), we 
investigated L-plastin Ser5 phosphorylation in our breast cancer cells after EGF stimulation. 
As expected, stimulation with EGF did not increase L-plastin phosphorylation in the two 
EGFR-negative cell lines MCF7 and MDA-MB-435S, even when stimulated with high EGF 
concentrations (Figure 4.2.5.2). However, EGF treatment highly increased L-plastin Ser5 
phosphorylation in SK-BR-3 and BT-20 cells at all tested concentrations (Figure 4.2.5.2).  
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Figure 4.2.5.2 Analysis of EGF-dependent L-plastin Ser5 phosphorylation. Cells were 
stimulated for 15 min with different EGF concentrations and cell extracts were subjected to 
immunoblot analysis using antibodies specific for Ser5 phosphorylated L-plastin  
(P-LPL) and total L-plastin (LPL). Adapted from (Lommel et al., 2015). 
 
Importantly, preincubation with inhibitors of the ERK/MAPK pathway impaired L-plastin 
phosphorylation upon PMA or EGF stimulation in all tested cell lines (Figure 4.2.5.3A). To 
exclude off-target effects, we confirmed our results with a second RSK inhibitor, SL0101, 
which also impaired EGF-triggered L-plastin phosphorylation in SK-BR-3 and BT-20 cells 
and decreased baseline L-plastin phosphorylation in invasive cell lines (Figure 4.2.5.4). 
Interestingly, the strongest decrease of L-plastin Ser5 phosphorylation was obtained for the 
combined inhibition of RSK and PKC (Figure 4.2.5.3A). Finally, Trametinib, a clinical MEK 
inhibitor approved by the U.S. Food and Drug Administration for melanoma treatment (trade 
name Mekinist), clearly reduced baseline L-plastin Ser5 phosphorylation in invasive cell lines 
and prevented an EGF-triggered increase of L-plastin Ser5 phosphorylation in SK-BR-3 and 
BT-20 cells (Figure 4.2.5.3B). Altogether these results provide solid evidence for a major 
involvement of the ERK/MAPK signalling pathway in L-plastin Ser5 phosphorylation. 
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Figure 4.2.5.3 Involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation in 
breast cancer cells. A) Cells were preincubated with inhibitors of the ERK/MAPK pathway, 
GF109203X (GF), PD98059 (PD) and BI-D1870 (BID), and then stimulated with EGF (for the 
two EGFR expressing cell lines) or PMA (for the four cell lines). Quantification was 
performed as described in Figure 4.2.1.2. Data are represented as means +/- SD. For each 
immunoblot shown, samples were run on the same gel, but for MDA-MB-435S bands were 
cut and put in another order for presentation purposes. B) Cells were treated with Trametinib 
(Tram) with or without subsequent EGF stimulation. Quantification was performed as 
described in Figure 4.2.1.2. Data are represented as means +/- SD. Statistical significance 
was determined by an unpaired T-test with Welch’s correction. P<0.05 was considered 
significant. *P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant. Adapted from (Lommel 
et al., 2015). 
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Figure 4.2.5.4 The RSK inhibitor SL0101 decreases L-plastin Ser5 phosphorylation. Cells 
were treated with SL0101 and with EGF as indicated. For quantification the ratio between the 
intensities obtained for phosphorylated L-plastin (P-LPL) versus total L-plastin (LPL) was 
determined. For each immunoblot shown, samples were run on the same gel, but in some 
cases bands were cut and put in another order for presentation purposes. 
 
4.2.6 2-D gel electrophoresis suggests that RSK phosphorylates 
L-plastin on Ser5 but not on other residues 
These experiments were performed in collaboration with Prof. Christophe Ampe and Prof. 
Marleen van Troys from the University of Ghent. 
 
In order to analyse the phosphorylation of L-plastin in more detail, with a specific focus on 
the extent of phosphorylation in response to different treatment conditions, we performed 
two-dimensional gel electrophoresis with lysates of differentially treated BT-20 cells. Using 
the PhosphoSitePlus® website we found the isoelectric point of L-plastin to be 5.29 for the 
unsphosphorylated form, 5.24 for L-plastin with one phosphorylated residue and 5.2, 5.15, 
5.11, 5.07 for increasing numbers of phosphorylated residues. As the isoelectric point 
corresponds to the pH level at which L-plastin has no global electrical charge, we performed 
isoelectric focusing in a pH range from 4 to 7. Figure 4.2.6 shows blots after isoelectric 
focusing (horizontal separation) and SDS-PAGE (vertical separation). Highly negatively 
charged and thus highly phosphorylated proteins are found on the ‘+’ side and less 
phophorylated proteins are found on the ‘-’ side.  In contrast to our expectation to see clearly 
seperated spots corresponding to L-plastin proteins with distinct numbers of phosphorylated 
residues, we rather detected a line where only some spots can be recognised. As we count 
five to six spots, L-plastin seems to be phosphorylated on five to six residues. Since the 
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spots corresponding to phosphorylated L-plastin were not clearly distinguishable from the 
spot of non-phosphorylated L-plastin, we were not able to calculate an exact ratio of 
phosphorylated versus non-phosphorylated protein. Interestingly however, with the staining 
for Ser5 phosphorylated L-plastin, we reveal that Ser5 is a crucial phosphorylation site as all 
L-plastin spots except the very left, non-phosphorylated spot, are phosphorylated on Ser5. 
We can thus also conclude that an important part of L-plastin is Ser5 phosphorylated. This is 
true for non-treated cells as well as for cells treated with PMA or EGF. However, upon 
treatment with the RSK inhibitor BID, L-plastin Ser5 phosphorylation is dramatically 
decreased whereas overall L-plastin phosphorylation seems to be largely unaffected. This 
indicates that RSKs are involved in the phosphorylation of L-plastin on Ser5 but not of other 
L-plastin phosphorylation residues. 
 
Figure 4.2.6 Analysis of L-plastin phosphorylation by 2-D gel electrophoresis. BT-20 cells 
were treated with PMA, EGF or EGF + BI-D1870 and then lysed. Isoelectric focusing and 
SDS-PAGE were performed and membranes were blotted against L-plastin (LPL) and Ser5 
phosphorylated L-plastin (P-LPL)-specific antibodies. 
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4.2.7 Modelling of the L-plastin signalling pathway using a probabilistic 
Boolean network (PBN) approach 
This part was accomplished in collaboration with Dr. Panuwat Trairatphisan and Prof. 
Thomas Sauter from the Systems Biology Group of the University of Luxembourg, who 
performed probabilistic Boolean network modelling on our experimental data. 
 
Literature reports as well as our experimental data presented before (section 4.2.1) show the 
involvement of PKA (Janji et al., 2006; Wang and Brown, 1999) and PKC (Al Tanoury et al., 
2010; Freeley et al., 2012; Janji et al., 2010; Jones et al., 1998; Lin et al., 1998; Paclet et al., 
2004; Pazdrak et al., 2011) in L-plastin Ser5 phosphorylation, and most importantly, our 
newest results also highlight a role for RSK kinases in this process. As the network of 
signalling events that control L-plastin Ser5 phosphorylation is not clearly understood, 
quantitative computational simulation of signalling cascades was applied for a better 
understanding of the hierarchy of these regulatory events. We applied the optPBN toolbox to 
further study and analyse these pathways in the PBN framework (Trairatphisan et al., 2014). 
We built a PBN model which represents the network topology of signalling pathways 
upstream of L-plastin Ser5 phosphorylation based on literature information and own findings 
(Figure 4.2.7.1). Our model is mainly focused on the ERK/MAPK pathway (downstream of 
the EGFR) and includes Src, PKC and PKA kinases which are known to interact with this 
pathway. Then, we fitted the PBN model to our extensive dataset comprising activation and 
inhibition of various network nodes which modulate the signals towards the two measured 
output nodes, i.e. L-plastin Ser5 phosphorylation and PKA substrate phosphorylation in four 
breast cancer cell lines. To this end, we took into account the described off-target effects of 
the inhibitors GF109203X and H89 on RSK (Alessi, 1997; Davies et al., 2000). As a result, 
we obtained a model which explained well our experimental data for all four cell lines as 
shown in Figure 4.2.7.2.  
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Figure 4.2.7.1 Literature-derived and experiment-based L-plastin signalling network. A 
candidate network for the signalling pathways upstream of L-plastin Ser5 phosphorylation 
was built based on literature information and own experimental findings. The network 
interactions were analysed by applying a probabilistic Boolean network approach taking into 
account cell line-specific immunoblot-based quantifications of phosphorylated L-plastin and 
phosphorylated PKA substrates. Various conditions were tested in breast cancer cell lines 
including activation by EGF, PMA or 8-Bromo-cAMP (8Br) and/or inhibition by GF109203X 
(GF), H89, PP2, PD98059 (PD) or BI-D1870 (BID). Adapted from (Lommel et al., 2015). 
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Figure 4.2.7.2 PBN model fitting results in comparison to experimental data for the various 
tested conditions. Coloured bars at the right of the figure indicate the conditions tested for the 
individual cell lines MCF7, SK-BR-3 (SK), BT-20 (BT), MDA-MB-435S (MDA). For 
quantification the ratios between the intensities obtained for phosphorylated L-plastin (P-LPL) 
respectively phosphorylated PKA substrates (P-PKAsubstrates) versus total L-plastin (LPL) 
were determined to make individual samples comparable and then normalised to the mean 
of all the values obtained in one experiment to make blots comparable by accounting for 
technical day-to-day variability. Data generated from different experimental sets were 
normalised to the calibrator PMA, subsequently pooled and scaled to the highest signal (of 
each respective graph) for presentation purposes. Means of ten simulated values from the 
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PBN model (black stars) were compared against the experimental data (multi-coloured 
squares [mean] and error bars [SD]). Adapted from (Lommel et al., 2015). 
 
As we found RSK kinases to be essential for L-plastin Ser5 phosphorylation, the fitted PBN 
model was used to investigate whether RSK kinases have a larger effect on L-plastin in the 
four cell lines than PKA and PKC. In addition, we analysed whether the crosstalk interactions 
between PKC and PKA suggested in the literature (Sugita et al., 1997; Yao et al., 2008) are 
important to modulate the signal transduction upstream of L-plastin Ser5 phosphorylation. 
We therefore applied an in silico knockout approach where we removed an interaction from 
the model one-at-a-time and checked if the removal affected the fitting quality. Five 
interactions situated in close proximity to our output nodes were analysed, i.e. 
RSK→L-plastin, PKC→L-plastin, PKA→L-plastin, PKC→PKA and PKA→PKC (Table 
4.2.7.1). We found that removing the interactions RSK→L-plastin and PKC→PKA led to a 
dramatic increase of the model fitting costs in all four cell lines, meaning that the networks 
missing one of these two interactions fitted our experimental data less well. The individual 
knockout of the other three interactions only led to minor changes in fitting costs, suggesting 
that none of these three interactions is necessary to explain our experimental data. 
 
Table 4.2.7.1 The fitting costs of model variants after removing individual interactions were 
compared to those of the initial model structure prior to removal. The fitting cost is the sum of 
squared error between simulated state values and the mean values of the experimental data. 
Adapted from (Lommel et al., 2015). 
 MCF7 SK-BR-3 BT-20 MDA-MB-435S 
Initial model 0.2298 0.2942 0.2961 0.3126 
RSK → LPL removed 0.7872 1.0344 0.6921 1.2369 
PKC → LPL removed 0.2298 0.2942 0.2962 0.3126 
PKA → LPL removed 0.2318 0.2942 0.2966 0.3126 
PKC → PKA removed 0.7163 0.4520 0.4245 0.4622 
PKA → PKC removed 0.2298 0.2942 0.3045 0.3452 
 
We then proceeded by examining the optimised selection probability weights of each 
interaction and their distributions obtained via bootstrapping (see Materials and Methods 
section). A subset of the obtained weight distributions of the interactions is shown in Table 
4.2.7.2. All weights are illustrated in Figure 4.2.7.3. Strikingly, in all four cell lines the 
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activation of L-plastin by RSK is largely predominant as compared to its activation by PKC or 
PKA. In addition, the weights attributed to the investigated interactions indicate that in all four 
cell lines the PKC-PKA interaction appears to be directed from PKC to PKA rather than from 
PKA to PKC. The relatively low standard deviations on the weights ensured that these 
findings are robust against experimental variation in the dataset. Figure 4.2.7.4 shows the 
final structure of the L-plastin signalling pathway as revealed by PBN modelling. 
 
 
Table 4.2.7.2 The distributions of identified weights obtained via bootstrapping have been 
investigated for the five interactions in the four cell lines. The obtained weights are shown as 
mean and (standard deviation). Adapted from (Lommel et al., 2015). 
  MCF7 SK-BR-3 BT-20 MDA-MB-435S 
RSK → LPL 0.888 (0.081) 1.000 (0.000) 0.948 (0.070) 1.000 (0.000) 
PKC → LPL 0.004 (0.023) 0.000 (0.000) 0.025 (0.058) 0.000 (0.000) 
PKA → LPL 0.108 (0.073) 0.000 (0.000) 0.027 (0.023) 0.000 (0.000) 
PKC → PKA 0.407 (0.060) 0.236 (0.049) 0.262 (0.059) 0.252 (0.093) 
PKA → PKC 0.072 (0.112) 0.005 (0.017) 0.256 (0.189) 0.204 (0.068) 
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Figure 4.2.7.3 Optimised weights of interactions for the L-plastin signalling network. 
Bootstrapping was performed by randomly sampling 100 artificial datasets based on means 
and standard deviations as acquired from the experimental data. Optimisation was 
subsequently performed 100 times to identify the distribution of the identified selection 
probabilities. Means and standard deviations of the weights of the interactions were 
compared among the four cell lines. Adapted from (Lommel et al., 2015). 
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Figure 4.2.7.4 L-plastin signalling pathway as revealed by PBN modelling. A PBN modelling 
approach based on cell line-specific immunoblot-based quantifications of Ser5 
phosphorylated L-plastin and phosphorylated PKA substrates revealed that RSK is crucial for 
L-plastin Ser5 phosphorylation whereas PKC and PKA play a minor role in this event in the 
four tested cell lines. In addition, our PBN modelling results indicate that in all four cell lines 
the PKC-PKA interaction appears to be directed from PKC to PKA rather than from PKA to 
PKC. Adapted from (Lommel et al., 2015). 
 
 
 
4.2.8 Combined RSK1 and RSK2 knockdown by siRNA decreases 
L-plastin Ser5 phosphorylation 
Altogether, we provide evidence that RSK kinases are involved in L-plastin Ser5 
phosphorylation by in vitro kinase assays, by inhibition with two different RSK inhibitors as 
well as by computational modeling. To further consolidate our findings, we simultaneously 
knocked down RSK1 and RSK2 by an siRNA approach. Albeit RSK knockdown was not 
equally efficient in all the investigated cell lines, we were able to observe a decrease of Ser5 
phosphorylated L-plastin in all four cell lines following the combined knockdown of RSK1 and 
RSK2 (Figure 4.2.8). It is interesting to note that for SK-BR-3 and MDA-MB-435S, for which 
an efficient RSK knockdown could be obtained, the decrease in L-plastin Ser5 
phosphorylation was more important than for MCF7 and BT-20, with a less efficient RSK 
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knockdown. The remaining L-plastin Ser5 phosphorylation might be due to residual RSK1 
and RSK2 protein presence after knockdown. Altogether, even though phosphorylation was 
not completely abolished, our data clearly confirm an important role for RSKs in L-plastin 
Ser5 phosphorylation.  
 
 
Figure 4.2.8 Combined RSK1 and RSK2 knockdown decreases L-plastin Ser5 
phosphorylation in breast cancer cells. siRNA against RSK1 and RSK2 or scrambled siRNA 
were transfected in the four cancer cell lines as indicated and L-plastin Ser5 phosphorylation, 
RSK1 and RSK2 expression were assessed by immunoblot analysis 72 h post transfection. 
Non-invasive cell lines were treated with EGF or PMA as indicated. Quantification was 
performed as described in Figure 4.2.1.2. For presentation purposes, the values obtained 
with RSK1+2 siRNA were scaled to the signal obtained with scrambled siRNA. The resulting 
graphs depict means +/- SD from two (for SK-BR-3 and BT-20 cells), three (for MCF7 cells) 
and six (for MDA-MB-435S cells) biological replicates. For experiments with at least 3 
replicates, statistical significance was determined by an unpaired T-test with Welch’s 
correction (*P<0.05, **P<0.01, ***P<0.001 and n.s. – non-significant). Representative blots 
are shown. Adapted from (Lommel et al., 2015). 
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Overall, our data presented in section 4.2 clearly reveal a role for the ERK/MAPK pathway 
and its downstream kinases RSK1 and RSK2 in L-plastin Ser5 phosphorylation in breast 
cancer cells. Notably, a whole genome microarray analysis pointed to the involvement of the 
ERK/MAPK pathway in this phosphorylation step and this finding was confirmed by a 
detailed analysis of this pathway performing activation/inhibition studies. Moreover, in vitro 
kinase assays and siRNA-mediated knockdown experiments revealed the implication of 
RSK1 and RSK2 in this phosphorylation. Finally, a computational modelling approach 
corroborated that in all four cell lines RSK is largely predominant as compared to PKC and 
PKA in the event of L-plastin Ser5 phosphorylation. 
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4.3 Link between L-plastin Ser5 phosphorylation by RSK and 
invasion and migration of breast cancer cells 
In order to investigate whether there is a link between RSK activity responsible for L-plastin 
Ser5 phosphorylation and cell migration and invasion capacities, we investigated the effect of 
RSK knockdown on migration and invasion in MDA-MB-435S cells. This cell line was 
selected as it has the highest invasive capacity as shown in Figure 4.1.3.2. In vitro scratch 
wound assays revealed that the combined knockdown of RSK1 and RSK2 considerably 
slowed down MDA-MB-435S cell migration and invasion by up to 30% (Figure 4.3.1) 
whereas cell proliferation remained largely unaffected (data not shown).  
 
 
Figure 4.3.1 Combined RSK1 and RSK2 knockdown impairs migration and invasion in 
breast cancer cells. MDA-MB-435S cells were seeded in collagen I-coated (200 µg/ml) 
96-well plates and transfected with siRNA against RSK1 and RSK2 or with scrambled siRNA. 
After 24 h, a wound was scratched across each well with the Cellplayer 96-well woundmaker. 
To study invasion, cells were covered with collagen I (1.5 mg/ml) diluted in cell culture 
medium. To study migration, cell culture medium was added to the cells. Migration and 
invasion were monitored by measuring wound confluence every 3 h for a total of 72 h with 
the Incucyte LiveCell Imaging System. The graphs depict means +/- SEM from all technical 
replicates obtained from three independent experiments. Efficient knockdown of RSK1 and 
RSK2 as well as efficient decrease of L-plastin Ser5 phosphorylation were confirmed by 
immunoblot analysis (quantifications included in Figure 4.2.8). Adapted from (Lommel et al., 
2015). 
 
Moreover, we investigated whether endogenous RSK activity affects actin, L-plastin and 
Ser5 phosphorylated L-plastin localisation in migrating cells. To this end, SK-BR-3 cells were 
plated on glass coverslips coated with fibronectin and at approximately 90% confluence a 
wound was scratched. Immunofluorescent staining of L-plastin, Ser5 phosphorylated 
L-plastin and actin was performed after EGF treatment with or without prior treatment with 
the RSK inhibitor BI-D1870 in cells migrating into the scratched wound. As a result we 
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observed that EGF treatment led to an increased formation of ruffling membranes, 
microspikes and even longer filopodia-like structures embedded in the cortical region of the 
cell, all of which are structures playing a role in cell migration. Strikingly, L-plastin was highly 
enriched in these structures. Interestingly, RSK inhibition with BI-D1870 treatment prior to 
EGF stimulation did not abolish, but clearly reduced the formation of these migratory 
structures and the redistribution of L-plastin to these structures. Ser5 phosphorylated 
L-plastin could only be visualised in the cells following EGF treatment and was also found in 
ruffling membranes and in microspikes. The staining for Ser5 phosphorylated L-plastin 
completely disappeared with RSK inhibition. The same experiment was performed with 
BT-20 cells and led to similar conclusions although the phenotype was less obvious as these 
cells display a less well-organised actin cytoskeleton at all tested conditions (data not 
shown). Altogether, these results indicate a qualitative link between L-plastin Ser5 
phosphorylation by RSK and its localisation to migratory structures upon EGF stimulation.  
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Figure 4.3.2 L-plastin Ser5 phosphorylation and localisation in migratory structures upon 
EGF stimulation is dependent on RSK activity. SK-BR-3 cells were plated on fibronectin-
coated coverslips and were serum-starved for 24h. At approximately 90% confluence a 
wound was scratched with a micropipette tip and cells were subsequently treated with 
vehicle or EGF (100 ng/ml) with or without prior treatment with BI-D1870 (5 μM). 1 h 
following treatment, the coverslips were fixed and subsequently stained with phalloidin and 
an antibody specific for L-plastin or Ser5 phosphorylated L-plastin (anti-Ser5-P antibody, 
P-L-plastin) before being analysed by confocal microscopy. The scale bar shown represents 
25 μm. Adapted from (Lommel et al., 2015). 
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4.4 L-plastin interaction partners 
 
4.4.1 GFP-Trap followed by immunoblotting 
In osteoclasts, L-plastin has been found to induce the formation of actin aggregates 
functioning as a core in the recruitment of signalling molecules (Ma et al., 2010) which 
suggests that L-plastin may act as a scaffolding protein. Indeed, L-plastin has been shown to 
form a complex with cortactin in MCF7 cells (Al Tanoury et al., 2010). Cortactin is an actin 
filament-binding protein that connects signalling pathways to cytoskeleton restructuring for 
migration and invasion (Lai et al., 2009). It is found in lamellipodia, invadopodia, podosomes, 
and at intercellular contact sites (El Sayegh et al., 2004; Linder and Aepfelbacher, 2003). 
Cortactin is a major substrate of the tyrosine kinase Src (Wu et al., 1991) and previous 
pulldown assays performed in our lab have pointed to an interaction of L-plastin with Src in 
HEK cells (Al Tanoury, 2009). These preliminary pulldown results prompted us to perform 
coimmunoprecipitation experiments using the GFP-Trap assay (Rothbauer et al., 2008) in 
HEK cells. This assay makes use of bead-linked monovalent lama antibodies directed 
against GFP and allows fast and efficient purification of GFP fusion proteins and their 
associated complexes formed in the cell. HEK cells transiently expressing GFP, L-plastinWT-
GFP, L-plastinSA-GFP (unphosphorylatable L-plastin variant due to substitution of Ser5 into 
alanine) or L-plastinSE-GFP (mimics L-plastin phosphorylation by the substitution of Ser5 
into glutamic acid) were harvested and precipitated with the GFP-Trap beads followed by 
immunoblot analysis. The GFP-Trap efficiently precipitated the GFP fusion proteins from cell 
extracts (Figure 4.4.1). Importantly, immunoblot analysis revealed that Src efficiently 
coprecipitated with all L-plastin variants for all treatment conditions (Figure 4.4.1), indicating 
that L-plastin is present in a complex with Src and that this interaction is independent of the 
PMA treatment and the phosphorylation status of L-plastin. Ser5 phosphorylation is thus not 
required for binding of Src. These data suggest that L-plastin may play a role in the assembly 
of signalling complexes, containing cortactin and Src kinase, two proteins known to promote 
cell invasiveness.  
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Figure 4.4.1. Coimmunoprecipitation of GFP fusion proteins in HEK cells. HEK cells 
transfected with GFP or L-plastin-GFP variants were treated with 0.1 μM PMA for 1 h at 37°C 
as indicated. Following cell lysis, protein extracts were subjected to immunoprecipitation with 
GFP-Trap. Aliquots of input (In), non-bound (NB) and bound (B) fractions were separated by 
SDS-PAGE and visualised by immunoblot analysis using GFP- and Src-specific antibodies. 
 
 
 
 
4.4.2 GFP-Trap followed by mass spectrometry 
In order to identify further interaction partners of L-plastin, we performed mass spectrometry 
experiments in collaboration with Prof. Christophe Ampe and Prof. Kris Gevaert from the 
University of Ghent, in the framework of the PRIME-XS consortium. 
 
Stable isotope labelling by amino acids in cell culture (SILAC) of HEK cells was performed. 
Four cultures of HEK cells were grown in light medium containing the natural isotype amino 
acids 12C arginine and 12C lysine and one culture of HEK was grown in heavy medium 
containing 13C arginine and 13C lysine (Figure 4.4.2). After thirteen days of culture, three light 
cultures were transfected with GFP and the remaining cultures (one light and one heavy) 
were transfected with the construct of interest (Figure 4.4.2). This procedure was performed 
for two constructs of interest: L-plastinWT-GFP and L-plastinSE-GFP. This was meant to 
allow the identification of L-plastin binding partners and to determine whether some partners 
only bind to one of these two constructs. In that case, the binding would depend on the 
phosphorylation status of L-plastin. For each of these two experiments we performed five 
immunoprecipitations using GFP-Trap and afterwards the precipitates were mixed. The 
resulting mixture was then analysed by LC-MS/MS in order to determine the ratio of the 12C 
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and 13C peptides of the identified proteins. A ratio of 4 light to 1 heavy represents unspecific 
binding to GFP and to L-plastin-GFP and a ratio of 1 light to 1 heavy represents specific 
binding to L-plastin-GFP only (Figure 4.4.2).  
 
 
Figure 4.4.2. SILAC labelling performed in HEK cells for the identification of L-plastin binding 
partners. Four cultures of HEK cells were grown in light medium and one was grown in heavy 
medium. After a cultivation period of thirteen days, three light cultures were transfected with 
GFP and one light and one heavy culture were transfected with L-plastin-GFP. Five 
immunoprecipitations using GFP-Trap were subsequently mixed and analysed by LC-MS/MS 
to determine the ratio of light and heavy peptides of the identified proteins. 
 
For L-plastinWT-GFP only L-plastin was identified in the 1/1 ratio distribution and for 
L-plastinSE-GFP, L-plastin and also prothymosin α were identified in the 1/1 ratio distribution 
(Table 4.5.2). Prothymosin α is a 12.5 kDa protein with a highly conserved primary structure 
and a wide cellular distribution. It has been described to suppress cell proliferation 
(Kobayashi et al., 2006). Prothymosin α can also be found in the blood and its extracellular 
functions include cytokine-like, antiviral, antifungal and anti-ischemic activities (Mosoian, 
2011). Prothymosin α was shown to be overexpressed in different cancer types but it was 
also reported to exhibit anticancer activity (Shiau et al., 2001). Our result that this protein 
interacts with L-plastin is highly interesting but deserves further investigation and validation.  
Two other proteins, heterogeneous nuclear ribonucleoprotein M (HNRPM) and β-actin, 
displayed one peptide with good ratios indicating their binding to L-plastinSE (Table 4.4.2). 
Even though these proteins only had one peptide found in the 1/1 ratio distribution, the fact 
that we know that β-actin is a partner of L-plastin strengthens the prothymosin α data and 
Results   
101 
 
supports a possible interaction between HNRPM and L-plastin which however also needs 
further validation. 
For the L-plastinWT experiment it seems that the incorporation of the SILAC labels has not 
functioned properly, thus explaining the lack of identification of interaction partners. For the 
L-plastinSE experiment a shift in the ratios was observed so that ratios indicating a specific 
interaction are around 0.5 instead of 1. 
Full lists of proteins identified with the mass spectrometry analysis can be found in the 
appendix. 
Table 4.4.2 L-plastin interaction partners identified by LC-MS/MS. 
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Chapter 5 Discussion and perspectives 
 
5.1 Discussion 
Parts of the discussion section are taken from a manuscript which can be found in the 
appendix and which was recently published in The FASEB Journal: L-plastin Ser5 
phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the 
ERK/MAPK pathway (Lommel et al., 2015). 
 
Previous studies by our group have shown that the phosphorylation of L-plastin on residue 
Ser5 increases the F-actin-binding and -bundling activity of L-plastin (Al Tanoury et al., 2010; 
Janji et al., 2006). Furthermore, L-plastin Ser5 phosphorylation was shown to be essential for 
cell invasion and metastasis formation (Janji et al., 2006; Klemke et al., 2007; Riplinger et al., 
2014). The signalling pathways leading to L-plastin Ser5 phosphorylation being unclear, this 
thesis focused on unravelling the signalling pathways leading to L-plastin Ser5 
phosphorylation in breast cancer cells.  
  
Even though PKC, PKA and PI3K were shown to be involved in L-plastin Ser5 
phosphorylation in different studies, mainly PKC seems to mediate L-plastin Ser5 
phosphorylation in cancer cells (Al Tanoury et al., 2010; Janji et al., 2010). This observation 
led us to initially focus on investigating the implication of PKC in our four breast cancer cell 
lines. Indeed we could show a role for PKC in this phosphorylation event by diverse 
experiments. Notably, L-plastin Ser5 phosphorylation was increased by the PKC activator 
PMA and this increase was prevented by the PKC inhibitor GF109203X in all four breast 
cancer cell lines. Moreover, also the PKC activator endothelin increased L-plastin Ser5 
phosphorylation in HEK cells. In addition, constitutively active PKCδ was shown to increase 
this phosphorylation in HEK cells and knockdown of endogenous PKCδ decreased this 
phosphorylation in BT-20 and MDA-MB-435S cells. Nevertheless, as we showed that PKC 
knockdown was not decreasing L-plastin Ser5 phosphorylation in SK-BR-3 cells and as an in 
vitro kinase assay could not show direct phosphorylation of L-plastin Ser5 by PKC, we 
concluded that other kinases must be responsible for this phosphorylation event and we 
emitted the hypothesis that signalling pathways leading to this phosphorylation might be cell 
type-dependent. 
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Following these observations and knowing that also PKA has been described in the literature 
to be involved in L-plastin Ser5 phosphorylation in cells of the immune system (Janji et al., 
2006; Matsushima et al., 1987; Wang and Brown, 1999), in HEK cells (Janji et al., 2006) and 
in vitro (Janji et al., 2006; Wang and Brown, 1999), we also investigated the involvement of 
this protein kinase in L-plastin Ser5 phosphorylation in our four model breast cancer cell 
lines. Interestingly, the PKA activator 8-Bromo-cAMP only weakly increased L-plastin Ser5 
phosphorylation in BT-20 cells and did not increase L-plastin Ser5 phosphorylation in MCF7, 
SK-BR-3 and MDA-MB-435S cells. Interestingly, even though PKA seems to play a less 
important role than PKC in L-plastin Ser5 phosphorylation in breast cancer cells, our results 
also point to a crosstalk between these two kinases in this phosphorylation event. Indeed, 
PKA inhibition prevented PKC activation-mediated increase in L-plastin Ser5 phosphorylation 
in all four breast cancer cell lines.  
 
To further investigate such a potential crosstalk between PKC and PKA, we took the 
approach of analysing PKA substrate phosphorylation upon PKA or PKC stimulation. We 
found that the phosphorylation of PKA substrates was not only increased with the PKA 
activator 8-Bromo-cAMP but also with the PKC activator PMA which could be an indication 
that PKC is an upstream activator of PKA. Another less plausible explanation would be that 
PMA does not only activate PKC but also PKA. However, even though PMA is a widely used 
PKC activator, PMA-dependent PKA activation has never been described in the literature. 
Furthermore in that case the phosphorylation of PKA substrates should not decrease with 
PMA+GF compared to PMA alone, assuming that GF is specific for PKC and has no effect 
on PKA. However, we observe such a decrease for all four cell lines. A further explanation 
could be that the antibody we are using does not only recognise phosphorylated PKA but 
also PKC substrates. Even though this is likely to occur it is probably not the only reason for 
our observation that phosphorylated PKA substrates increase with the PKC activator PMA. If 
this observation was due to the recognition of phosphorylated PKC then we would not expect 
a considerable decrease upon PMA+H89 treatment compared to PMA alone which we 
observe in all four cell lines. Overall, the most likely scenario is that PKC is an upstream 
activator of PKA.  
 
In the literature, crosstalks of PKC and PKA have already been suggested for other cell types 
but the detailed mechanisms of this interplay remained unclear (Fricke et al., 2004; Mau et 
al., 1997; Motzkus et al., 2000; Sugita et al., 1997; Yao et al., 2008). Our hypothesis that 
PKC acts upstream of PKA was further validated by a probabilistic Boolean network 
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modelling approach applying two different strategies. First, an in silico knockout study and 
second, a study analysing optimised selection probability weights of all interactions, 
demonstrated the importance of the PKC-PKA crosstalk and indicated that in all four cell 
lines the interaction appears to be directed from PKC to PKA rather than from PKA to PKC.  
 
As pulldown experiments performed by a former group member Ziad Al Tanoury (Al Tanoury, 
2009) and GFP-Trap co-immunoprecipitation performed by myself suggest that L-plastin 
interacts with the proto-oncogene tyrosine protein kinase Src, we investigated whether Src 
would be indirectly involved in L-plastin Ser5 phosphorylation. Indeed, L-plastin Ser5 
phosphorylation was increased following transfection with constitutively active v-Src in all 
four model cell lines and decreased upon Src inhibition with three different inhibitors in 
SK-BR-3, BT-20 and MDA-MB-435S cells but not in MCF7 cells. Src being a tyrosine kinase, 
it cannot be responsible for direct L-plastin Ser5 phosphorylation. Our results thus suggest 
that Src acts upstream of the serine kinases responsible for L-plastin Ser5 phosphorylation. 
In addition, this observation is in line with the suggestion of Ma and colleagues (Ma et al., 
2010) that L-plastin might act as a scaffolding protein functioning as a core in the recruitment 
of signalling molecules. 
 
As we found that L-plastin Ser5 phosphorylation correlates with the invasive capacity of 
breast cancer cell lines, we chose to take a whole genome microarray-based gene 
expression profiling approach to compare cells with differential L-plastin Ser5 
phosphorylation in order to detect underlying differences in signal transduction pathways. In 
the context of the cofilin pathway in breast cancer invasion and metastasis (Wang et al., 
2007a), the authors have pointed out that not only individual genes, but whole pathways with 
differential regulation and activity states of the corresponding molecules should be taken into 
account for phenotype interpretation. Similarly, in our study the whole genome microarray 
analysis approach allowed us to identify three canonical pathways enriched in DEGs, namely 
ERK/MAPK signalling, UVA-induced MAPK signalling and role of osteoblasts, osteoclasts 
and chondrocytes in rheumatoid arthritis. The latter pathway can only be linked to cancer 
progression in the broadest sense considering that both cancer and rheumatoid arthritis 
involve inflammation but this pathway cannot explain differential L-plastin Ser5 
phosphorylation. UVA-induced MAPK signalling, in contrast to UVB and UVC-induced 
signalling, involves ERK/MAPK signalling (Zhong et al., 2011). Our microarray experiment 
thus reveals two out of three pathways which involve the prominent ERK/MAPK signalling 
pathway and thereby indicates a role for this pathway in L-plastin Ser5 phosphorylation. In 
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addition, the in vitro kinase assay screen carried out in parallel identified the ERK/MAPK 
pathway downstream kinases RSK1 and RSK2 as the most prominent candidate kinases for 
L-plastin Ser5 phosphorylation. This kinase screening was performed on N-terminal L-plastin 
peptides with the initiator methionine removed and the subsequent alanine acetylated as this 
co-translational modification was described by the UniProtKB/Swiss-Prot database 
(www.uniprot.org). Nevertheless we also included non-modified peptides in order to make 
sure that this difference does not completely change the ability of the kinases to 
phosphorylate L-plastin peptides. Indeed a similar ranking was observed for kinases 
phosphorylating peptides with or without this N-terminal modification. However, peptides 
containing the initiator methionine displayed much higher radioactivity counts for almost all 
kinases than peptides without methionine but with acetylated alanine in the N-terminal part. 
This could be explained by the fact that acetylation of the alanine residue abolishes the 
amine group at the N-terminus and converts a basic amino acid into a neutral one. Most 
kinases prefer to have basic amino acids in the -3 position and to a lesser extent in the -2 
and -4 positions before the phosphor-acceptor residue (Rust and Thompson, 2011). Even 
though the methionine is at the -4 position which is less influential, it still exhibits a free 
amine and a positive charge and might still improve substrate recognition by most protein 
kinases. 
  
All these findings together with a previous report describing L-plastin as an ERK/MAPK 
pathway-regulated protein (Lewis et al., 2000) prompted us to proceed to an in-depth 
investigation of this pathway, whose deregulation has also been associated with breast 
cancer progression (Whyte et al., 2009). Several approaches were used to unravel the 
involvement of the ERK/MAPK pathway with its downstream kinases RSK1 and RSK2 in the 
L-plastin Ser5 phosphorylation event. To trigger this pathway we stimulated the cells with 
EGF or with PMA, both described as activators of the ERK/MAPK pathway. Evidence for an 
involvement of the ERK/MAPK pathway downstream kinases RSK1 and RSK2 in L-plastin 
Ser5 phosphorylation was provided both by an siRNA knockdown approach and by the use 
of two different RSK inhibitors BI-D1870 and SL0101. This reduces the probability that the 
observed inhibitor-dependent decrease of phosphorylation is due to off-target effects. 
Indeed, BI-D1870 and SL0101 have only one common off-target, Aurora B (Bain et al., 
2007), which demonstrated considerably weaker potency in phosphorylating L-plastin 
peptides than RSK1 or RSK2 as shown by the in vitro kinase assays from KINEXUS (Table 
4.2.3). Most importantly, the two kinases RSK1 as well as RSK2 were able to directly 
phosphorylate the recombinant L-plastin protein on residue Ser5 in an in vitro kinase assay. 
Further evidence for the importance of the ERK/MAPK pathway is provided by the data 
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obtained with the MEK inhibitor PD98059 as well as with the clinically used MEK inhibitor 
Trametinib. Moreover, our finding that L-plastin Ser5 phosphorylation can be mediated by 
RSK upon activation of the ERK/MAPK pathway was confirmed by our computational model.  
  
The applied PBN modelling approach revealed to be a very useful method to deepen our 
understanding of signalling pathways upstream of L-plastin Ser5 phosphorylation in our four 
breast cancer cell lines. This model allowed us to calculate normalised steady-state values 
that fit our extensive set of normalised experimental data and that give us quantitative 
information on the importance of all interactions included in our signalling network. This 
quantitative outcome of the PBN modelling study allowed us to corroborate our initial 
hypothesis that RSK is an important activator of L-plastin in breast cancer cells and that this 
signal can be modulated by an upstream crosstalk directed from PKC to PKA. 
 
In an effort to correlate invasiveness and concomitant L-plastin Ser5 phosphorylation with 
RSK expression and activity, we found that higher RSK1 and RSK2 protein levels in invasive 
versus non-invasive cells seem to largely correlate with higher baseline L-plastin Ser5 
phosphorylation in invasive versus non-invasive cells. However, we were not able to 
correlate the invasive status of breast cancer cell lines and thus differential L-plastin Ser5 
phosphorylation levels with differential RSK activities. Since it is known from the literature 
that multiple phosphorylation events are required for the activation of RSKs, the antibody 
used to detect P-RSK was chosen in order to reveal the last phosphorylation step 
(phosphorylated serine residues 221 and 227 of RSK1 and RSK2 respectively) by PDK1 
which is required for full activation of RSK1/2 and subsequent substrate phosphorylation. 
Even though this antibody is described to recognise phosphorylated forms of RSK1 and 
RSK2, the company does not specify whether it also recognises the phosphorylated form of 
RSK3 (RSK4 does not need phosphorylation of this residue to be active). Furthermore, it 
should be considered that myristoylation of RSK and its translocation to the plasma 
membrane have also been described to be necessary for maximal activation of RSKs 
(Richards et al., 2001). These factors should be taken into account when analysing the 
existence of a correlation between RSK activities and L-plastin Ser5 phosphorylation level. 
Most importantly, it cannot be excluded that L-plastin might also be phosphorylated by other 
kinases in addition to RSKs. 
 
Although our results provide strong evidence for a role of the ERK/MAPK pathway with the 
downstream kinases RSK1 and RSK2 being able to directly phosphorylate L-plastin on 
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residue Ser5, they do not rule out that L-plastin Ser5 phosphorylation can also be mediated 
by other pathways. As mentioned before, until now mainly PKA (Janji et al., 2006; Wang and 
Brown, 1999) and PKC (Al Tanoury et al., 2010; Freeley et al., 2012; Janji et al., 2010; Jones 
et al., 1998; Lin et al., 1998; Paclet et al., 2004; Pazdrak et al., 2011) have been reported to 
play a role in L-plastin Ser5 phosphorylation. Even though siRNA-mediated knockdowns of 
PKCδ (Al Tanoury et al., 2010; Janji et al., 2010) and PKCβII (Pazdrak et al., 2011) reduced 
L-plastin Ser5 phosphorylation, it has to be taken into account that most studies were based 
on activation and/or inhibition studies. Strikingly, all inhibitors (H89, GF109203X, Gö6976 
and Ro-31-8220) used to demonstrate the involvement of PKA and PKC in L-plastin Ser5 
phosphorylation also strongly inhibit RSK2 (Alessi, 1997; Davies et al., 2000). Moreover, 
PMA used as a PKC activator does not only activate PKC but has also been shown to 
activate the ERK1/2 pathway either through PKC and c-Src or through RasGRP (Amos et al., 
2005; Brose and Rosenmund, 2002; Kazanietz, 2000). Finally, the effect of the PKA activator 
cAMP on the ERK1/2 pathway appears to depend on the cellular context since cAMP has 
been demonstrated to activate ERK in a B-Raf dependent manner or to suppress ERK 
signalling in many cells through its ability to target C-Raf (reviewed in (Dumaz and Marais, 
2005)). Altogether these observations imply that findings about L-plastin Ser5 
phosphorylation revealed by activation and inhibition studies only, may have to be 
reconsidered keeping in mind the important off-target effects of the used inhibitors and 
especially the fact that they all unspecifically inhibit RSK2. In line with this, our computational 
model suggests that activation of L-plastin by RSK is largely predominant as compared to its 
activation by PKC or PKA. This result is in line with previous findings of Hagi and 
collaborators who reported that cAMP stimulation was not able to trigger L-plastin Ser5 
phosphorylation in macrophages (Hagi et al., 2006).  
 
Regarding a potential involvement of the PI3K/AKT pathway in the phosphorylation of 
L-plastin Ser5 in breast cancer cells, future studies which were out of the scope of the 
present work, have to be dedicated to the investigation of this prominent signalling pathway. 
Indeed, our in vitro kinase screening assays on L-plastin peptides have revealed further 
kinases, which are downstream effectors of the PI3K/AKT pathway, to be able to 
phosphorylate L-plastin Ser5. These include serum and glucocorticoid- regulated kinases 2 
and 3 (SGK2 and SGK3) as well as p70 ribosomal protein S6 kinase (p70S6K), a kinase with 
substantial homology to the NTKD of RSK. It is interesting to note that the ERK/MAPK and 
the PI3K/AKT pathways interact at several levels and cannot be considered as linear 
signalling pathways (Mendoza et al., 2011). Moreover, this crosstalk has a high significance 
in cancer therapeutics. As a high proportion of human cancers display oncogenic mutations 
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in ras (Bos, 1989), the inhibition of the ras downstream target MEK was tested in the clinic 
and in patient-derived xenograft models with unfortunately deceiving results (Sun et al., 
2014). This lack of response is thought to arise from feedback activation of pathways that 
circumvent the roadblock imposed by the drug. This can occur through loss of negative-
feedback regulation which is mediated through direct phosphorylation of almost all 
components of the RTK-RAS-MAPK cascade by ERK (Lito et al., 2013). In addition, MEK 
inhibition causes a transcriptional upregulation of both ErbB2 and ErbB3 with the formation of 
active ErbB1-ErbB3 and ErbB2-ErbB3 complexes that activate downstream PI3K/AKT and 
ERK/MAPK signalling (Sun et al., 2014). Thus MEK inhibition results on the one hand in a 
reduction of pERK and on the other hand in an increase of pAKT (Mirzoeva et al., 2009; Sun 
et al., 2014). As both AKT and ERK routes are involved in the inactivation of pro-apoptotic 
proteins and thus in proliferation, and as the inhibition of one pathway was shown to result in 
compensatory activation of the other pathway, the inhibition of only one of these pathways is 
not sufficient to reduce proliferation (Sun et al., 2014). Combination therapies have notably 
been shown to have synergistic cellular effects in breast cancer with combined MEK and 
PI3K inhibition (Mirzoeva et al., 2009) and in non-small cell lung cancer and colorectal 
cancer with combined MEK and ErbB2 and ErbB1 inhibition (Sun et al., 2014). The effect of 
such combination therapies in the clinic remains to be tested. It also remains to be 
investigated whether L-plastin Ser5 phosphorylation is a target of the ERK/MAPK pathway 
only or also of the PI3K/AKT pathway.  
 
RSKs have been described as versatile regulators controlling migration and invasion 
downstream of ERK/MAPK activation (Sulzmaier and Ramos, 2013) by altering the 
transcription of many genes involved in epithelial to mesenchymal transition, by regulating 
cell adhesion through phosphorylation events with subsequent modulation of integrin activity 
and/or by remodelling the actin cytoskeleton. Notably, RSK2 expression has been correlated 
to the expression of the actin-bundling protein fascin in head and neck squamous cell 
carcinoma and to filopodia formation (Li et al., 2013). RSK2 phosphorylates the transcription 
factor CREB which upregulates the transcription of fascin and thereby increases filopodia 
formation and actin-bundling providing a proinvasive and prometastatic advantage to human 
cancers. In our study, both RSK1 and RSK2 were able to phosphorylate the actin-bundling 
protein L-plastin and combined knockdown of the two isoforms led to a clear decrease in cell 
migration and invasion. In addition, we showed that L-plastin phosphorylation and 
localisation in migratory structures upon EGF stimulation is linked to RSK activity. The 
identification of the actin-bundling protein L-plastin as a new target of RSK kinases 
consolidates the role of these kinases in the regulation of the actin cytoskeleton. Our results 
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extend the findings of Doehn and colleagues, who investigated the effects of RSK1 and 
RSK2 on migration and invasion in epithelial breast cells and showed that combined 
knockdown of RSK1 and RSK2 or the use of RSK inhibitors suppressed the ERK pathway-
dependent induction of promotile and proinvasive genes (Doehn et al., 2009). 
 
Interestingly, RSK2 has been described to phosphorylate a further actin-binding protein, 
filamin A (Ohta and Hartwig, 1996), on residue Ser2152 (Woo et al., 2004). This RSK-
dependent phosphorylation was shown to promote filamin A binding to β integrin tails 
(Gawecka et al., 2012) which leads to inhibition of cell adhesion through integrin inactivation 
(Gawecka et al., 2012; Vial and McKeown-Longo, 2012). Furthermore, the phosphorylation 
of filamin A and the subsequent inactivation of integrins was shown to be involved in EGF-
induced cell migration (Gawecka et al., 2012; Woo et al., 2004). In our work we have 
revealed that L-plastin is phosphorylated by RSK and that RSK activity is important for the 
recruitment of L-plastin to migratory structures and for migration and invasion. Overall, we 
suggest that the effect of RSK knockdown on the promotile capacities of cancer cells may 
also be due, at least in part, to the decrease of L-plastin phosphorylation on Ser5, 
comparable to the decrease of filamin A-dependent cell migration observed upon RSK 
inhibition. We thus speculate whether L-plastin, similarly to filamin A, was able to modulate 
integrin activation. In this regard it is interesting to note that also L-plastin was described to 
interact with β1 and β2 integrin subunits (Le Goff et al., 2010). Our preliminary results show 
that L-plastin indeed reduces integrin activation and we intend to deepen the investigation of 
L-plastin effects on integrin affinity in future studies (see under 5.2 Perspectives). 
 
To our knowledge our results show the first evidence for the involvement of the ERK/MAPK 
pathway in L-plastin Ser5 phosphorylation in breast cancer cells. These findings corroborate 
Ser5 phosphorylated L-plastin as a molecular marker for invasive carcinomas with 
deregulated ERK/MAPK pathway signalling.  
 
One could also make a slightly more daring consideration regarding a potential therapeutic 
application of our findings. L-plastin Ser5 phosphorylation was shown to promote invasion in 
HEK and melanoma cells as well as to increase in vivo metastasis formation in melanoma 
(Janji et al., 2006; Klemke et al., 2007; Riplinger et al., 2014). It remains to be established 
whether this link is also observed in breast cancer. In cancers where this link between L-
plastin Ser5 phosphorylation and cancer cell invasion and metastasis can be confirmed, 
blocking of L-plastin Ser5 phosphorylation could be a potential cancer therapy. As we have 
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identified RSK kinases to be responsible for this phosphorylation, inhibition of these kinases 
could be helpful to reduce L-plastin Ser5 phosphorylation and thereby invasion and 
metastasis formation. Our identification of a new RSK1 and RSK2 kinase substrate which is 
involved in invasion and metastasis, consolidates the formerly described role of these 
kinases in cancer progression (Anjum and Blenis, 2008). In contrast to MEK and Raf, RSKs 
are not “global regulators” and thus their inhibition by therapeutic drugs may have less 
severe side effects. Knowing that RSKs are overexpressed in approximately 50% of human 
breast cancer tissues (Smith et al., 2005), this kinase family could be considered as a highly 
promising therapeutic drug target in certain invasive carcinomas. 
 
Alternatively, nanobodies could be used to directly inhibit L-plastin Ser5 phosphorylation. 
Nanobodies are the smallest functional fragment of a naturally occurring single chain 
antibody (15 kDa) and similarly to conventional antibodies they have high target specificity 
and affinity and low inherent toxicity. Advantages include their small size, high stability and 
ease of production. In contrast to knockdown approaches, nanobodies do not eradicate 
protein expression but only target one specific protein domain and thus only inhibit a 
particular function. A team of the University of Ghent led by Prof. Gettemans has produced 
such nanobodies targeting L-plastin and has shown that two nanobodies were able to 
consistently delay and reduce CD3/CD28-stimulated L-plastin Ser5 phosphorylation in Jurkat 
T cells (De Clercq et al., 2013b). The same nanobodies however did not affect PMA-
stimulated L-plastin Ser5 phosphorylation in THP-1 cells (De Clercq et al., 2013a) indicating 
that distinct pathways occur in distinct cell types and/or with distinct stimulators. Moreover, 
one of the nanobodies efficient to block L-plastin Ser5 phosphorylation in Jurkat cells also 
strongly inhibited actin-bundling by L-plastin which subsequently inhibited filopodia formation, 
motility, and invasion upon transfection into PC-3 prostate cancer cells (Delanote et al., 
2010). In breast cancer cells, the effects of such nanobodies on L-plastin Ser5 
phosphorylation, on actin-bundling and on subsequent migration and invasion capacities 
remain to be investigated. Ideally, nanobodies could be developed further into a therapeutic 
drug to block L-plastin Ser5 phosphorylation and related invasion. Nanobodies have already 
proven to be successful in the treatment of diverse diseases including epidermoid carcinoma 
(Roovers et al., 2007) where intra-peritoneally administered nanobodies directed against the 
EGFR reduced tumor growth in mice. So far, the use of nanobodies has not yet been 
approved for disease treatment, but several clinical trials using nanobodies are ongoing in 
phases I and II (http://ablynx.com/rd-portfolio/overview/). 
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Another option for targeting L-plastin-dependent invasion could be to inhibit L-plastin-
dependent actin-bundling with small molecule inhibitors. A similar strategy targeting another 
actin-bundling protein, fascin, proved effective for reducing migration and invasion in vitro 
and metastasis formation in vivo (Huang et al., 2015). In contrast to microtubule proteins 
which have been successfully used as drug targets for decades, no actin cytoskeletal protein 
has yet been used clinically as therapeutic target for cancer treatment. Nevertheless, the 
study by Huang and colleagues points to the potential of using actin-binding proteins as 
novel targets for cancer treatment. They identified a small molecule inhibitor against the 
actin-bundling protein fascin which specifically inhibits the biochemical function of fascin to 
bundle actin filaments and thereby blocks the formation of filopodia. Similarly to L-plastin, 
fascin expression is low or absent in normal adult epithelial cells whereas elevated levels of 
fascin were found in many types of metastatic tumours and are correlated with a clinically 
aggressive phenotype, poor prognosis and shorter survival (Hashimoto et al., 2011; 
Machesky and Li, 2010; Tan et al., 2013). This fascin-targeting drug not only reduces breast 
tumour cell migration and invasion in vitro but also lung metastases of 4T1 mouse breast 
tumour cells and MDA-MB-231 human breast tumour cells in vivo by approximately 95% 
(Huang et al., 2015). This strongly advocates the testing of such inhibitors in clinical trials. 
L-plastin small molecule inhibitors would need to be identified and to be tested regarding 
their effect on metastasis reduction in vivo. In addition to small molecule inhibitors, the use of 
the above-described nanobodies targeting L-plastin function could also be of interest as such 
molecules have been shown to directly inhibit F-actin-bundling or to prevent L-plastin 
activation (De Clercq et al., 2013a; Delanote et al., 2010). 
  
5.2 Perspectives 
Our work has demonstrated that ERK/MAPK signalling leads to Ser5 phosphorylation of 
L-plastin. Since our in vitro kinase assay screening however also indicates that some 
selected downstream kinases of the PI3K/AKT pathway potentially phosphorylate L-plastin 
Ser5, it will be interesting to investigate if this phosphorylation can also result from alternative 
signalling pathways, in particular from the prominent PI3K/AKT signalling pathway. An 
expanded PBN study will be applied to analyse the role of this pathway in addition to the 
ERK/MAPK pathway upstream of the L-plastin Ser5 phosphorylation event. EGF, hepatocyte 
growth factor and insulin-like growth factor or cell adhesion onto fibronectin and collagen via 
integrins will be used to stimulate the activation of the PI3K/AKT and ERK/MAPK pathways 
and key signalling molecules of these pathways will be inhibited. Subsequently L-plastin Ser5 
phosphorylation will be monitored together with further output nodes such as activated ERK, 
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RSK, FAK and AKT. Based on the generated data, the model will allow making quantitative 
predictions on the relevance of interactions within the network leading to the identification 
and validation of key signalling molecules important for L-plastin Ser5 phosphorylation. Such 
an approach will allow us to establish whether L-plastin Ser5 phosphorylation, in addition to 
the ERK/MAPK signalling pathway, is also a target of the PI3K/AKT pathway and will reveal 
whether Ser5 phosphorylated L-plastin can serve as a molecular marker for the deregulation 
of only one or of both signalling pathways involved in cancer progression.  
 
Moreover, the L-plastin Ser5 phosphorylation state is planned to be analysed in breast 
cancer patient tissues to confirm the results obtained in cells and to validate Ser5 
phosphorylated L-plastin as a diagnostic or prognostic marker. Immunohistochemistry on 
breast cancer tissue samples would allow us to analyse the expression of L-plastin, the L-
plastin Ser5 phosphorylation state, the presence and activity of key signalling molecules of 
the signal transduction network and of the candidate kinases for L-plastin Ser5 
phosphorylation. These experiments would also enable us to investigate whether a link exists 
between our results and the molecular subtype and clinicopathological parameters of the 
analysed breast cancer samples. A collaboration with the Integrated BioBank of Luxembourg 
has recently been established and the collection of breast cancer tissues is about to be 
started. 
.  
Importantly, we also need to check whether the observed effects of RSK knockdown on 
migration and invasion are indeed due to the decrease in L-plastin Ser5 phosphorylation or 
due to another RSK-dependent mechanism. A possibility to investigate this would be to use 
the existing L-plastin-specific nanobodies to block L-plastin Ser5 phosphorylation and to 
analyse L-plastin Ser5 phosphorylation-dependent migration and invasion in breast cancer 
cells. This is planned in the framework of a collaboration with Prof. Gettemans from 
University of Ghent. 
 
A further interesting follow-up of this work would be to test and extend our findings in a 
mouse model. In this regard we could use human breast tumour cells in which L-plastin or L-
plastin Ser5 phosphorylation is inhibited (f.ex. by stable RSK shRNA expression or by stable 
L-plastin-targeting nanobody expression) and analyse whether they lead to a lower formation 
of metastatic lesions upon injection in mice. Alternatively, we could treat mice injected with 
human breast cancer cells with RSK inhibitors, L-plastin targeting nanobodies or small 
Discussion and perspectives   
113 
 
molecule inhibitors against L-plastin (to be identified) and then monitor metastasis formation 
compared to non-treated mice. 
 
Moreover, we intend to confirm the results obtained by mass spectrometry by pulldown, 
immunoprecipitation, GFP-Nanotrap and/or mitochondrial targeting experiments and we also 
plan to repeat the whole experiment as we had some technical issues preventing us from 
detecting interaction partners of L-plastinWT. 
 
And finally, as described in the discussion section, we investigated whether L-plastin was 
able to modulate integrin activity. In order to determine the effect of L-plastin and L-plastin 
phosphorylation variants on the activation state of integrin αIIbβ3, we took advantage of CHO 
cells expressing either human αIIbβ3WT at the resting state or mutant human αIIbβ3T562N 
in a constitutively active state (Kashiwagi et al., 1999; Salsmann et al., 2005). Following 
transient transfection of GFP, L-plastinWT-GFP, L-plastinS5A-GFP (unphosphorylatable) or 
L-plastinS5E-GFP (phosphomimic), we compared the binding of the activation-specific mAb 
PAC-1 as well as of a β3-specific or a αIIbβ3-specific mAb to the transfected cells. As shown 
in Figure 5.2, neither the transfection of L-plastinWT nor the transfection of the 
phosphomutants was able to activate integrin αIIbβ3WT. In contrast, the expression of L-
plastin considerably reduced PAC-1 binding to CHO αIIbβ3T562N cells, and thus decreased 
αIIbβ3 integrin activity. The effect was even clearer for the L-plastin phosphomutants than for 
L-plastinWT. Even though these preliminary results will need to be confirmed, they point to a 
link between L-plastin expression and the integrin activity state. As a follow-up of this 
experiment it would be interesting to use other constitutively active integrin variants with 
mutations in distinct localisations than the extracellular β3 localisation of the αIIbβ3T562N 
mutant. We could notably use the intracellular αIIbβ3D723A mutation which disturbs salt 
bridge formation between residues β3D723 and αIIbR995 restraining the integrin in the 
inactive state. In case of a mutation in this area, the integrin complex is found to be activated. 
This mutant would be of particular interest with regard to the results of Le Goff et al. reporting 
an interaction between L-plastin and the cytoplasmic domain of integrin β1 and β2 (Le Goff 
et al., 2010). Furthermore it would be interesting to use different L-plastin fragments in order 
to identify which part of L-plastin is required for integrin binding and affinity modulation. 
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Figure 5.2 The ectopic expression of human L-plastin into CHO cells affects the activity state 
of a constitutively active αIIbβ3 integrin mutant. CHO cells expressing either human 
αIIbβ3WT at the resting state or mutant human αIIbβ3T562N in a constitutively active state 
were transiently transfected with GFP, L-plastinWT-GFP, L-plastinS5A-GFP or L-plastinS5E-
GFP. Binding of the activation-specific mAb PAC-1 as well as of a β3-specific or αIIbβ3-
specific mAb was measured by flow cytometry. 
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Ser5 phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream 
of the ERK/MAPK pathway 
 Survival curves for L-plastin 
 Supplemental in vitro kinase assay data 
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 Supplemental LC-MS/MS data for the L-plastinSE experiment 
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ABSTRACT Deregulated cell migration and invasion
are hallmarks of metastatic cancer cells. Phosphorylation
on residue Ser5 of the actin-bundling protein L-plastin ac-
tivates L-plastin and has been reported to be crucial for
invasion and metastasis. Here, we investigate signal trans-
duction leading to L-plastin Ser5 phosphorylation using 4
human breast cancer cell lines. Whole-genomemicroarray
analysis comparing cell lines with different invasive ca-
pacities and corresponding variations in L-plastin Ser5
phosphorylation level revealed that genes of the ERK/
MAPK pathway are differentially expressed. It is note-
worthy that in vitro kinase assays showed that ERK/MAPK
pathway downstream ribosomal protein S6 kinases a-1
(RSK1) and a-3 (RSK2) are able to directly phosphorylate
L-plastin on Ser5. Small interfering RNA- or short hairpin
RNA-mediated knockdown and activation/inhibition
studies followed by immunoblot analysis and computa-
tionalmodelingconﬁrmed that ribosomal S6kinase (RSK)
is an essential activator ofL-plastin.Migration and invasion
assays showed that RSKknockdown led to a decrease of up
to 30% of migration and invasion of MDA-MB-435S cells.
Although the presence of L-plastin was not necessary for
migration/invasion of these cells, immunoﬂuorescence
assays illustrated RSK-dependent recruitment of Ser5-
phosphorylated L-plastin to migratory structures. Alto-
gether, we provide evidence that the ERK/MAPK pathway
is involved in L-plastin Ser5 phosphorylation in breast
cancer cells with RSK1 and RSK2 kinases able to directly
phosphorylate L-plastin residue Ser5.—Lommel, M. J.,
Trairatphisan, P., Ga¨bler, K., Laurini, C., Muller, A.,
Kaoma, T., Vallar, L., Sauter, T., Schaffner-Reckinger, E.
L-plastin Ser5 phosphorylation in breast cancer cells and in
vitro is mediated by RSK downstream of the ERK/MAPK
pathway. FASEB J. 30, 000–000 (2016). www.fasebj.org
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cytoskeleton
Tumor cell migration and invasion are largely dependent
onactin cytoskeletonchanges,whichareunder thecontrol
of a plethora of actin-binding proteins, such as coﬁlin, ﬁl-
amin, fascin, or the plastins (1, 2). In this context, our
previous studies have shown that the actin-bundling pro-
tein L-plastin regulates the turnover of actin ﬁlaments
in addition to its cross-linking activities (3). Although
L-plastin is typically expressed inhematopoietic cells where
it plays a role in the immune response [reviewed inMorley
(4)], it is also frequently ectopically expressed in carci-
noma cells [reviewed in Shinomiya (5)]. L-plastin localizes
to actin-rich structures such as focal adhesions, ﬁlopodia,
and membrane rufﬂes, which are involved in adhesion,
signaling, or locomotion (6, 7).
L-plastin activity has been shown to be increased fol-
lowingphosphorylationonresidueSer5 in vitroand incells.
In leukocytes, phosphorylation of L-plastin is part of the
immune response (8, 9). Moreover, F-actin–binding
and –bundling activities of L-plastin are increased upon
Ser5 phosphorylation, and this phosphorylation is required
for its efﬁcient targeting to focal adhesions (7). It is note-
worthy that recentﬁndingshavedemonstrated thatL-plastin
Ser5 phosphorylation is crucial for in vitro invasion (7, 10)
and in vivo metastasis (11). Distinct protein kinases have
been reported to play a role in L-plastin Ser5 phosphoryla-
tion, depending on the cell type and environment. Candi-
date kinases include PKA (7, 12), PKC (3, 13–18), and PI3K
(13, 16). Nevertheless, the detailed signaling pathway lead-
ing toL-plastinSer5phosphorylationremains tobe resolved.
Besides the deregulation of the actin cytoskeleton, also
the deregulation of signaling pathways is an important
feature of many cancers (19). Breast cancers as well as
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other cancer types frequently display an up-regulation of
members of the epidermal growth factor (EGF) receptor
(EGFR) family (20). TheEGFR[also calledHER1 (human
epidermal growth factor receptor 1)] and its relatives
HER2, HER3, and HER4 are known as oncogenic drivers
in various cancers, including lung cancer (21), breast
cancer (22), and glioblastoma (23–25). In particular,
EGFR andHER2 aremutated to constitutively active forms
in a large number of epithelial tumors. Signaling path-
ways downstream of these receptors that are frequently
deregulated in cancer are the Ras/Raf proto-oncogene
serine/threonine-protein kinase (Raf)/MEK/ERK and
thephosphatase and tensinhomolog/PI3K/RAC-a serine/
threonine-protein kinase (AKT)/mammalian target of
rapamycin pathways [for review, see (26, 27)].
In this study, we investigated the signaling pathways
leading to L-plastin Ser5 phosphorylation in breast cancer
cells, and we demonstrate that the ERK/MAPK pathway is
crucial for L-plastin Ser5 phosphorylation. In vitro kinase
assays revealed that phosphorylation of L-plastin residue
Ser5 canbedirectlymediatedby theERK/MAPK-activated
protein kinases ribosomal protein S6 kinase a-1 (RSK1)
and ribosomal protein S6 kinasea-3 (RSK2). Although the
presence of L-plastin per se does not appear to be required
for enabling migration and invasion of the breast cancer
cell line MDA-MB-435S, we provide clear evidence that
L-plastin, andmore precisely Ser5-phosphorylated L-plastin
(P-LPL), is redistributed to migratory structures upon ri-
bosomal S6 kinase (RSK) activation.
MATERIALS AND METHODS
Cell culture and transfection
SK-BR-3 and BT-20 cells were grown in McCoy’s 5A and Eagle’s
minimal essential media (Lonza Group, Basel, Switzerland), re-
spectively, and MCF7 and MDA-MB-435S cells were cultured in
Roswell Park Memorial Institute medium (Lonza Group). All
media were supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, and 100 U/ml penicillin and streptomycin (com-
plete medium)(Lonza Group). Cells were grown at 37°C under
5%CO2 atmosphere. All cells were bought fromor authenticated
by American Type Culture Collection (Manassas, VA, USA).
Transient transfection of MDA-MB-435S or SK-BR-3 cells was
performedusingLipofectamine2000 (LifeTechnologies,Ghent,
Belgium) according to the manufacturer’s instructions.
Antibodies, reagents, and cDNA constructs
Mouse monoclonal IgG1 antibody against L-plastin (LPL4A.1,
MA5-11921) was purchased from Thermo Scientiﬁc (Erembo-
degem, Belgium). Rabbit polyclonal anti-Ser5-P antibody specif-
ically recognizing L-plastin phosphorylated on Ser5 was raised
against a peptide encoding L-plastin residues 2–17 in which Ser5
was phosphorylated [ARGS(P)VSDEEMMELREA] [character-
ized in (7)]. Rabbit pAbs against RSK1 (sc-231) or RSK2 (#9340)
were purchased from Santa Cruz Biotechnology (Heidelberg,
Germany) and Cell Signaling Technology (Leiden, The Nether-
lands), respectively. Mouse anti-b-actin (A5441) and mouse anti-
a-tubulin (T5168) antibodies were obtained from Sigma-Aldrich
(Diegem,Belgium),mouse anti-HA(hemagglutinin) tag (#2367)
and rabbit anti-EGFR (#2232) antibodies were from Cell Signal-
ing Technology, and a rabbit anti-b-tubulin (sc-9104) antibody
was from Santa Cruz Biotechnology. Phorbol 12-myristate 13-
acetate (PMA), EGF, 8-Bromo-cAMP,H89, and PP2were obtained
from Sigma-Aldrich, GF109203X, SL0101, and BI-D1870 were
from Calbiochem Merck Millipore (Nottingham, United King-
dom), and PD98059 was from Cell Signaling Technology. The
HA-tagged mouse RSK2 wild-type (RSK2wt) and constitutively
active RSK2Y707A constructs were obtained from JoeW. Ramos
(University ofHawaii,Honolulu,HI,USA)andoriginate fromthe
lab of Thomas W. Sturgill (University of Virginia, Charlottesville,
VA, USA).
Treatment of cells with pharmacologic agents
Cells were treated with PMA at a concentration of 0.1 mM for 1 h,
EGF at 1 ng/ml for 15 min, 8-bromo-cAMP at 1 mM for 1 h,
GF109203Xat1mMfor3h,H89at50mMfor1h,PP2at10mMfor
1 h, PD98059 at 10 mM for 1 h, BI-D1870 at 5 mM for 30 min, or
SL0101 at 80 mM for 4 h. In case of combined treatment with
activators and inhibitors, the incubation with the inhibitor was
performed before the incubation with the activator. For serum
starvation prior to EGF treatment, cells were cultured in the ab-
sence of serum for 24 h.
Microarrays
RNA extraction was performed using TRIzol reagent (Thermo
Scientiﬁc). RNA quality and concentration were evaluated spec-
troscopically using a NanoDrop 2000c instrument (Thermo Sci-
entiﬁc). RNA integrity was subsequently analyzed on an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Only good-quality RNA with integrity numbers .9 was used.
Transcriptome-proﬁling assays were performed using the Affy-
metrix Human GeneChip 1.0 ST arrays (Affymetrix, Santa Clara,
CA, USA). Brieﬂy, 250 ng total RNA was reverse transcribed into
cDNA, then transcribed into cRNA and labeled into biotinylated
cRNA using the GeneChip WT PLUS Reagent kit (Affymetrix)
according to the manufacturer’s protocols (P/N 4425209 Rev.B
05/2009 and P/N 702808 Rev.6). Labeled cRNA products were
randomly fragmented and hybridized onto Affymetrix Gene-
Chips. Arrays were washed and stained with the Affymetrix Gene-
Chip WT Terminal Labeling and Hybridization Kit, before
being scanned using a GeneChip Scanner 3000 (Affymetrix). Cell
intensity ﬁles containing hybridization raw signal intensities were
imported into the Partek GS software (Partek, St. Louis, MO,
USA)usingdefaultoptions.Resultingexpressiondata (transcript
cluster level) were imported into R statistical environment for
further analysis. Transcript clusters without chromosome loca-
tion were removed. Quality of the data was assessed through
boxplot, relative log expression, and Pearson correlation. Linear
Models for Microarray Data from Bioconductor was used to
compare transcript cluster expression between different condi-
tions, according to the author’s recommendations (Linear
Models for Microarray Data User’s Guide section 9.5) (https://
bioconductor.org/). Resulting P values were adjusted for false
discovery rate (FDR) with Benjamini and Hochberg’s FDR (28),
and transcript clusters with FDR,0.05 and absolute fold change
$1.5 were considered as signiﬁcantly differentially expressed and
(continued from previous page)
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used for further analyses. The Ingenuity Pathway Analysis (IPA)
software (Ingenuity Systems, Redwood City, CA, USA; www.
ingenuity.com)wasused for transcript clustermapping,which led
to the identiﬁcation of differentially expressed genes (DEGs),
and for data mining, including functional analyses and gene
network reconstruction. Right-tailed Fisher’s exact test was used
to calculate a P value for functional enrichment analysis: thresh-
old, -log(P value) .1.301. Microarray expression data are avail-
able in the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under the accession number E-MTAB-3487.
Kinase screening
The phosphorylation prediction algorithm, kinase substrate
predictor version 2.0 from Kinexus Bioinformatics Corpora-
tion (Vancouver, BC, Canada), identiﬁed the 50 best-scored
candidate kinases for L-plastin phosphorylation on residue
Ser5, out of which 43 were subsequently screened by Kinexus
Bioinformatics Corporation. The following peptides corre-
sponding to the L-plastin N terminus and comprising residue
Ser5 were chosen to be used in the kinase assays: ARGSVS-
DEERR [wild-type (WT)] and ARGSVADEERR [mutant
(MT)], both starting with an N-acetylalanine (taking into ac-
count cotranslational modiﬁcations described by the UniProt
Knowledgebase/Swiss-Prot database), as well as native
MARGSVSDEERR (M-WT) and MARGSVADEERR (M-MT),
both still comprising the initial methionine residue. Residue
Ser7 was substituted by an alanine in order to be able to dis-
tinguish between Ser5 and Ser7 phosphorylation and to ex-
clude false-positives. There were 2 arginine residues added at
the C-terminal end of the peptides to ensure adhesion of the
peptides to the capture phosphocellulose ﬁlter paper following
the kinase assay, and placed far enough from the Ser5 site so as
not to affect the kinase recognition of this site. In brief, L-plastin
peptides were mixed with individual protein kinases in the
presence of [g233P]ATP for 20–40 min, depending on the
protein kinase tested. The assay was terminated by spotting
10 ml of the reaction mixture onto a multiscreen phosphocellu-
lose P81 plate. After removing unreacted [g233P]ATP from
the reaction, radioactivity was quantiﬁed in a scintillation
counter.
In vitro kinase assays of full-length recombinant L-plastin
A total of 10 mg full-length recombinant L-plastin was incubated
with 50mMATPand 100ng recombinant kinase [RSK1,RSK2, or
ribosomal protein S6 kinase a-5 (MSK1)] obtained from Signal-
Chem (Richmond, BC, Canada) in a reaction volume of 25 ml,
according to the manufacturer’s protocol. For the controls, the
respective kinase was omitted. Following an incubation of 15min
at 30°C, Laemmli buffer was added, and the samples were boiled
at 100°C for 5 min and then analyzed by immunoblotting.
Immunoblotting
Cells were lysed in situ in ice-cold lysis buffer [50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 5 mM
EDTA, 1% Nonidet P-40, 1% Triton X-100, 1% sodium-
deoxycholate, 1 mM Na3VO4, 10 mM NaF, 100 mM leupeptin,
and 100mME64D] containing a cocktail of protease inhibitors
(Roche Diagnostics Gesellschaft mit beschra¨nkter Haftung,
Mannheim, Germany). Lysates were cleared by centrifugation
at 13,200 rpm for 15 min at 4°C. The total protein concen-
tration was determined by Bradford assay (Bio-Rad, Temse,
Belgium). Protein separation was performed by SDS-PAGE
under reducing conditions, and proteins were transferred
onto nitrocellulose membranes by semidry transfer. The
membranes were saturated with 1% bovine serum albumin in
Tris-buffered saline supplemented with 0.1% Tween for 1 h at
room temperature, then incubated with primary antibodies
overnight at 4°C and with secondary antibodies coupled to a
ﬂuorescent dye for 1 h at room temperature. Antibody incu-
bations were followed by membrane washings with Tris-
buffered saline supplemented with 0.1% Tween. Signal
intensities were detected by the Odyssey Infrared Image Sys-
tem (LI-COR Biosciences, Westburg, Leusden, The Nether-
lands). For quantiﬁcation, the ratio between the intensities
obtained for P-LPL [or phosphorylated PKA (P-PKA) sub-
strates] versus total L-plastin (LPL) was determined to make
individual samples comparable and then normalized to the
mean of all the values obtained in one experiment to make
blots comparable by accounting for technical day-to-day vari-
ability. For representative purposes, data were scaled to the
highest signal and are represented as means 6 SD. Statistical
signiﬁcance was determined by an unpaired t test withWelch’s
correction. P , 0.05 was considered signiﬁcant.
Small interfering RNA knockdown
Small interfering RNA (siRNA) against RSK1 (Hs_RPS6KA1_10)
and RSK2 (Hs_RPS6KA3_5) was purchased from QIAGEN Ge-
sellschaftmit beschra¨nkterHaftung (Venio, TheNetherlands). A
total of 60 nM siRNA was transfected using Lipofectamine 2000
according to the manufacturer’s protocol.
Invasion and migration assays
Cells were seeded in collagen I-coated (200 mg/ml) 96-well
plates (Essen ImageLock; Essen Bioscience, Hertfordshire,
United Kingdom). At;90% conﬂuence, a wound was scratched
across each well with the CellPlayer 96-wellWoundMaker (Essen
Bioscience). For siRNA knockdown, cells were transfected
with siRNA 24 h before wound scratching. To study invasion,
cells were covered with collagen I (1.5 mg/ml) diluted in cell
culture medium. To study migration, cell culture medium was
added to the cells. Wound conﬂuence was monitored with the
IncuCyte LiveCell Imaging System (Essen Bioscience) by
measuring cell conﬂuence over a total of 72 h. Graphs depict
means 6 SEM.
Immunoﬂuorescence assay
Cells were plated on ﬁbronectin-coated (20 mg/ml) glass cover-
slips. In case of transient transfection, cells were transfected 48 h
prior toﬁxation. Incaseof treatment, cellswere serumstarved24h
prior to treatment. A woundwas scratched with amicropipette tip
and then the cells were treated with vehicle or EGF (100 ng/ml)
with or without prior treatment with BI-D1870 (5 mM). At 1 h
following treatment, the cells were ﬁxed with 4% para-
formaldehyde for 10 min, permeabilized with 0.5% Triton
X-100 in PBS for 5min, and blocked in 2% bovine serum albumin
in PBS-Tween 0.05% for 10 min. Between steps, the cells were
washed with PBS-Tween. The cells were stained with phalloidin
and antibodies against the HA tag of RSK2 constructs, against
L-plastin or Ser5-P-LPL. Imaging was performed on an Andor
SpinningDiskRevolution system (CSU-W1; AndorTechnology,
Belfast, United Kingdom) based on a Nikon Ti microscope
(Nikon, Konan, Minato-ku, Tokyo, Japan) with an Andor iXon
Ultra EMCCD camera and a 3100-1.4 NA oil objective. Image
acquisition was performed using Andor Technology iQ3 software,
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and image analysis was performed using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD, USA).
Modeling
The literature-derived model topology of L-plastin signaling
including the interactions between Src, PKC, PKA and the
ERK/MAPK pathway was described as Boolean rules with
corresponding selection probabilities in the probabilistic
Boolean network (PBN) framework [see review in (29)]. The
experimental data obtained for ratios of P-LPL:LPL andP-PKA
substrates:LPL from the 4 cell lines were used for model con-
textualization. Normalization of immunoblot data was per-
formed as described above. Data generated from different
experimental sets were normalized to the calibrator PMA,
subsequently pooled, and scaled to the maximal value. We
applied an improved version of the optPBN toolbox (30) to
optimize the selection probabilities of the L-plastin signaling
model in PBN format.Optimizationwas performedon a stand-
alone machine (Intel CPU Xeon at 3.50 GHz, 16 GB random-
access memory; Intel Corp., Santa Clara, CA, USA) for the
different model variants based on random initial conditions.
Bootstrapping was performed by randomly sampling 100 ar-
tiﬁcial data sets based on means and SD as acquired from our
experimental data sets. Optimization was performed sub-
sequently 100 times to identify the distribution of the identi-
ﬁed selection probabilities.
Generation of stable RSK1, RSK2, and L-plastin knockdown
MDA-MB-435S cells
Lentiviral vectors
The packaging vector psPAX2 and the envelope vector pMD2.G
were obtained from Addgene (LGC Standards, Middlesex,
United Kingdom). The transfer vectors containing short hairpin
RNA (shRNA) for L-plastin (GIPZ Lentiviral shRNA Library,
pool of clones V2LHS_133928, V2LHS_133929, V2LHS_238253,
V2LHS_311716, and V2LHS_311717; Thermo Fisher Scientiﬁc,
Waltham, MA, USA) as well as the GIPZ nonsilencing lentiviral
shRNA control were purchased from GE Dharmacon (Diegem,
Belgium).
Lentivirus production
Lentiviral particles were prepared by transient transfection of
human embryonic kidney (HEK)293T/17 cells (American
Type Culture Collection). In brief, 93 106 HEK293T/17 cells
was seeded in Iscove’s modiﬁed Dulbecco’s medium (Lonza
Group) with 10% fetal bovine serum in T75 cell culture ﬂasks
precoated with poly-L-lysine (Sigma-Aldrich). The next day,
HEK293T/17 cells were cotransfected with 18 mg transfer
vector, 15 mg packaging vector psPAX2, and 5.25 mg envelope
vector pMD2.G in 12 ml OptiMEM medium (Thermo Fisher
Scientiﬁc) using polyethylenimine (Polysciences, Eppelheim,
Germany). The transfection mix was replaced by 12 ml Iscove’s
modiﬁed Dulbecco’s medium with 2% fetal bovine serum per
ﬂask after 7–8 h. The virus-containing supernatant was har-
vested 40–48 h after medium change, cleared by centrifuga-
tion at 2000 rpm and 4°C for 10 min, and ﬁltered through a
0.45 mm ﬁlter. Concentration of lentiviral particles was per-
formed by precipitation with PEG10000 (1:5 volume of 40%
PEG10000 solution; Sigma-Aldrich) at 4°C overnight followed
by centrifugation at 1500 g and 4°C for 30 min. Subsequently,
the virus was resuspended in 1:100 of the original volume of
50mMTris-HCl buffer (pH 7.4), divided in aliquots, and stored at
280°C. For determination of the lentivirus titer, 1 3 105 HT-
1080 cells per well was transduced with limiting virus dilutions
(1:100 to 1:106) in the presence of 8 mg/ml polybrene (hex-
adimethrine bromide; Sigma-Aldrich) in a 6-well cell culture
plate for 16 h. Transduced cells expressed green ﬂuorescent
protein and were quantiﬁed by ﬂuorescence-activated cell
sorting analysis after 3 d. Titers of concentrated lentivirus were
in the range of 35,000 IU/ml.
Transduction of target cells
Ready-to-use lentiviral particles containing shRNA for RSK1 or
RSK2 (Thermo ScientiﬁcGIPZLentiviral shRNALibrary, human
RPS6KA1, V2LHS_32012, and human RPS6KA3, V2LHS_47382)
were obtained from GE Dharmacon. A total of 3.2 3 105 MDA-
MB-435S cells in a 6-well cell culture plate was transduced with
lentiviral particles containing shRNA for RSK1, shRNA for RSK2,
shRNA for RSK1 and RSK2, shRNA for L-plastin (pool), or non-
silencing shRNA as a control (multiplicity of infection, 3) in the
presence of 8 mg/ml Polybrene for 16 h. Subsequently, the
transduced cells, positive for green ﬂuorescent protein expres-
sion, were selected with 0.5 mg/ml puromycin in complete
medium.
RESULTS
Invasive breast cancer cell lines display higher
baseline L-plastin Ser5 phosphorylation than
noninvasive breast cancer cell lines
The 4 breast cancer cell lines MCF7, SK-BR-3, BT-20, and
MDA-MB-435S chosen as a working model for this study
were carefully selected in order to cover different molec-
ular proﬁles (31–33) with the main prerequisite being the
expression of our protein of interest L-plastin. It is note-
worthy however that considerable doubt had been raised
about the origin of the cell clone MDA-MB-435S (34). In-
deed, evidence was provided that MDA-MB-435S cells and
the M14 melanoma cell line are genetically identical,
which was conﬁrmed by microsatellite analysis (35, 36).
Although the correct origin of the 2 cell lines is still under
debate, themost recent ﬁndings strongly suggest that both
cell linesmay be of breast origin (37, 38). For this study, the
invasive phenotype of the chosen breast cancer cell lines is
of particular importance, with MCF7 and SK-BR-3 being
considered as non- or merely weakly invasive cell lines in
contrast to BT-20 and MDA-MB-435S, which have been
described as invasive cell lines (39, 40). By performing in
vitro scratch wound assays, we reassessed the invasive ca-
pacities of our 4 cell lines. In line with the literature, our
results conﬁrmed that MCF7 and SK-BR-3 cells are only
weakly invasive, whereas invasiveness was considerably in-
creased in BT-20 and highly increased in MDA-MB-435S
cells (Fig. 1A). Because a correlation between the invasive
capacity of melanoma cells and the phosphorylation state
of L-plastin on Ser5 has been suggested before (10), we
continued by investigating L-plastin Ser5 phosphoryla-
tion in the 4 breast cancer cell lines. To this end, we used
an antibody speciﬁcally recognizing Ser5-P-LPL (anti-
Ser5-P antibody) raised and characterized by our group
(3, 7, 14). Although theL-plastin expression level is higher
in the invasive compared with the noninvasive cell lines,
our results clearly show high-baseline L-plastin Ser5
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phosphorylation in the invasive cell lines BT-20 andMDA-
MB-435S as compared to absent or extremely weak phos-
phorylation in the noninvasive cell lines MCF7 and SK-BR-3
(Fig. 1B).
The ERK/MAPK pathway is enriched in DEGs when
comparing breast cancer cells with differential
L-plastin Ser5 phosphorylation
Whole-genome microarray analysis was performed to
detect differences in signal transduction pathways
leading to differential L-plastin Ser5 phosphorylation in
noninvasive breast cancer cells with low-baseline Ser5-P-
LPL versus invasive breast cancer cells with high-baseline
Ser5-P-LPL. In addition, we treated the 2 noninvasive
cell lines with PMA because this treatment has been
shown previously to increase L-plastin Ser5 phosphory-
lation in MCF7 cells (3). As expected, PMA treatment
led to a considerable increase in L-plastin Ser5 phos-
phorylation in both cell lines MCF7 and SK-BR-3 as
compared to their respective untreated control (Fig. 2,
left). In order to performmicroarray analysis, total RNA
was isolated from triplicate cell cultures, andmicroarray
data were obtained using Affymetrix technologies. Lists of
differentially expressed transcript clusters were established
as described under Materials and Methods, and transcript
cluster mapping and analysis were performed using IPA.
For the comparison of PMA-treated versus untreated
controls, we thus obtained a ﬁrst list of DEGs for MCF7
and a second for SK-BR-3 cells. For the comparison of
our 2 model invasive and 2 model noninvasive cancer
cell lines, we obtained another 4 lists of differentially ex-
pressed transcript clusters (Fig. 2, right), the intersection of
which was mapped by IPA to obtain a third list of DEGs.
Taking the intersection of the 4 lists enabled us to focus
on the genes that are differentially expressed between
all comparisons of invasive versus noninvasive cells, thus
setting a stringent ﬁlter. The 3 lists of DEGs can be found
in Supplemental Data.
To assess a difference in signaling pathways between the
compared conditions, we focused on canonical signaling
pathways in IPA. For each of the 3 comparisons of interest,
IPA revealed a list of canonical signaling pathways (Sup-
plemental Data) from which we selected those that were
signiﬁcant [-log(P value) .1.301] and thus enriched by
genes that are signiﬁcantly differentially expressed. In-
terestingly, we identiﬁed 3 canonical signaling pathways
that were common to the 3 lists: ERK/MAPK signaling,
UVA-induced MAPK signaling, and role of osteoblasts, os-
teoclasts and chondrocytes in rheumatoid arthritis (Fig. 2,
bottom). These results suggest an involvement of $1 of
these pathways in L-plastin Ser5 phosphorylation.
RSK1 as well as RSK2 speciﬁcally phosphorylate
residue Ser5 of recombinant full-length L-plastin
in vitro
L-plastin peptides were synthesized and screened for Ser5
phosphorylation by 43 candidate kinases identiﬁed using
the phosphorylation prediction algorithm, kinase sub-
strate predictor version 2.0 from Kinexus Bioinformatics
Corporation. In addition to PKA, which was previously
shown tobe able tophosphorylate L-plastin Ser5 in vitro (7,
12), our screening identiﬁed RSKs as well as MSK1 as top
candidate kinases for phosphorylating this residue. As
shown in Table 1, these kinases led to high radioactivity
counts for the WT L-plastin peptide as well as for the Ser7-
to-Ala-mutated peptide (MT), both peptides being devoid
of the initiatormethionine and acetylated on theN-terminal
alanine. The WT peptide displayed higher counts for the
named kinases than the MT peptide, indicating that phos-
phorylation occurs not only on residue Ser5 but also on
Ser7. It is however noteworthy that Ser7 phosphorylation
is not required for Ser5 phosphorylation by the investi-
gated kinases because strong Ser5 phosphorylation was
observed in the absence of Ser7. It is also noteworthy that
the same kinases appear in the top positions for both
peptides. Validation experiments as well as experiments
with the WT and MT peptides still containing the initiator
methionine were performed and showed similar rankings
(data not shown).
Because the in vitro kinase assays performed onL-plastin
peptides identiﬁed RSK1, RSK2, and MSK1 as candidate
kinases (Table 1), we also tested these kinases for their
ability to phosphorylate recombinant full-length L-plastin
on residue Ser5 in vitro. As shown in Fig. 3, both RSK1 and
RSK2 were able to strongly phosphorylate L-plastin on
Figure 1. High-baseline L-plastin Ser5 phosphorylation in
highly invasive vs. low-baseline L-plastin Ser5 phosphorylation
in non- or weakly invasive breast cancer cell lines. A) There
were 4 breast cancer cell lines seeded in collagen I-coated
(200 mg/ml) 96-well plates. At ;90% conﬂuence, a wound
was scratched across each well with the CellPlayer 96-well
WoundMaker. Cells were covered with collagen I (1.5 mg/ml)
diluted in cell culture medium. Wound conﬂuence was moni-
tored with the IncuCyte LiveCell Imaging System by measuring
cell conﬂuence every 3 h over a total period of 72 h. The graph
depicts mean6 SEM from all technical replicates obtained from
3 independent experiments. B) Cell extracts were subjected to
immunoblot analysis using antibodies speciﬁc for Ser5-P-LPL
(anti-Ser5-P antibody) and LPL.
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residue Ser5, whereas MSK1 was merely able to induce a
weak L-plastin Ser5 phosphorylation.
The ERK/MAPK pathway and its downstream RSKs
are involved in L-plastin Ser5 phosphorylation in
breast cancer cells
The 2 newly identiﬁed prime candidate kinases capable of
phosphorylatingL-plastinonSer5 in vitro, RSK1andRSK2,
are downstream effectors of the ERK/MAPK pathway
(41). In addition, the results of our microarray experi-
ments have also suggested an involvement of the ERK/
MAPK pathway in L-plastin Ser5 phosphorylation. Alto-
gether, these ﬁndings prompted us to further investigate
the role of the ERK/MAPK pathway in L-plastin Ser5
phosphorylation. In a ﬁrst step, we inhibited selected sig-
naling molecules of this pathway, and we showed that
PKC inhibition with the widely used pan-PKC inhibitor
GF109203X, MEK1/MEK2 inhibition with PD98059, as
well as RSK inhibition with BI-D1870 decreased baseline
L-plastin Ser5 phosphorylation in invasive cells (Fig. 4A).
In a second step, we took advantage of the fact that the
ERK/MAPK pathway is one of the major signaling path-
ways activated upon binding of various growth factors to
the corresponding receptor tyrosine kinases. Knowing that
the EGFR family, a prominent receptor tyrosine kinase
family, plays a key role in normal and malignant breast
development (42) and is capable to trigger cell migration
through ERK/MAPK pathway signaling (43), we checked
forEGFRexpression inour4model cell lines.Aspreviously
described by others (33), both SK-BR-3 and BT-20 cells
expressed high levels of EGFR, whereas in MCF7 and
MDA-MB-435S cells, the expression was very low or absent
(Supplemental Fig. 1A).As expected, stimulationwithEGF
as a key EGFR-binding ligand did not increase L-plastin
phosphorylation in the 2 EGFR-negative cell lines MCF7
and MDA-MB-435S, even when stimulated with high
EGF concentrations. However, EGF treatment highly
increased L-plastin Ser5 phosphorylation in SK-BR-3 and
BT-20 cells at all tested concentrations (Supplemental
Fig. 1B). We have shown previously that treatment with
PMA, a well-known activator of PKCs that has also been
described to activate the ERK/MAPK pathway (44–46),
was able to induce L-plastin Ser5 phosphorylation in
MCF7 (3) and SK-BR-3 cells (Fig. 2). Accordingly, PMA
treatment of the 2 invasive cell lines BT-20 andMDA-MB-
435S, displaying already high-baseline L-plastin Ser5
phosphorylation, was able to further increase this phos-
phorylation (Fig. 4B). Importantly, preincubation with
inhibitors of the ERK/MAPK pathway impaired L-plastin
phosphorylation upon PMA or EGF stimulation in all
tested cell lines (Fig. 4B). To exclude off-target effects, we
conﬁrmed our results with a second RSK inhibitor,
SL0101, which also impaired EGF-triggered L-plastin
phosphorylation in SK-BR-3 and BT-20 cells and de-
creased baseline L-plastin phosphorylation in invasive
cell lines (data not shown). Interestingly, the strongest
decrease of L-plastin Ser5 phosphorylation was obtained
for the combined inhibition of RSK and PKC (Fig. 4B).
Figure 2. ERK/MAPK pathway enriched by genes that are signiﬁcantly differentially expressed in breast cancer cells exhibiting
differential L-plastin Ser5 phosphorylation levels. Noninvasive cell lines were treated with PMA, and resulting L-plastin Ser5
phosphorylation was determined by immunoblot analysis. Whole-genome microarray analysis was then used to compare breast
cancer cells with differential L-plastin Ser5 phosphorylation levels and invasive capacities. There were 3 comparisons analyzed: 1)
PMA-treated vs. untreated MCF7 cells; 2) PMA-treated vs. untreated SK-BR-3 cells; and 3) intersection between comparisons of
invasive vs. noninvasive cells (BT-20 vs. MCF7, MDA-MB-435S vs. MCF7, BT-20 vs. SK-BR-3, and MDA-MB-435S vs. SK-BR-3).
Differentially expressed transcript clusters (DE transcr. cl.) were identiﬁed for the 3 comparisons and were mapped and analyzed
by IPA. For each of the 3 comparisons of interest, IPA revealed a list of canonical signaling pathways (Supplemental Data) from
which we selected those that were signiﬁcant [-log(P value) .1.301] and thus enriched by genes that are differentially expressed.
There were 3 canonical signaling pathways common to the 3 lists: ERK/MAPK Signaling, UVA-Induced MAPK Signaling, and
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis. ctrl, control.
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And ﬁnally, trametinib, a clinical MEK inhibitor ap-
proved by the U.S. Food and Drug Administration for mel-
anoma treatment (trade name Mekinist), clearly reduced
L-plastin Ser5 phosphorylation in invasive cell lines and pre-
vented an EGF-triggered increase in L-plastin Ser5 phos-
phorylation in SK-BR-3 and BT-20 cells (Fig. 4C). Altogether,
these results point to a major involvement of the ERK/
MAPK signaling pathway in L-plastin Ser5 phosphorylation.
Modeling of the L-plastin signaling pathway with PBNs
The signaling pathways leading to L-plastin Ser5 phos-
phorylation are not clearly understood, and so far, it was
assumed that the identity of the protein kinase re-
sponsible for this phosphorylation event depends on
the cell type and environment. In addition to reports on
the involvement of PKA (7, 12) and PKC (3, 13–18), our
results presented here highlight a role of RSKs in this
process. In order to obtain a better quantitative un-
derstanding of the signaling pathways upstream of
L-plastin Ser5 phosphorylation, we applied the optPBN
toolbox to further study and analyze these pathways in
the PBN framework (30). We built a PBN model that
represents the network topology of signaling pathways
upstream of L-plastin Ser5 phosphorylation based on
literature information and our own ﬁndings (Fig. 5A).
Our model is mainly focused on the ERK/MAPK pathway
TABLE 1. In vitro kinase screening assay for L-plastin Ser5 phosphorylation
Ranking Kinases Cpm ARGSVSDEERR (WT)a Kinases Cpm ARGSVADEERR (MT)a
1 RSK2 116,698 RSK1 55,774
2 PKAca 109,766 PKAca 53,986
3 RSK1 101,952 MSK1 53,254
4 MSK1 86,947 RSK2 48,800
5 RSK3 71,917 PKAcb 34,148
6 PKAcb 54,673 PKAcg 33,572
7 RSK4 45,174 RSK3 32,917
8 PKAcg 40,167 PRKG2 26,041
9 SGK3 32,646 RSK4 22,477
10 SGK2 32,129 SGK2 22,249
11 PRKG2 29,921 SGK3 20,290
12 PKCh 29,273 STK33 10,761
13 p70S6Kb 19,894 PKCh 10,007
14 AURORA B 12,688 AURORA B 9696
15 STK33 9990 PRKG1 9110
16 PKCq 9671 PRKX 8113
17 VRK1 9054 DCAMKL1 5899
18 PRKX 8310 VRK1 5745
19 PRKG1 8189 VRK2 5470
20 CAMK1b 8126 MNK1 5430
21 VRK2 7876 PKCe 5053
22 CAMK4 6955 CAMK4 4668
23 PKCe 6779 DCAMKL2 4447
24 DCAMKL2 5726 p70S6Kb 4242
25 MNK1 5718 CAMK1b 3996
26 DCAMKL1 5437 NDR 3797
27 NDR 5072 PKCq 3589
28 PKCd 4597 IKKe 3422
29 PIM2 4405 NDR2 3284
30 SGK1 4243 ASK1 2771
31 NDR2 3821 SGK1 2540
32 MSK2 3741 PKCd 2329
33 IKKe 3437 AKT1 1920
34 AKT1 3257 p70S6K 1911
35 ASK1 3241 PIM2 1813
36 PIM3 2732 PIM3 1537
37 p70S6K 2454 AKT3 1460
38 AKT3 2196 AKT2 1242
39 AKT2 2142 MSK2 1005
40 PIM1 892 PIM1 922
41 CK2a2 892 AURORA C 663
42 AURORA C 588 CHK1 256
43 CHK1 176 CK2a2 44
For in vitro kinase assays on L-plastin peptides, the peptides were mixed with individual protein kinases in the presence of [g233P]ATP for
20–40 min, depending on the protein kinase tested. The assay was terminated by spotting 10 ml of the reaction mixture onto a multiscreen
phosphocellulose P81 plate. After removing unreacted [g233P]ATP from the reaction, radioactivity was quantiﬁed in counts per minute (Cpm)
in a scintillation counter. aN-terminal alanine is acetylated.
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(downstream of the EGFR) and includes Src, PKC, and
PKA kinases, which are known to interact with this path-
way. Then, we ﬁtted the PBN model to an extensive data
set comprising activation and inhibition of various net-
work nodes that modulate the signals toward the 2 mea-
sured output nodes (i.e., L-plastin Ser5 phosphorylation
and PKA substrate phosphorylation in 4 breast cancer cell
lines). To this end, we took into account the described off-
target effects of the inhibitors GF109203X and H89 on
RSK (47, 48). As a result, we obtained a model that ex-
plained well our experimental data for all 4 cell lines as
shown in Fig. 5B.
Because we found RSKs to be essential for L-plastin
Ser5 phosphorylation, the ﬁtted PBNmodel was used to
investigate whether RSKs have more inﬂuence on
L-plastin in the 4 cell lines than PKA and PKC. In addition,
we checked whether the crosstalk interactions between
PKC and PKA suggested in the literature (49, 50) are
important to modulate the signal transduction up-
stream of L-plastin Ser5 phosphorylation. We therefore
applied an in silico knockout approach where we re-
moved an interaction from the model one at a time and
checked if the removal affected theﬁtting quality. There
were 5 interactions situated in close proximity to our
output nodes analyzed (i.e., RSK→L-plastin, PKC→L-
plastin, PKA→L-plastin, PKC→PKA, and PKA→PKC)
(Table 2). We found that removing the interactions
RSK→L-plastin and PKC→PKA led to a dramatic in-
crease of the model-ﬁtting costs in all 4 cell lines,
meaning that the networks missing 1 of these 2 inter-
actions ﬁtted our experimental data less well. The in-
dividual knockout of the other 3 interactions only led to
minor changes in ﬁtting costs, suggesting that none of
these 3 interactions is necessary to explain our experi-
mental data.
We then proceeded by examining the optimized selec-
tion probability weights of each interaction and their dis-
tributions obtained via bootstrapping (see Materials and
Methods). A subset of the obtained weight distributions of
the interactions is shown in Table 3. All weights can be
found in Supplemental Fig. 2. Strikingly, in all 4 cell lines,
the activation of L-plastin by RSK is largely predominant as
compared to its activation by PKC or PKA. In addition, the
weights attributed to the investigated interactions indicate
that in all 4 cell lines, the crosstalk appears to be directed
from PKC to PKA rather than from PKA to PKC. The
relatively low SDs on theweights ensured that theseﬁndings
are robust against experimental variation in the data set.
RSK1 and RSK2 are involved in breast cancer cell
migration and invasion and in L-plastin redistribution
to migratory structures
Altogether, we provide evidence that RSKs are involved in
L-plastin Ser5 phosphorylation by in vitro kinase assays,
inhibition with 2 different RSK inhibitors, as well as com-
putational modeling. To consolidate our ﬁndings, we si-
multaneously knocked down RSK1 and RSK2 by an siRNA
approach. Albeit RSK knockdown was not equally efﬁcient
in all the investigated cell lines, we were able to observe a
decrease of Ser5-P-LPL in all 4 cell lines following the
combined knockdown of RSK1 and RSK2 (Fig. 6A).
Comparing P-LPL/LPL between cell lines, it is interesting
to note that for SK-BR-3 and MDA-MB-435S for which an
efﬁcient RSK knockdown was reached, the decrease in
L-plastin Ser5 phosphorylation was more important than for
MCF7 and BT-20, with a less-efﬁcient RSK knockdown. The
remaining L-plastin Ser5 phosphorylation might be due to
residual RSK1 and RSK2 protein presence after knock-
down. Altogether, even though phosphorylation was not
completely abolished, our data clearly conﬁrm an impor-
tant role for RSKs in L-plastin Ser5 phosphorylation.
Moreover, we investigated the effect of siRNA-dependent
RSK knockdown on migration and invasion in MDA-
MB-435S cells. This cell line was selected because it
has the highest invasive capacity as shown in Fig. 1A. In vitro
scratch wound assays revealed that the combined knock-
down of RSK1 and RSK2 considerably slowed down MDA-
MB-435S cell migration and invasion by up to 30% (Fig.
6B), whereas cell proliferation remained largely unaf-
fected (data not shown). To further corroborate this
ﬁnding, we stably knocked down RSK1, RSK2, combined
RSK1 andRSK2, or L-plastin inMDA-MB-435S cells using
shRNA-expressing lentiviral vectors. Knockdown was more
successful for RSK2 than for RSK1, explaining the larger
decrease of L-plastin Ser5 phosphorylation in RSK2
knockdown compared to RSK1 knockdown MDA-MB-
435S cells (Fig. 6C). It is noteworthy that the previously
observed siRNA-dependent reduction in migration and
invasion (Fig. 6B) was conﬁrmed by combined RSK1 and
RSK2 knockdown (Fig. 6D), whereas knockdown of RSK1
or RSK2 alone was not sufﬁcient to affect migration or
invasion (data not shown).Notably, a stable knockdownof
L-plastin to an undetectable level on immunoblot (Fig. 6C)
did not signiﬁcantly decrease migration and invasion of
MDA-MB-435S cells (Fig. 6D).
Furthermore,we investigatedwhether endogenousRSK
activity affects actin, L-plastin, and Ser5-P-LPL localization
inmigrating cells. To this end, SK-BR-3 cells wereplatedon
glass coverslips coated with ﬁbronectin, and at ;90%
conﬂuence, a wound was scratched. Immunoﬂuorescent
staining of L-plastin, Ser5-P-LPL, and actin was performed
after EGF treatment with or without prior treatment with
the RSK inhibitor BI-D1870 in cells migrating into the
scratched wound. As a result, we observed that EGF treat-
ment led toan increasedformationof rufﬂingmembranes,
microspikes, and even longer ﬁlopodia-like structures
embedded in the cortical region of the cell, all of which are
Figure 3. RSK1 and RSK2 are able to directly phosphorylate
L-plastin Ser5 in vitro. A total of 10 mg recombinant full-length
L-plastin was incubated with 100 ng recombinant kinase and
with 50 mM ATP in a reaction volume of 25 ml according to
the manufacturer’s protocol. For each kinase assay, a control
(ctrl) was performed by omitting the respective kinase. Sam-
ples were incubated for 15 min at 30°C. Following incubation,
Laemmli buffer was added, and the samples were boiled at
100°C for 5 min and analyzed by immunoblot visualizing
Ser5-P-LPL and LPL.
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Figure 4. Involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation in breast cancer cells. A) Invasive cell lines
exhibiting high-baseline L-plastin Ser5 phosphorylation were treated with inhibitors of selected signaling molecules of the ERK/
MAPK pathway: GF109203X (GF), PD98059 (PD), and BI-D1870 (BID). Subsequent to inhibitor treatment, residual L-plastin
Ser5 phosphorylation was determined by immunoblot analysis. For quantiﬁcation, the ratio between the intensities obtained for
P-LPL vs. LPL was determined to make individual samples comparable and then normalized to the mean of all the values
obtained in 1 experiment to make blots comparable by accounting for technical day-to-day variability. B) Cells were preincubated
with inhibitors of the ERK/MAPK pathway and then stimulated with EGF (for the 2 EGFR-expressing cell lines) or PMA (for the 4
cell lines). L-plastin Ser5 phosphorylation was quantiﬁed as described under (A). C) Cells were treated with trametinib (Tram)
(continued on next page)
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structures playing a role in cell migration (Fig. 7). It is
noteworthy that L-plastin was highly enriched in these
structures. Interestingly, RSK inhibition with BI-D1870
treatment prior to EGF stimulation did not abolish but
clearly reduced the formationof thesemigratory structures
and the redistribution of L-plastin to these structures (Fig.
7). Ser5-P-LPL could only be visualized in the cells follow-
ing EGF treatment and was also found in rufﬂing mem-
branes and in microspikes. The staining for Ser5-P-LPL
disappeared with RSK inhibition (Fig. 7).
Figure 5. Literature-derived and experiment-based L-plastin signaling network and model-ﬁtting results. A) A candidate network
for the signaling pathways upstream of L-plastin Ser5 phosphorylation was built based on literature information and our own
experimental ﬁndings. The network interactions were analyzed by applying a PBN approach taking into account cell line-speciﬁc
immunoblot-based quantiﬁcations of P-LPL and P-PKA substrates. Various conditions were tested in the 4 cell lines MCF7, SK-BR-3
(SK), BT-20 (BT), and MDA-MB-435S (MDA) including activation by EGF, PMA, or 8-Bromo-cAMP (8Br) and/or inhibition by
GF109203X (GF), H89, PP2, PD98059 (PD), or BI-D1870 (BID). B) PBN model-ﬁtting results in comparison to experimental data
for the various tested conditions. Colored bars indicate the conditions tested for the individual cell lines. For quantiﬁcation, the
ratio between the intensities obtained for P-LPL, respectively, P-PKA substrates vs. LPL was determined to make individual
samples comparable and then normalized to the mean of all the values obtained in 1 experiment to make blots comparable by
accounting for technical day-to-day variability. Data generated from different experimental sets were normalized to the calibrator
PMA, subsequently pooled, and scaled to the highest signal (of each respective graph) for representative purposes. Means of 10
simulated values from the PBN model (black stars) were compared against the experimental data [multicolored squares (means)
and error bars (SD)].
with or without subsequent EGF stimulation, and L-plastin Ser5 phosphorylation was quantiﬁed as described under (A). For each
immunoblot shown, samples were run on the same gel, but for BT-20 shown under (A) and MDA-MB-435S shown under (B),
bands were cut and put in another order for representative purposes. For representative purposes, data were scaled to the highest
signal and are represented as means 6 SD. Statistical signiﬁcance was determined by an unpaired t test with Welch’s correction.
P , 0.05 was considered signiﬁcant. *P , 0.05; **P , 0.01; ***P , 0.001; n.s., nonsigniﬁcant.
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Finally, MDA-MB-435S cells stably knocked down for
RSK2 and exhibiting a strong decrease of L-plastin Ser5
phosphorylation were transfected with RSK2wt or consti-
tutively active RSK2Y707A. Notably, both transfections led
to a rescue of the level of Ser5-P-LPL to a normal level
(Supplemental Fig. 3A). In parallel, we analyzed the lo-
calization of Ser5-P-LPL by performing immunoﬂuores-
cence studies. Similar to the effect observed upon EGF
treatment in SK-BR-3 cells, the ectopic expression of
RSK2wt and RSK2Y707A in MDA-MB-435S cells increased
the formation of microspike-like structures with a re-
distribution of Ser5-P-LPL to these structures (Supple-
mental Fig. 3B). To corroborate our ﬁndings, we also
performed transient transfectionofRSK2wtorRSK2Y707A
inSK-BR-3 cells.Weobserved an increased stainingof Ser5-
P-LPL in cells overexpressing RSK2wt or RSK2Y707A and,
in parallel, the recruitment of Ser5-P-LPL to actin-rich
migratory structures (Supplemental Fig. 3C).
Altogether, these results indicate a qualitative link be-
tween L-plastin Ser5 phosphorylation by RSK and its re-
distribution to migratory structures.
DISCUSSION
In our previous studies, we have shown that phosphoryla-
tion of L-plastin on residue Ser5 plays a critical role in
L-plastin activation (3, 7). Here, we have unraveled a major
signaling pathway responsible for L-plastin Ser5 phos-
phorylation in breast cancer cells. We have revealed the
involvement of the ERK/MAPK pathway with its down-
stream target kinases RSK1 and RSK2 being able to directly
phosphorylate L-plastin on Ser5. In addition, we have il-
lustrated an RSK-dependent recruitment of L-plastin and,
more precisely, Ser5-P-LPL to migratory structures.
In this study, we chose to take a microarray-based gene
expression-proﬁling approach in order to correlate con-
ditions and cell lines presenting differential L-plastin Ser5
phosphorylation levels with patterns of changes in gene
expression. In the context of the coﬁlin pathway in breast
cancer invasion and metastasis (51), the authors have
pointed out that not only individual genes but whole
pathways with differential regulation and activity states of
the correspondingmolecules shouldbe taken intoaccount
for phenotype interpretation. Likewise, in our study, the
whole-genomemicroarray analysis approach allowed us to
identify 3 canonical pathways enriched in DEGs, namely
ERK/MAPK signaling, UVA-inducedMAPK signaling, and
role of osteoblasts, osteoclasts and chondrocytes in rheu-
matoid arthritis, of which the ERK/MAPK pathway is a
prominent oncogenic signaling pathway. In addition, the
in vitro kinase assays carried out in parallel identiﬁed the
ERK/MAPK pathway downstream kinases RSK1 and RSK2
as themost prominent candidate kinases for L-plastin Ser5
phosphorylation. These ﬁndings together with a previous
report describing L-plastin as an ERK/MAPK pathway-
regulated protein (52) prompted us to proceed to an in-
depth investigation of this pathway, whose deregulation
has also been associated with breast cancer progression
[reviewed in Whyte et al. (53)].
Several approaches were used to unravel the involve-
ment of the ERK/MAPK pathway with its downstream
kinases RSK1 and RSK2 in the L-plastin Ser5 phosphory-
lation event. To trigger this pathway, we stimulated the cells
with EGF or with PMA, both described as activators of the
ERK/MAPK pathway. Evidence for a direct involvement of
the ERK/MAPK pathway downstream kinases RSK1 and
RSK2 in L-plastin Ser5 phosphorylation was provided both
by a knockdownapproach andby theuse of 2 differentRSK
inhibitors: BI-D1870 and SL0101. This reduces the proba-
bility that the observed inhibitor-dependent decrease of
phosphorylation is due to off-target effects. Indeed, BI-
D1870 and SL0101 have only 1 common off target, Aurora
B (54), which demonstrated considerably weaker potency
in phosphorylating L-plastin peptides than RSK1 or RSK2,
as shown by the in vitro kinase assays from Kinexus Bio-
informatics Corporation (Table 1). In line, and most im-
portantly, the 2 kinases RSK1 as well as RSK2 were able to
directly phosphorylate the recombinant L-plastin protein
on residue Ser5 in an in vitro kinase assay. Further evidence
for the importance of the ERK/MAPK pathway is provided
by the data obtained with the MEK inhibitor PD98059 as
well as with the clinically used MEK inhibitor trametinib.
Moreover, our ﬁnding that L-plastin phosphorylation can
be mediated by RSK upon activation of the ERK/MAPK
TABLE 2. Model-ﬁtting costs obtained via in silico knockout
Model variant MCF7 SK-BR-3 BT-20 MDA-MB-435S
Initial model 0.2298 0.2942 0.2961 0.3126
RSK → LPL removed 0.7872 1.0344 0.6921 1.2369
PKC → LPL removed 0.2298 0.2942 0.2962 0.3126
PKA → LPL removed 0.2318 0.2942 0.2966 0.3126
PKC → PKA removed 0.7163 0.4520 0.4245 0.4622
PKA → PKC removed 0.2298 0.2942 0.3045 0.3452
The ﬁtting costs of model variants after removing individual
interactions were compared to those of the initial model structure prior
to removal. The ﬁtting cost is the sum of squared error between
simulated state values and the mean values of the experimental data.
TABLE 3. Optimized selection probability weights and their distributions obtained via bootstrapping
Interaction MCF7 SK-BR-3 BT-20 MDA-MB-435S
RSK → LPL 0.888 (0.081) 1.000 (0.000) 0.948 (0.070) 1.000 (0.000)
PKC → LPL 0.004 (0.023) 0.000 (0.000) 0.025 (0.058) 0.000 (0.000)
PKA → LPL 0.108 (0.073) 0.000 (0.000) 0.027 (0.023) 0.000 (0.000)
PKC → PKA 0.407 (0.060) 0.236 (0.049) 0.262 (0.059) 0.252 (0.093)
PKA → PKC 0.072 (0.112) 0.005 (0.017) 0.256 (0.189) 0.204 (0.068)
The distributions of identiﬁed mean weights (SD) obtained via bootstrapping are shown for the 5 interactions under investigation in the 4
cell lines.
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Figure 6. Combined RSK1 and RSK2 knockdown decreases L-plastin Ser5 phosphorylation and impairs migration and invasion,
whereas an L-plastin stable knockdown does not affect MDA-MB-435S cell motility. A) siRNA against RSK1 and RSK2 or scrambled
siRNA was transfected in the 4 cancer cell lines as indicated, and L-plastin Ser5 phosphorylation and RSK1 and RSK2 expression
were assessed by immunoblot analysis 72 h posttransfection. Noninvasive cell lines were treated with EGF or PMA as indicated. B)
MDA-MB-435S cells were seeded in collagen I-coated (200 mg/ml) 96-well plates and transfected with siRNA against RSK1 and
RSK2 or with scrambled siRNA. After 24 h, a wound was scratched across each well with the CellPlayer 96-well WoundMaker. To
study invasion, cells were covered with collagen I (1.5 mg/ml) diluted in cell culture medium. To study migration, cell culture
medium was added to the cells. Migration and invasion were monitored by measuring wound conﬂuence every 3 h for a total of
72 h with the IncuCyte LiveCell Imaging System. Graphs depict means 6 SEM from all technical replicates obtained from 3
independent experiments. Efﬁcient knockdown of RSK1 and RSK2 as well as efﬁcient decrease of L-plastin Ser5 phosphorylation
were conﬁrmed by immunoblot analysis (quantiﬁcation included in A). C) MDA-MB-435S cells were transduced with lentiviral
particles containing shRNA for RSK1, RSK2, RSK1 and RSK2, and L-plastin or nonsilencing shRNA as a control (Ctrl).
Subsequently, the transduced cells were selected with puromycin in complete medium. RSK1, RSK2, and L-plastin expression as
(continued on next page)
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pathway was conﬁrmed by our computational model,
which suggests that RSK is themost important activator of
L-plastin in all 4 cell lines. Our PBN modeling approach
proved to be a useful tool to integrate the information
from literature together with our vast experimental data set,
in particular because signaling tends to occur in complex
networks.
Although our results provide strong evidence for a role
of the ERK/MAPK pathway with the downstream kinases
RSK1 and RSK2 being able to directly phosphorylate
L-plastin on residue Ser5, they do not rule out that L-plastin
Ser5 phosphorylation can also be mediated by other
pathways. So far, only PKA has been reported to directly
phosphorylate L-plastin in vitro (7, 12), whereas other
kinases such as PKCd, catalytic domain of PKC, casein ki-
nase II,Pak1,PKB,M2K,M3K,andp38-regulated/activated
protein kinase failed to directly phosphorylate L-plastin in
vitro (12, 13). In cells, by contrast, distinct protein kinases
have been reported to play a role in triggering L-plastin
phosphorylation depending on the cell type and environ-
ment.Most frequent are reports of the involvement of PKA
(7, 12) and PKC (3, 13–18). PI3K has also been reported to
play a role in L-plastin phosphorylation in human neutro-
phils (13, 16), but not in T lymphocytes (18). Although an
siRNA knockdown of PKCd (3, 14) and PKCbII (17) re-
duced L-plastin Ser5 phosphorylation, it has to be taken
into account thatmost reports are based on activation and/
or inhibition studies. Strikingly, all inhibitors used to dem-
onstrate the involvement of PKA and PKC (H89,
GF109203X, Go¨6976, and Ro-31-8220) in L-plastin phos-
phorylation also strongly inhibit RSK2 (47, 48). Moreover,
PMAused as a PKCactivator does not only activate PKCbut
has also been shown to activate the ERK1/2module either
through PKC and c-Src or through RasGRP (44–46). Fi-
nally, the effect of the PKA activator cAMP on the ERK1/2
module appears to depend on the cellular context be-
cause cAMP has been demonstrated to stimulate ERK in a
B-Raf–dependent manner or to suppress ERK signaling in
many cells through its ability to target C-Raf [reviewed in
Dumaz and Marais (55)]. In the present study, we have
demonstrated a clear anddirect activity of the kinases RSK1
andRSK2 in L-plastin Ser5 phosphorylation supported by a
modeling approach. A potential involvement of the pre-
viously described kinases PKA, PKC, and PI3K cannot be
ruled out, although in our model, PKA and PKC appear to
play a rather indirect role in L-plastin activation. This result
is in line with previous ﬁndings of Hagi et al. (56), who
reported that cAMP stimulation was not able to trigger
L-plastin Ser5 phosphorylation in macrophages. Regarding
a potential involvement of PI3K, future studies that were out
of the scope of the present work have to be dedicated to
the investigation of the phosphatase and tensinhomolog/
PI3K/AKT/mammalian target of rapamycin pathway in
mediating L-plastin Ser5 phosphorylation.
RSKs have been described as versatile regulators con-
trolling migration and invasion downstream of ERK/
MAPKactivation (57) by altering the transcription ofmany
genes involved in epithelial-to-mesenchymal transition,
regulating cell adhesion through phosphorylation events
with subsequent modulation of integrin activity, and/or
remodeling the actin cytoskeleton. In this context, the
phosphorylation of the RSK1/2 target integrin subunit b4
has been found to play a role in hemidesmosome disas-
sembly regulation and hence in migration (58). It is note-
worthy that RSK2 expression has been correlated to the
expression of the actin-bundling protein fascin-1 in tumor
samples from patients with head and neck squamous cell
carcinoma and to ﬁlopodia formation in cancer cells (59),
suggesting that the RSK2-cAMP response element-binding
protein pathway increases proinvasive and prometastatic
capacities. Interestingly, RSK2 has been described to
phosphorylate a further actin-binding protein ﬁlamin A
(60) on residue Ser2152 (61). This phosphorylation event
is involved in EGF-induced cell migration (61) and in-
hibition of cell adhesion through integrin inactivation
(62). Indeed, RSK-dependent phosphorylation was shown
topromoteﬁlaminAbinding tob integrin tails (63). In this
regard, it is interesting to note that also L-plastin was de-
scribed to interact with b1 and b2 integrin subunits (64)
and thatL-plastin aswell appears tomodulate theafﬁnityof
integrins (unpublished results). In our study, both RSK1
and RSK2 were able to phosphorylate the actin-binding
protein L-plastin, and combined knockdown of the 2 iso-
forms led toa clear decrease in cellmigration and invasion.
Surprisingly, however, stable knockdown of L-plastin did
not signiﬁcantly affectmigration and invasionofMDA-MB-
435Scells,which suggests that theeffectofRSKknockdown
on the promotile/invasive capacities of these cells is not, or
only modestly, mediated through L-plastin. This ﬁnding is
not in line with the ﬁnding that L-plastin knockdown re-
duced haptotacticmigration of themelanoma cell line IF6
(10). Similar contradictory results have been found inPC-3
prostate cancer cells, where one study showed that L-plastin
down-regulation decreased migration and invasion rates
(65), whereas another study showed that L-plastin down-
regulation did not affect ﬁlopodia formation and had
merely a low effect on motility. The latter study however
provided evidence that a nanobody-mediated inhibition
ofL-plastin bundling led to inhibitedﬁlopodia formation
and highly decreased migration and invasion of PC-3
cells (66). The authors suggested that the depletion of
the L-plastin protein could lead to a compensation of the
L-plastin function by a functionally redundant protein.
Such a compensatorymechanismmight not take place in
case of a nanobody-mediated knockout of a speciﬁc func-
tion of L-plastin (66).
Nevertheless, our results provide evidence for a link
between RSK activity and L-plastin phosphorylation and
well as L-plastin Ser5 phosphorylation were determined by immunoblot analysis. D) MDA-MB-435S cells with stable knockdown
for L-plastin, combined RSK1 and RSK2, or transduced with a nonsilencing control shRNA were seeded in collagen I-coated
(200 mg/ml) 96-well plates. A wound was scratched across each well with the CellPlayer 96-well WoundMaker. To study invasion,
cells were covered with collagen I (1.5 mg/ml) diluted in cell culture medium. To study migration, cell culture medium was added to
the cells. Migration and invasion were monitored by measuring wound conﬂuence over a total of 72 h with the IncuCyte ZOOM
LiveCell Imaging System. The graphs depict means 6 SEM of at least 10 technical replicates, and shown is 1 representative
experiment of 4 independent repeats.
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redistribution to migratory structures formed upon EGF
stimulation or RSK2 overexpression. The identiﬁcation of
L-plastin as a new target of RSKs consolidates their role in
the regulationof the actin cytoskeleton.Our results extend
the ﬁndings of Doehn et al. (67), who investigated the ef-
fects of RSK1 and RSK2 on migration and invasion in epi-
thelial breast cells and showed that combined knockdown
of RSK1 and RSK2 or RSK inhibition suppressed the ERK
pathway-dependent induction of promotile and proinvasive
genes. The detailed functional outcome of L-plastin
Ser5 phosphorylation by RSK deserves further in-depth
investigation.
Overall, our results show the ﬁrst evidence, to our
knowledge, of the involvement of the ERK/MAPK
pathway in L-plastin Ser5 phosphorylation. These ﬁnd-
ings corroborate Ser5-P-LPL as a molecular marker for
invasive carcinomas with deregulated ERK/MAPK path-
way signaling.
Figure 7. L-plastin Ser5 phosphorylation and localization in migratory structures upon EGF stimulation are dependent on RSK
activity. SK-BR-3 cells were plated on ﬁbronectin-coated coverslips and serum starved for 24 h. At ;90% conﬂuence, a wound was
scratched with a micropipette tip, and cells were subsequently treated with vehicle or EGF (100 ng/ml) with or without prior
treatment with BI-D1870 (5 mM). At 1 h following treatment, the coverslips were ﬁxed and subsequently stained with phalloidin
and an antibody speciﬁc for L-plastin or Ser5-P-LPL (anti-Ser5-P antibody, P-L-plastin) before being analyzed by confocal
microscopy.
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Legend:
Supplemental Figure 2 Optimized interactions’ weights for the L-plastin signaling network. Bootstrapping was performed by
randomly sampling 100 artificial data sets based on means and standard deviations as acquired from the experimental data.
Optimization was subsequently performed 100 times to identify the distribution of the identified selection probabilities. Means
and standard deviations of the interactions’ weights were compared among the four cell lines.
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Supplemental Figure 1 Analysis of EGF-dependent L-plastin Ser5
phosphorylation. A) EGF receptor (EGFR) is expressed in SK-BR-3 and
BT-20 breast cancer cell lines. Cell extracts were subjected to immunoblot
analysis using antibodies specific for the EGFR and β-actin, used as a loading
control. B) Cells were stimulated for 15 min with different EGF
concentrations as indicated and cell extracts were subjected to immunoblot
analysis using antibodies specific for Ser5 phosphorylated L-plastin or total
L-plastin.
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Supplemental Figure 3 Overexpression of RSK2 leads to increased L-plastin Ser5 phosphorylation and
to its redistribution to migratory structures. A) MDA-MB-435S cells were transduced with lentiviral
particles containing shRNA for RSK2 or non-silencing shRNA as a control. The transduced cells were
selected with puromycine in complete medium. Cells were subsequently transfected with RSK2wt or
constitutively active RSK2Y707A and the levels of RSK2 and L-plastin Ser5 phosphorylation were
determined by immunoblot analysis. B) MDA-MB-435S cells expressing a non-silencing control
shRNA or RSK2-targeting shRNA were plated on fibronectin-coated coverslips and transfected with
HA-tagged RSK2wt or RSK2Y707A. The coverslips were fixed 48 h after transfection and
subsequently stained with an antibody specific for Ser5 phosphorylated L-plastin (anti-Ser5-P antibody,
P-L-plastin) and with an anti-HA tag antibody to monitor the transfected cells. GFP-positive cells
express the corresponding shRNA. Cells were then analyzed by confocal microscopy. The scale bar
shown represents 25 μm. C) SK-BR-3 cells were plated on fibronectin-coated coverslips and transfected
with HA-tagged RSK2wt or RSK2Y707A. The coverslips were fixed 48 h after transfection and
subsequently stained with an antibody specific for Ser5 phosphorylated L-plastin (anti-Ser5-P antibody,
P-L-plastin), with an anti-HA tag antibody to monitor the transfected cells and with phalloidin. Cells
were then analyzed by confocal microscopy. The scale bar shown represents 25 μm.
Survival curves for L-plastin (LCP1)
PhD Thesis - Maiti Lommel  
Analysis of signal transduction pathways linking L-plastin Ser5 phosphorylation to
breast cancer cell invasion
The following survival curves were generated using the online Kaplan-Meier
Plotter tool (www.kmplot.com):
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray
data of 1809 patients, Breast Cancer Res Treatment, 2010 Oct;123(3):725-31.
Overall survival curves for LCP1, 
including 1117 patients
Relapse-free survival curves for LCP1, 
including 3557 patients
Distant metastasis-free survival curves for LCP1, 
including 1610 patients
Supplemental in vitro  kinase assay data
PhD Thesis - Maiti Lommel
Analysis of signal transduction pathways linking L‑plastin Ser5 phosphorylation to breast cancer cell invasion
First run
Ranking Kinases Counts (cpm) Kinases Counts (cpm) Kinases Counts (cpm)
1 RSK2 116698 RSK1 55774 RSK1 135794
2 PKAca 109766 PKAca 53986 MSK1 129651
3 RSK1 101952 MSK1 53254 RSK2 115547
4 MSK1 86947 RSK2 48800 PKAca 97124
5 RSK3 71917 PKAcb 34148 PKAcg 94447
6 PKAcb 54673 PKAcg 33572 SGK2 82033
7 RSK4 45174 RSK3 32917 RSK3 81498
8 PKAcg 40167 PRKG2 26041 PKAcb 66998
9 SGK3 32646 RSK4 22477 PRKG2 46081
10 SGK2 32129 SGK2 22249 RSK4 44022
11 PRKG2 29921 SGK3 20290 SGK3 43761
12 PKCh 29273 STK33 10761 AURORA B 26998
13 p70S6Kb 19894 PKCh 10007 PKCh 19741
14 AURORA B 12688 AURORA B 9696 PKCq 18726
15 STK33 9990 PRKG1 9110 PRKG1 17159
16 PKCq 9671 PRKX 8113 STK33 11019
17 VRK1 9054 DCAMKL1 5899 PKCe 10347
18 PRKX 8310 VRK1 5745 PRKX 10004
19 PRKG1 8189 VRK2 5470 PKCd 7763
20 CAMK1b 8126 MNK1 5430 MNK1 7224
21 VRK2 7876 PKCe 5053 CAMK4 6258
22 CAMK4 6955 CAMK4 4668 SGK1 6216
23 PKCe 6779 DCAMKL2 4447 DCAMKL1 6179
24 DCAMKL2 5726 p70S6Kb 4242 p70S6Kb 6088
25 MNK1 5718 CAMK1b 3996 DCAMKL2 5788
26 DCAMKL1 5437 NDR 3797 VRK1 5346
27 NDR 5072 PKCq 3589 AKT1 5038
28 PKCd 4597 IKKe 3422 NDR 4478
29 PIM2 4405 NDR2 3284 CAMK1b 4072
30 SGK1 4243 ASK1 2771 IKKe 3956
31 NDR2 3821 SGK1 2540 NDR2 3458
32 MSK2 3741 PKCd 2329 AKT3 3102
33 IKKe 3437 AKT1 1920 VRK2 3090
34 AKT1 3257 p70S6K 1911 AURORA C 2777
35 ASK1 3241 PIM2 1813 ASK1 2713
36 PIM3 2732 PIM3 1537 MSK2 2496
37 p70S6K 2454 AKT3 1460 PIM3 2139
38 AKT3 2196 AKT2 1242 p70S6K 2075
39 AKT2 2142 MSK2 1005 PIM2 2011
40 PIM1 892 PIM1 922 AKT2 1525
Wild type (WT) 
*ARGSVSDEERR 
Mutant (MT)    
*ARGSVADEERR 
Mutant with initiator 
methionine (M-MT) 
MARGSVADEERR 
41 CK2a2 892 AURORA C 663 PIM1 1083
42 AURORA C 588 CHK1 256 CHK1 830
43 CHK1 176 CK2a2 44 CK2a2 202
Second run with 12 selected kinases from the first run
Ranking Kinases Counts (cpm) Kinases Counts (cpm) Kinases Counts (cpm) Kinases Counts (cpm)
1 RSK1 115889 RSK1 63496 RSK1 141297 RSK1 272191
2 RSK2 70341 PKAca 38409 PKAca 62897 RSK2 153281
3 PKAca 63735 RSK2 27985 RSK2 61065 PKAca 144318
4 PKAcb 52764 PKAcb 27511 PKAcb 54069 PKAcb 106928
5 SGK3 28710 SGK3 19745 SGK3 40186 MSK1 76195
6 RSK3 27353 MSK1 17742 MSK1 39916 SGK3 74101
7 MSK1 25077 RSK3 14042 RSK3 32396 RSK3 59572
8 PKAcg 13848 PKAcg 12524 PKAcg 25959 SGK2 32246
9 SGK2 10796 SGK2 7878 SGK2 21964 PKAcg 31010
10 STK33 7143 STK33 7104 STK33 8209 PKCh 17918
11 VRK2 2065 PKCh 2545 PKCh 2443 STK33 14074
12 PKCh 1631 VRK2 2013 VRK2 2024 VRK2 13082
N.B. The in vitro  kinase assay screen was performed by KINEXUS
WT with initiator 
methionine (M-WT) 
MARGSVSDEERR 
Wild type (WT) 
*ARGSVSDEERR 
Mutant (MT)    
*ARGSVADEERR 
MT with initiator 
methionine (M-MT) 
MARGSVADEERR 
